US20190367541A1 - Natural lipids containing non-oxidizable fatty acids - Google Patents
Natural lipids containing non-oxidizable fatty acids Download PDFInfo
- Publication number
- US20190367541A1 US20190367541A1 US16/384,307 US201916384307A US2019367541A1 US 20190367541 A1 US20190367541 A1 US 20190367541A1 US 201916384307 A US201916384307 A US 201916384307A US 2019367541 A1 US2019367541 A1 US 2019367541A1
- Authority
- US
- United States
- Prior art keywords
- fatty acid
- group
- lipid
- tta
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 199
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 177
- 239000000194 fatty acid Substances 0.000 title claims abstract description 177
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 177
- 150000002632 lipids Chemical class 0.000 title claims abstract description 172
- 239000000203 mixture Substances 0.000 claims abstract description 168
- 150000003904 phospholipids Chemical class 0.000 claims description 85
- 230000000975 bioactive effect Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical group CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 7
- 229960001231 choline Drugs 0.000 claims description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 6
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 6
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 6
- 229960001153 serine Drugs 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 3
- 229940031098 ethanolamine Drugs 0.000 claims description 2
- 150000003248 quinolines Chemical group 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 150
- 238000000034 method Methods 0.000 abstract description 72
- 238000004519 manufacturing process Methods 0.000 abstract description 24
- 150000001875 compounds Chemical class 0.000 description 121
- IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical group CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 description 120
- 239000003795 chemical substances by application Substances 0.000 description 81
- 230000000694 effects Effects 0.000 description 70
- -1 phospholipid compounds Chemical class 0.000 description 60
- 238000011282 treatment Methods 0.000 description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 54
- 125000000217 alkyl group Chemical group 0.000 description 53
- 206010028980 Neoplasm Diseases 0.000 description 50
- 238000007254 oxidation reaction Methods 0.000 description 47
- 150000003839 salts Chemical class 0.000 description 47
- 229910052717 sulfur Inorganic materials 0.000 description 46
- 125000001183 hydrocarbyl group Chemical group 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 42
- 125000004429 atom Chemical group 0.000 description 37
- 239000003814 drug Substances 0.000 description 36
- 201000010099 disease Diseases 0.000 description 34
- 239000003921 oil Substances 0.000 description 34
- 235000019198 oils Nutrition 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 27
- 125000000304 alkynyl group Chemical group 0.000 description 26
- 206010012601 diabetes mellitus Diseases 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 25
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical class CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 241000124008 Mammalia Species 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 229920000642 polymer Polymers 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 230000002757 inflammatory effect Effects 0.000 description 20
- 102000003814 Interleukin-10 Human genes 0.000 description 19
- 108090000174 Interleukin-10 Proteins 0.000 description 19
- 208000008589 Obesity Diseases 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 19
- 230000004071 biological effect Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 235000020824 obesity Nutrition 0.000 description 19
- 230000002265 prevention Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 229910052711 selenium Inorganic materials 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 229940076144 interleukin-10 Drugs 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 125000005647 linker group Chemical group 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 150000003626 triacylglycerols Chemical class 0.000 description 17
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 16
- 201000004681 Psoriasis Diseases 0.000 description 16
- 208000027866 inflammatory disease Diseases 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 239000002243 precursor Substances 0.000 description 15
- 235000001508 sulfur Nutrition 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000004430 oxygen atom Chemical group O* 0.000 description 14
- 239000011593 sulfur Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 125000004122 cyclic group Chemical group 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000011669 selenium Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 12
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 11
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 125000004434 sulfur atom Chemical group 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 241000203069 Archaea Species 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 150000003905 phosphatidylinositols Chemical class 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 208000017520 skin disease Diseases 0.000 description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 208000031481 Pathologic Constriction Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 208000010706 fatty liver disease Diseases 0.000 description 9
- 229960005150 glycerol Drugs 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 230000036262 stenosis Effects 0.000 description 9
- 208000037804 stenosis Diseases 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 8
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 235000021323 fish oil Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000003466 anti-cipated effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 229940106189 ceramide Drugs 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 229960000367 inositol Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 125000000547 substituted alkyl group Chemical group 0.000 description 7
- 125000004426 substituted alkynyl group Chemical group 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 6
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 102000023984 PPAR alpha Human genes 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 0 [1*]OCC(COP(=O)([O-])O[3*])O[2*] Chemical compound [1*]OCC(COP(=O)([O-])O[3*])O[2*] 0.000 description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 6
- 201000008980 hyperinsulinism Diseases 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 125000005629 sialic acid group Chemical group 0.000 description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 241000206602 Eukaryota Species 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 235000019486 Sunflower oil Nutrition 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
- 229930183167 cerebroside Natural products 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 150000001982 diacylglycerols Chemical class 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 208000016097 disease of metabolism Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- 229940013317 fish oils Drugs 0.000 description 5
- 150000002270 gangliosides Chemical class 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
- 150000003408 sphingolipids Chemical class 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 241000617156 archaeon Species 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 4
- 229960002199 etretinate Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 150000002327 glycerophospholipids Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 150000002759 monoacylglycerols Chemical class 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 229940067626 phosphatidylinositols Drugs 0.000 description 4
- 150000008106 phosphatidylserines Chemical class 0.000 description 4
- 229920000962 poly(amidoamine) Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000011581 secondary neoplasm Diseases 0.000 description 4
- 229940001941 soy protein Drugs 0.000 description 4
- 150000003410 sphingosines Chemical group 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 3
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001784 cerebrosides Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004322 lipid homeostasis Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 229940042880 natural phospholipid Drugs 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 210000002824 peroxisome Anatomy 0.000 description 3
- 150000008103 phosphatidic acids Chemical class 0.000 description 3
- 239000010773 plant oil Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 206010043778 thyroiditis Diseases 0.000 description 3
- 229940125379 topical corticosteroid Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- NCMJSVDTRDLWJE-LUWBGTNYSA-N (1R,2R,3S,7R)-2-acetamido-7-[(1R)-1,2-dihydroxyethyl]-3-hydroxy-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid Chemical compound O1C2(C(O)=O)C[C@H](O)[C@@H](NC(C)=O)[C@]1([H])[C@@H]([C@H](O)CO)O2 NCMJSVDTRDLWJE-LUWBGTNYSA-N 0.000 description 2
- CBSKVDDQKSMPQJ-PGIATKPXSA-N (1R,2R,3S,7R)-7-[(1R)-1,2-dihydroxyethyl]-3-hydroxy-2-[(2-hydroxyacetyl)amino]-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid Chemical compound O1C2(C(O)=O)C[C@H](O)[C@@H](NC(=O)CO)[C@]1([H])[C@@H]([C@H](O)CO)O2 CBSKVDDQKSMPQJ-PGIATKPXSA-N 0.000 description 2
- RZRZZWVHNURYHU-RIZHGAQMSA-N (1R,2R,3S,7S)-3-hydroxy-2-[(2-hydroxyacetyl)amino]-7-[(1R)-2-hydroxy-1-methoxyethyl]-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid Chemical compound O1C2(C(O)=O)C[C@H](O)[C@@H](NC(=O)CO)[C@]1([H])[C@@H]([C@@H](CO)OC)O2 RZRZZWVHNURYHU-RIZHGAQMSA-N 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- UJZYBTQCNFXSTG-MTESWFDDSA-N (4S,5R,6R)-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1S,2R)-1,2,3-triacetyloxypropyl]oxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO UJZYBTQCNFXSTG-MTESWFDDSA-N 0.000 description 2
- XGWNWUZLPNFYOU-AKEWWUJNSA-N (4S,5R,6R)-4-acetyloxy-2-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound CC(=O)O[C@H]1CC(O)(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H]1NC(=O)CO XGWNWUZLPNFYOU-AKEWWUJNSA-N 0.000 description 2
- YCXFWJURAUFUBE-HGZSSABNSA-N (4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1S,2R)-1,2,3-triacetyloxypropyl]oxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O YCXFWJURAUFUBE-HGZSSABNSA-N 0.000 description 2
- JRMJOWSRMPCHEK-YKISKQTBSA-N (4S,5R,6R)-5-acetamido-3-acetyl-4-acetyloxy-6-[(1R,2R)-1,2-dihydroxy-3-(2-hydroxypropanoyloxy)propyl]-2-hydroxyoxane-2-carboxylic acid Chemical compound C(C)(=O)N[C@@H]1[C@H](C(C(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)COC(C(O)C)=O)C(C)=O)OC(C)=O JRMJOWSRMPCHEK-YKISKQTBSA-N 0.000 description 2
- LVBIMVQYUKOENY-OABCVWDLSA-N (4S,5R,6R)-5-acetamido-4-acetyloxy-2-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](OC(C)=O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO LVBIMVQYUKOENY-OABCVWDLSA-N 0.000 description 2
- RHMZYKJVBNTERT-IHWHIZQQSA-N (4S,5R,6R)-5-acetamido-4-acetyloxy-6-[(1R,2R)-3-acetyloxy-1,2-dihydroxypropyl]-2-hydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](OC(C)=O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)COC(C)=O RHMZYKJVBNTERT-IHWHIZQQSA-N 0.000 description 2
- NIHNZVQGPXTJRU-FPZNIPKMSA-N (4S,5R,6R)-5-acetamido-6-[(1R,2R)-1,3-diacetyloxy-2-hydroxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](OC(C)=O)[C@H](O)COC(C)=O NIHNZVQGPXTJRU-FPZNIPKMSA-N 0.000 description 2
- DUOKWMWKFGDUDQ-CHNADMEASA-N (4S,5R,6R)-5-acetamido-6-[(1R,2R)-1-acetyloxy-2,3-dihydroxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](OC(C)=O)[C@H](O)CO DUOKWMWKFGDUDQ-CHNADMEASA-N 0.000 description 2
- ZVAHXTZYENOSAX-PQYSTZNASA-N (4S,5R,6R)-5-acetamido-6-[(1S,2R)-1,3-dihydroxy-2-methoxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CO[C@H](CO)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(C)=O ZVAHXTZYENOSAX-PQYSTZNASA-N 0.000 description 2
- SNPUTPFDCJSSGZ-LUWBGTNYSA-N (4S,5R,6R)-5-acetamido-6-[(1S,2R)-1,3-dihydroxy-2-sulfooxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@@H](CO)OS(O)(=O)=O SNPUTPFDCJSSGZ-LUWBGTNYSA-N 0.000 description 2
- WJADSVJQCQMABK-FPZNIPKMSA-N (4S,5R,6R)-5-acetamido-6-[(1S,2R)-2,3-diacetyloxy-1-hydroxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@@H](COC(C)=O)OC(C)=O WJADSVJQCQMABK-FPZNIPKMSA-N 0.000 description 2
- PPOPOQUIFLBQOB-CHNADMEASA-N (4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-acetyloxy-1,3-dihydroxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@@H](CO)OC(C)=O PPOPOQUIFLBQOB-CHNADMEASA-N 0.000 description 2
- PDUISSOECWOIJO-MXGFJXJESA-N (4S,5R,6R)-5-acetamido-6-[(1S,2R)-3-acetyloxy-1-hydroxy-2-methoxypropyl]-2,4-dihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](OC)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(C)=O PDUISSOECWOIJO-MXGFJXJESA-N 0.000 description 2
- XIIYORNOQCMRQB-GSFIAQKXSA-N (4S,5R,6R)-6-[(1R,2R)-3-acetyloxy-1,2-dihydroxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO XIIYORNOQCMRQB-GSFIAQKXSA-N 0.000 description 2
- UYIAKSLBZCGVPJ-OXWSVYLXSA-N (4S,5R,6R)-6-[(1S,2R)-1,3-diacetyloxy-2-methoxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](OC)[C@@H](OC(C)=O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO UYIAKSLBZCGVPJ-OXWSVYLXSA-N 0.000 description 2
- OPLHZHKSIOUCED-RIZHGAQMSA-N (4S,5R,6R)-6-[(1S,2R)-1,3-dihydroxy-2-methoxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CO[C@H](CO)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO OPLHZHKSIOUCED-RIZHGAQMSA-N 0.000 description 2
- XMPHHNSDESVMCV-PGIATKPXSA-N (4S,5R,6R)-6-[(1S,2R)-1,3-dihydroxy-2-sulfooxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound OS(=O)(=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO XMPHHNSDESVMCV-PGIATKPXSA-N 0.000 description 2
- FIOUPKIHVYLEII-CIOHLJSHSA-N (4S,5R,6R)-6-[(1S,2R)-2,3-diacetyloxy-1-hydroxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FIOUPKIHVYLEII-CIOHLJSHSA-N 0.000 description 2
- SCXUTQAVGHNCLN-GSFIAQKXSA-N (4S,5R,6R)-6-[(1S,2R)-2-acetyloxy-1,3-dihydroxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CC(=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO SCXUTQAVGHNCLN-GSFIAQKXSA-N 0.000 description 2
- ABBDJSJISYCQAV-ALNOGQTASA-N (4S,5R,6R)-6-[(1S,2R)-3-acetyloxy-1-hydroxy-2-methoxypropyl]-2,4-dihydroxy-5-[(2-hydroxyacetyl)amino]oxane-2-carboxylic acid Chemical compound CC(=O)OC[C@@H](OC)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO ABBDJSJISYCQAV-ALNOGQTASA-N 0.000 description 2
- PRHHYVQTPBEDFE-URZBRJKDSA-N (5Z,11Z,14Z)-icosatrienoic acid Chemical group CCCCC\C=C/C\C=C/CCCC\C=C/CCCC(O)=O PRHHYVQTPBEDFE-URZBRJKDSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- 206010062269 Adrenalitis Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- NCEJQWMPDHJFNL-CIOHLJSHSA-N CC(=O)OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO Chemical compound CC(=O)OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO NCEJQWMPDHJFNL-CIOHLJSHSA-N 0.000 description 2
- KUFNJYKNJNJQDZ-GSFIAQKXSA-N CC(=O)O[C@H]([C@H](O)CO)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO Chemical compound CC(=O)O[C@H]([C@H](O)CO)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO KUFNJYKNJNJQDZ-GSFIAQKXSA-N 0.000 description 2
- QSCCNEGLUYZVIO-CYBLOHLKSA-N CC(O)C(=O)OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO Chemical compound CC(O)C(=O)OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO QSCCNEGLUYZVIO-CYBLOHLKSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- NYWZBRWKDRMPAS-GRRZBWEESA-N N-acetyl-9-O-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)COC(C)=O NYWZBRWKDRMPAS-GRRZBWEESA-N 0.000 description 2
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010044210 PPAR-beta Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Chemical group 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Chemical group 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002313 glycerolipids Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000019171 interleukin-1 alpha production Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 238000007915 intraurethral administration Methods 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 208000001875 irritant dermatitis Diseases 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 201000005737 orchitis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 150000003019 phosphosphingolipids Chemical class 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- XLEMXJYQHRAPGY-HRGJGHNTSA-N *.C.CCC#CCCCCCCCCCCSCC(=O)O.CCCCCCC/C=C\CCCCCSCC(=O)O.CCCCCCCCCCCCCCSCC(=O)O.[3H][3H] Chemical compound *.C.CCC#CCCCCCCCCCCSCC(=O)O.CCCCCCC/C=C\CCCCCSCC(=O)O.CCCCCCCCCCCCCCSCC(=O)O.[3H][3H] XLEMXJYQHRAPGY-HRGJGHNTSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- VZNVUJNOJIDOAP-UHFFFAOYSA-N 14-ethylsulfanyltetradec-2-yne Chemical compound CCSCCCCCCCCCCCC#CC VZNVUJNOJIDOAP-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- ISDBCJSGCHUHFI-UMZPFTBHSA-N 2,3-di-O-phytanyl-sn-glycerol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCOC[C@@H](CO)OCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C ISDBCJSGCHUHFI-UMZPFTBHSA-N 0.000 description 1
- GGVPLFORRSOVIZ-UHFFFAOYSA-N 2-(dimethylamino)pentane-1,1,1,2-tetrol Chemical group CCCC(O)(N(C)C)C(O)(O)O GGVPLFORRSOVIZ-UHFFFAOYSA-N 0.000 description 1
- ZXHTVCPSKYJRAJ-UHFFFAOYSA-N 2-amino-5,5-dimethylhexane-1,1,1,2-tetrol Chemical group CC(CCC(C(O)(O)O)(O)N)(C)C ZXHTVCPSKYJRAJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- OINNEUNVOZHBOX-QIRCYJPOSA-N 2-trans,6-trans,10-trans-geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-QIRCYJPOSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- HQKAXDOJQRNAJF-UHFFFAOYSA-N CC(=O)C(C(C)=O)C(C)=O.CC(=O)[W]CC(C[W]C(C)=O)C[W]C(C)=O Chemical compound CC(=O)C(C(C)=O)C(C)=O.CC(=O)[W]CC(C[W]C(C)=O)C[W]C(C)=O HQKAXDOJQRNAJF-UHFFFAOYSA-N 0.000 description 1
- LJJSFYAGUSASJM-UHFFFAOYSA-N CC(=O)CC(C)=O.CC(=O)[W]CCC[W]C(C)=O Chemical compound CC(=O)CC(C)=O.CC(=O)[W]CCC[W]C(C)=O LJJSFYAGUSASJM-UHFFFAOYSA-N 0.000 description 1
- RAZNUOQCFVOSBY-YBYZZUHXSA-M CC(=O)OCC(CO)OC(C)=O.CC(=O)OCC(COC(C)=O)OC(C)=O.CC(=O)OCC(O)CO.CC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C.CC(=O)OC[C@H](COP(=O)(O)O)OC(C)=O.CC(=O)OC[C@H](COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-])OC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)NC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)=O.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O Chemical compound CC(=O)OCC(CO)OC(C)=O.CC(=O)OCC(COC(C)=O)OC(C)=O.CC(=O)OCC(O)CO.CC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C.CC(=O)OC[C@H](COP(=O)(O)O)OC(C)=O.CC(=O)OC[C@H](COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-])OC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)NC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)=O.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O RAZNUOQCFVOSBY-YBYZZUHXSA-M 0.000 description 1
- FINKRHFEXJQWKT-XQGRADOOSA-N CC(=O)OCC(COC(C)=O)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)=O.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O Chemical compound CC(=O)OCC(COC(C)=O)OC(C)=O.CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)=O.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O FINKRHFEXJQWKT-XQGRADOOSA-N 0.000 description 1
- VFAAXWLUTNICOV-UHFFFAOYSA-N CC(C)=O.CC[W]C(C)=O Chemical compound CC(C)=O.CC[W]C(C)=O VFAAXWLUTNICOV-UHFFFAOYSA-N 0.000 description 1
- KLWXPMQIKRJIRO-JJEOLRLVSA-L CC(C)CC(CC(C)C)C(C)C.CC(C)CC(CO)C(C)C.CC(C)CC(O)CO.CC(C)COP(=O)(O)O.CC(C)COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O.CC(C)COP(=O)([O-])OCCN(C)(C)C.CC(C)COP(=O)([O-])OCC[N+](C)(C)C.CC(C)COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-].CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)C(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)C(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)C(C)C.[H][N+]([H])([H])CCOP(=O)([O-])OCC(C)C Chemical compound CC(C)CC(CC(C)C)C(C)C.CC(C)CC(CO)C(C)C.CC(C)CC(O)CO.CC(C)COP(=O)(O)O.CC(C)COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O.CC(C)COP(=O)([O-])OCCN(C)(C)C.CC(C)COP(=O)([O-])OCC[N+](C)(C)C.CC(C)COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-].CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)C(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)C(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)C(C)C.[H][N+]([H])([H])CCOP(=O)([O-])OCC(C)C KLWXPMQIKRJIRO-JJEOLRLVSA-L 0.000 description 1
- KDDNLWPMQXAXGZ-GJBHSWICSA-M CC(C)OCC(CO)OC(C)C.CC(C)OCC(COC(C)C)OC(C)C.CC(C)OCC(O)CO.CC(C)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C.CC(C)OC[C@H](COP(=O)(O)O)OC(C)C.CC(C)OC[C@H](COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O)OC(C)C.CC(C)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)C.CC(C)OC[C@H](COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-])OC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)NC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)C.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)C)OC(C)C Chemical compound CC(C)OCC(CO)OC(C)C.CC(C)OCC(COC(C)C)OC(C)C.CC(C)OCC(O)CO.CC(C)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C.CC(C)OC[C@H](COP(=O)(O)O)OC(C)C.CC(C)OC[C@H](COP(=O)(O)OC1C(O)C(O)C(O)C(O)C1O)OC(C)C.CC(C)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)C.CC(C)OC[C@H](COP(=O)([O-])O[C@H]([NH3+])C(=O)[O-])OC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CC)NC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)C.CCCCCCCCCCCCCCC[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)C.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(C)C)OC(C)C KDDNLWPMQXAXGZ-GJBHSWICSA-M 0.000 description 1
- BKICBCVRTYZWEG-UHFFFAOYSA-N CC(C)OCC(COC(C)C)OC(C)C Chemical compound CC(C)OCC(COC(C)C)OC(C)C BKICBCVRTYZWEG-UHFFFAOYSA-N 0.000 description 1
- ZDYWPVCQPUPOJV-UHFFFAOYSA-N CCCC(=O)CC(=O)CCC Chemical compound CCCC(=O)CC(=O)CCC ZDYWPVCQPUPOJV-UHFFFAOYSA-N 0.000 description 1
- OIXHGHLAGSTINZ-NSHDSACASA-N CCCC(=O)OC[C@H](COC(=O)CC)OC(=O)CCC Chemical compound CCCC(=O)OC[C@H](COC(=O)CC)OC(=O)CCC OIXHGHLAGSTINZ-NSHDSACASA-N 0.000 description 1
- ANSOERKHHMOUOU-ITMPLDIFSA-N CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(=O)CCC)OC(=O)CCC Chemical compound CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC.[H][N+]([H])([H])CCOP(=O)([O-])OC[C@@H](COC(=O)CCC)OC(=O)CCC ANSOERKHHMOUOU-ITMPLDIFSA-N 0.000 description 1
- LUQGQZIVDLUXLE-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(O)=[Se] Chemical group CCCCCCCCCCCCCCCC(O)=[Se] LUQGQZIVDLUXLE-UHFFFAOYSA-N 0.000 description 1
- HXVFWJAWDQTACA-UHFFFAOYSA-N CC[W]C(C)=O Chemical compound CC[W]C(C)=O HXVFWJAWDQTACA-UHFFFAOYSA-N 0.000 description 1
- JIVNOZANEZPNAC-UHFFFAOYSA-N CSCC(=O)CC(=O)CSC Chemical compound CSCC(=O)CC(=O)CSC JIVNOZANEZPNAC-UHFFFAOYSA-N 0.000 description 1
- YIPAVMITUXKJDU-UHFFFAOYSA-N CSCC(=O)OCOC(=O)CSC Chemical compound CSCC(=O)OCOC(=O)CSC YIPAVMITUXKJDU-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 101710116898 Digeranylgeranylglyceryl phosphate synthase Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 201000001498 Froelich syndrome Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 101710195364 Glycerol-1-phosphate dehydrogenase [NAD(P)+] Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010048649 Koebner phenomenon Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010028624 Phosphoglycerol geranylgeranyltransferase Proteins 0.000 description 1
- 206010063985 Phytosterolaemia Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 208000002227 Sitosterolemia Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ISDBCJSGCHUHFI-UHFFFAOYSA-N archaeol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CCOCC(CO)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C ISDBCJSGCHUHFI-UHFFFAOYSA-N 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000004954 endothelial membrane Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 235000021235 fat-rich diet Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000003128 glycerophosphate group Chemical group 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical class O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229930000756 phytoceramide Natural products 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010485 smooth muscle tumor Diseases 0.000 description 1
- AWUCVROLDVIAJX-VKHMYHEASA-L sn-glycerol 1-phosphate(2-) Chemical compound OC[C@H](O)COP([O-])([O-])=O AWUCVROLDVIAJX-VKHMYHEASA-L 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000006491 synthase reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- fatty acid analogues are produced that are not catabolized by ⁇ -oxidation.
- European Patent Specification No. 0345038 described the preparation of non- ⁇ -oxidizable fatty acid analogues having the general formula
- Alkyl represents a saturated or unsaturated hydrocarbon group of from 8 to 22 carbon atoms
- X represents O, S, SO, and SO 2
- R represents hydrogen or a C 1 -C 4 alkyl.
- these compounds comprise one or several X groups (e.g., selenium or sulfur) at positions 3, 5, 7, 9, etc.
- the compounds Due to the X atom (e.g., sulfur or selenium) that is substituted in the carbon chain of these fatty acid analogues, the compounds are not ⁇ -oxidized in the mitochondria beyond the position of the X atom. Thus, the degradation of these molecules must start from the methyl end of the fatty acid, which is a rather slow metabolic process.
- the catabolism of these fatty acid analogues includes ⁇ -oxidation and chain shortening of the dicarboxylic acid by peroxisomes. Enzymes in the endoplasmic reticulum ⁇ -hydroxylate and further oxidize the hydroxylated fatty acid to a dicarboxylic acid. This acid may then be chain shortened by ⁇ -oxidation in the peroxisomes.
- non- ⁇ -oxidizable fatty acid analogues provide particular beneficial activities, for example, to treat and/or prevent obesity (NO 2000 5461); diabetes (NO 2000 5462); primary and secondary stenosis (NO 2000 5463); cancer (NO 2002 5930); proliferate skin disorders (NO 2003 1080); and inflammatory and autoimmune disorders (NO 2003 2054).
- WO/1999/058123 WO/2001/N000301, WO/2001/N000393, and WO/2001/N000470
- embodiments of the technology relate to providing a non- ⁇ -oxidizable fatty acid analogue as a nutrient to a living organism (e.g., a yeast, a bacterium, an alga, an archaeon, etc.) that produces a phospholipid incorporating the non- ⁇ -oxidizable fatty acid analogue and then isolating the phospholipid containing the non- ⁇ -oxidizable fatty acid analogue from the living organism.
- a living organism e.g., a yeast, a bacterium, an alga, an archaeon, etc.
- the technology also encompasses embodiments related to compositions comprising a phospholipid incorporating the non- ⁇ -oxidizable fatty acid analogue and uses of such compositions.
- the present invention provides composition comprising a natural lipid and a natural biomolecule, wherein the natural lipid comprises a non-beta-oxidizable fatty acid analogue.
- the natural biomolecule is a second lipid.
- the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film.
- the non-beta-oxidizable fatty acid analogue is tetradecylthioacetic acid (TTA).
- TSA tetradecylselenoacetic acid
- the natural lipid is a phospholipid. In some embodiments, the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a headgroup. In some embodiments, the natural lipid has a biological activity in a mammal. In some embodiments, the biomolecule has a biological activity in a mammal. In some embodiments, the natural lipid is a sphingolipid.
- the biomolecule is a protein, nucleic acid, steroid, cofactor, or vitamin.
- the natural lipid is an omega-3 fatty acid moiety.
- the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA.
- the natural lipid is an omega-6 fatty acid moiety.
- the natural lipid is a conjugated linoleic acid moiety.
- the present invention provides a composition comprising a natural lipid, the composition obtainable by a process comprising the steps of: 1) providing a biologically active biomolecule to a living organism in vitro; and 2) isolating the composition comprising the natural lipid from the living organism.
- the biologically active biomolecule is a non-beta-oxidizable fatty acid analogue.
- the biologically active biomolecule is TTA or a furan fatty acid.
- the lipid comprises a non-beta-oxidizable fatty acid analogue.
- the lipid comprises TTA or a furan fatty acid.
- the living organism is an alga.
- the living organism is a bacterium or an archaeon. In some embodiments, the living organism is a yeast. In some embodiments, the process further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a second living organism. In some embodiments, the process further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a marine organism. In some embodiments, the compositions further comprise a second biomolecule. In some embodiments, the second biomolecule is a lipid, protein, nucleic acid, steroid, cofactor, or vitamin. In some embodiments, the living organism is in a culture.
- the culture comprises a plurality of living organisms, wherein each living organism is characterized by a type and the culture comprises a plurality of the types.
- the type is a species, subspecies, isolate, clone, genus, family, division, kingdom, or other taxonomic classification.
- the living organism is a thermophile.
- the second living organism is a thermophile.
- the TTA is produced by reacting thioglycolic acid with bromotetradecane.
- the TTA is produced by a method comprising dissolving sodium hydroxide in methanol to produce a reaction solution, adding thioglycolic acid to the reaction solution, adding 1-bromotetradecane to the reaction solution, adding citric acid to the reaction solution, and isolating TTA from the reaction solution.
- the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film.
- the natural lipid is a phospholipid.
- the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a headgroup. In some embodiments, the natural lipid has a biological activity in a mammal. In some embodiments, the second biomolecule has a biological activity in a mammal. In some embodiments, the natural lipid is a sphingolipid. In some embodiments, the natural lipid further comprises an omega-3 fatty acid moiety.
- the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA.
- the natural lipid further comprises an omega-6 fatty acid moiety.
- the natural lipid further comprises a conjugated linoleic acid moiety.
- the present invention provides methods for producing a composition comprising a natural lipid, the method comprising: 1) providing a biologically active biomolecule to a living organism in vitro; and 2) isolating the composition comprising the natural lipid from the living organism.
- the biologically active biomolecule is a non-beta-oxidizable fatty acid analogue.
- the biologically active biomolecule is TTA.
- the natural lipid comprises a non-beta-oxidizable fatty acid analogue.
- the natural lipid comprises TTA.
- the living organism is an alga. In some embodiments, the living organism is a bacterium or an archaeon.
- the living organism is a yeast.
- the method further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a second living organism.
- the method further comprise producing an extract, fraction, or composition comprising the biologically active molecule from a marine organism.
- the composition comprising the natural lipid further comprises a second biomolecule.
- the second biomolecule is a lipid, protein, nucleic acid, steroid, cofactor, or vitamin.
- the living organism is in a culture.
- the culture comprises a plurality of living organisms, wherein each living organism is characterized by a type and the culture comprises a plurality of the types.
- the type is a species, subspecies, isolate, clone, genus, family, division, kingdom, or other taxonomic classification.
- the living organism is a thermophile.
- the second living organism is a thermophile.
- the TTA is produced by reacting thioglycolic acid with bromotetradecane.
- the TTA is produced by a method comprising dissolving sodium hydroxide in methanol to produce a reaction solution, adding thioglycolic acid to the reaction solution, adding 1-bromotetradecane to the reaction solution, adding citric acid to the reaction solution, and isolating TTA from the reaction solution.
- the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film.
- the natural lipid is a phospholipid.
- the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup.
- the natural lipid comprises an ether link between a lipid tail and a headgroup.
- natural lipid has a biological activity in a mammal.
- the biomolecule has a biological activity in a mammal.
- the natural lipid is a sphingolipid.
- the methods further comprise
- the natural lipid further comprises an omega-3 fatty acid moiety.
- the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA.
- the natural lipid further comprises an omega-6 fatty acid moiety.
- the natural lipid further comprises a conjugated linoleic acid moiety.
- the present invention provides structured phospholipid compositions comprising phospholipid molecules of the following structure:
- R1 and R2 are non-beta-oxidizable fatty acid analogue moiety and the other of R1 and R2 is a bioactive fatty acid moiety selected from the group consisting of an omega-3 fatty acid moiety, on omega-6 fatty acid moiety, a polyunsaturated fatty acid moiety, a conjugated linoleic fatty acid moiety, and combinations thereof.
- the composition comprises greater than 10%, 20%, 30%, 40%, 50%, 80%, 90% or 99% on a molar basis of the non-beta-oxidizable fatty acid analogue moiety at position R1.
- the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of the non-beta-oxidizable fatty acid analogue moiety at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of the bioactive fatty acid moieties or combinations thereof at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of the bioactive fatty acid moiety at position R1.
- the bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof. In some embodiments, the bioactive fatty acid moiety is EPA. In some embodiments, the bioactive fatty acid moiety is DHA. In some embodiments, the bioactive fatty acid moiety is conjugated linoleic acid.
- the present invention provides for the use of a composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a medicament.
- the present invention provides for the use of a composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a food product.
- the food product has a biological activity in a human.
- the present invention provides for the use of a composition for ameliorating a metabolic disease in a subject, the composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue or a furan fatty acid.
- the non-beta-oxidizable fatty acid analogue is TTA.
- the present invention provides for the use of a composition comprising a lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a medicament to treat a disease.
- the disease is a metabolic disease.
- the metabolic disease is obesity, diabetes, hypercholesterolemia, hyperlipidemia, glucose intolerance, aberrant adipose tissue storage and/or distribution, syndrome X, hypertension, fatty liver, hyperglycemia, hyperinsulinemia, or stenosis.
- the disease is cancer, vascular disease, skin condition, or an inflammatory disorder.
- the present invention provides a combination comprising a liposome and a composition as described above.
- a cosmetic formulation comprising a lipid composition as described above.
- the present invention provides methods of treating a condition chosen from syndrome X, obesity or an overweight condition, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia, insulin resistance, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia (HTG), and stenosis, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the method provides for producing weight loss or a reduction of fat mass in a human or non-human animal in need thereof.
- the present invention provides methods for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods of lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for the modification of the fat distribution and content of animals, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods of inhibiting the growth of tumors, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for the treatment or inhibition of primary and secondary metastatic neoplasms, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for the treatment of proliferative skin disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for the inhibition of proliferation or induction of differentiation of keratinocytes, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- IL-10 interleukin-10
- the present invention provides methods for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- IL-2 interleukin-2
- the present invention provides methods for the inhibition of proliferation of stimulated peripheral mononuclear cells (PBMC), comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- PBMC peripheral mononuclear cells
- the present invention provides a pharmaceutical composition comprising a natural lipid as described above, a natural biomolecule, and a pharmaceutically acceptable carrier.
- the present invention provides a pharmaceutical composition comprising a structured phospholipid as described above.
- the natural lipid comprises TTA or a furan fatty acid.
- the natural lipid comprises an ether link between a lipid tail and a lipid headgroup.
- the pharmaceutical composition is admixed with at least one of a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.
- the pharmaceutical composition is topically administrable.
- the pharmaceutical composition is parenterally administrable.
- the pharmaceutical composition is intravenously administrable.
- the present invention provides a composition comprising a physiologically effective amount of TTA or a derivative thereof, the composition characterized in by a substantial lack of side effects when administered to a human subject, the side effects selected from the group consisting of lethargy, muscle cramps, and muscle pain.
- the physiologically effective amount is from about 10 mg to 5 g TTA.
- the physiologically effective amount is from about 100 mg to 3 g TTA.
- the substantial lack of side effects is characterized by the presence of the side effects in less than 5% of a population.
- the substantial lack of side effects is characterized by the presence of the side effects in less than 1% of a population.
- the composition comprises at least one fatty acid in addition to the TTA or a derivative thereof.
- the derivative of TTA is an ester, triglyceride, or phospholipid comprising a TTA moiety.
- the composition is produced by distilling 1-bromotetradecane to remove contaminants and provide distilled 1-bromotetradecane, and reacting the distilled 1-bromotetradecane with a chemical moiety to provide TTA.
- the lipid compositions described above may be used in combination with one or more sialic acid analogs.
- sialic acid analogs include sialic acids and sialic acid precursors.
- sialic acids or sialic acid precursors are selected from the group consisting of n-glycolylneuraminic acid, n-acetylneuraminic acid and N-Acetyl-D-mannosamine.
- the composition may comprise two or more of the following sialic acids: Neuraminic acid, 5-N-Acetyl-4-O-acetyl-neuraminic acid, 5-N-Acetyl-7-O-acetyl-neuraminic acid, 5-N-Acetyl-8-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-neuraminic acid, 5-N-Acetyl-4,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-8,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,8,9-tri-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-L-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-7
- compositions may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sialic acid analogs.
- sialic acid analogs have a purity selected from the group consisting of greater than 90%, 95%, 99%, and 99.5% pure.
- the sialic acid precursor may be co-formulated in the same delivery vehicle as the lipid composition, or may be provided in a separated delivery vehicle.
- the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day.
- the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 0.1 to 10 mg/150 kg subject/day, 0.3 to 5 mg/150 kg subject/day, and 0.5 to 2 mg/150 kg subject/day.
- the administering is selected from the group consisting of enteral administration, parenteral administration, oral administration, sublingual administration, subcutaneous administration, intramuscular administration, and intravenous administration.
- the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise.
- the term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise.
- the meaning of “a”, “an”, and “the” include plural references.
- the meaning of “in” includes “in” and “on.”
- feeding refers to providing a substance, compound, composition, etc. to a living organism.
- the substance, compound, composition, etc. may be an energy source, a carbon source, a nutrient, or a source of other elements, molecules, and/or precursors of biological molecules that are used by the living organism and/or are metabolized (e.g., catabolized, anabolized) by the living organism.
- the substance, compound, composition, etc. is not necessarily a substance, compound, composition, etc. that the living organism encounters in its native milieu, but may be a synthetic substance, compound, composition, etc. or a natural substance, compound, composition, etc. that is nevertheless used by the living organism for metabolism.
- the substance, compound, composition, etc. may be added to a culture medium or a substrate in which or on which the living organism lives and/or grows.
- active or “activity” refers to native or naturally occurring biological and/or immunological activity.
- in vitro refers to an artificial environment and to processes or reactions that occur within an artificial environment.
- in vitro environments may include, but are not limited to, test tubes and cell cultures.
- in vivo refers to the natural environment (e.g., an animal or a cell) and to processes or reactions that occur within a natural environment.
- the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g., a human with a disease such as obesity, diabetes, or insulin resistance).
- the term “individual” refers to vertebrates, particularly members of the mammalian species. The term includes but is not limited to domestic animals, sports animals, primates, and humans.
- an effective amount refers to the amount of a composition sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
- the term “administration” refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment to a subject.
- exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (transdermal, topical), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.), and the like.
- co-administration refers to the administration of at least two agents or therapies to a subject. In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy.
- a first agent/therapy is administered prior to a second agent/therapy.
- the appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent.
- composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for therapeutic use.
- compositions that do not substantially produce adverse reactions, e.g., toxic, allergic, or immunological reactions, when administered to a subject.
- the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a disease or disorder through introducing in any way a therapeutic composition of the present technology into or onto the body of a subject.
- Treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
- Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
- sample is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like. Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples. Such examples are not however to be construed as limiting the sample types applicable to the present technology.
- alkyl and the prefix “alk-” are inclusive of both straight chain and branched chain saturated or unsaturated groups, and of cyclic groups, e.g., cycloalkyl and cycloalkenyl groups. Unless otherwise specified, acyclic alkyl groups are from 1 to 6 carbons. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 8 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl, and adamantyl groups. Alkyl groups may be substituted with one or more substituents or unsubstituted.
- substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halogen, alkylsilyl, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- alk the number of carbons contained in the alkyl chain is given by the range that directly precedes this term, with the number of carbons contained in the remainder of the group that includes this prefix defined elsewhere herein.
- C 1 -C 4 alkaryl exemplifies an aryl group of from 6 to 18 carbons (e.g., see below) attached to an alkyl group of from 1 to 4 carbons.
- aryl refers to a carbocyclic aromatic ring or ring system. Unless otherwise specified, aryl groups are from 6 to 18 carbons. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl, and indenyl groups.
- heteroaryl refers to an aromatic ring or ring system that contains at least one ring heteroatom (e.g., O, S, Se, N, or P). Unless otherwise specified, heteroaryl groups are from 1 to 9 carbons.
- Heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, oxatriazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazyl, triazyl, benzofuranyl, isobenzofuranyl, benzothienyl, indole, indazolyl, indolizinyl, benzisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphtyridinyl, phthalazinyl, phenanthrolinyl, purinyl, and carbazolyl groups.
- heterocycle refers to a non-aromatic ring or ring system that contains at least one ring heteroatom (e.g., O, S, Se, N, or P). Unless otherwise specified, heterocyclic groups are from 2 to 9 carbons. Heterocyclic groups include, for example, dihydropyrrolyl, tetrahydropyrrolyl, piperazinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophene, tetrahydrothiophene, and morpholinyl groups.
- Aryl, heteroaryl, or heterocyclic groups may be unsubstituted or substituted by one or more substituents selected from the group consisting of C 1-6 alkyl, hydroxy, halo, nitro, C 1-6 alkoxy, C 1-6 alkylthio, trifluoromethyl, C 1-6 acyl, arylcarbonyl, heteroarylcarbonyl, nitrile, C 1-6 alkoxycarbonyl, alkaryl (where the alkyl group has from 1 to 4 carbon atoms), and alkheteroaryl (where the alkyl group has from 1 to 4 carbon atoms).
- alkoxy refers to a chemical substituent of the formula —OR, where R is an alkyl group.
- aryloxy is meant a chemical substituent of the formula —OR′, where R′ is an aryl group.
- C x-y alkaryl refers to a chemical substituent of formula —RR′, where R is an alkyl group of x to y carbons and R′ is an aryl group as defined elsewhere herein.
- C x-y alkheteraryl refers to a chemical substituent of formula RR′′, where R is an alkyl group of x to y carbons and R′′ is a heteroaryl group as defined elsewhere herein.
- halide or “halogen” or “halo” refers to bromine, chlorine, iodine, or fluorine.
- non-vicinal O, S, or N refers to an oxygen, sulfur, or nitrogen heteroatom substituent in a linkage, where the heteroatom substituent does not form a bond to a saturated carbon that is bonded to another heteroatom.
- the compounds according to the technology are analogues of naturally occurring compounds and as such are recognized by the same systems that process the natural compounds, including the enzymes that ⁇ - and in some cases ⁇ -oxidize natural long chain fatty acids.
- the analogues differ from their naturally occurring counterparts in that they cannot be completely oxidized in this manner.
- the compounds according to the technology comprise non- ⁇ -oxidizable fa acid analogues as represented by the formula
- X is a sulfur atom, a selenium atom, an oxygen atom, a CH 2 group, a SO group, or a SO 2 group
- n is an integer of 0 to 11
- R′ is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of the R′ contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH 2 group, a SO group, and a SO 2 group
- R′′ is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms.
- Embodiments of the technology relate to phospholipids comprising a non- ⁇ -oxidizable fatty acid analogues. That is, in some embodiments the compounds are structures derived from one or more of said non- ⁇ -oxidizable fatty acid analogues, as represented by the general formulae I or II
- R1, R2, and R3 represent:
- These compounds are analogues of naturally occurring monoacylglycerols, diacylglycerols, or triacylglycerols; or phospholipids including phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, and diphosphatidyl glycerol.
- Said compounds may also comprise a substitution in the glycerol backbone, as shown in formula II. Said substitution of the oxygen(s) is achieved by replacing the oxygen(s) with sulfur or a nitrogen containing group. This may block hydrolysis before uptake by the intestines, thus increasing the bioavailability of the compounds.
- These structures derived from one or more non- ⁇ -oxidizable fatty acid entities have their effect because the fatty acid analogues are not capable of being fully ⁇ -oxidized.
- the structures may have an effect as complete structures and/or as naturally resulting degradation products comprising the fatty acid analogues. Because the compounds are not fully ⁇ -oxidized, they will build up and trigger an increase in the ⁇ -oxidation of naturally occurring fatty acids. Many of the effects of the compounds according to the technology relate to this increase in ⁇ -oxidation.
- ⁇ -oxidation a fatty acid is enzymatically cleaved between carbons 2 and 3 (relative to the carboxylic end of the fatty acid), resulting in the removal of two carbon atoms as acetic acid. This step is then repeated on the resulting shorter fatty acid and repeated again until the fatty acid is fully oxidized.
- ⁇ -oxidation is the usual way in which the majority of fatty acids is catabolized in vivo.
- the compounds according to the technology block ⁇ -oxidation due to the presence of a non-oxidizable group (e.g., S, O, SO, SO 2 , CH 2 or Se) in the X position in the structural formula of the present technology. These compounds all block ⁇ -oxidation in the same manner.
- a non-oxidizable group e.g., S, O, SO, SO 2 , CH 2 or Se
- the compounds may contain more than one block.
- the R′ comprising X may also optionally comprise one or more additional heterogroups selected from the group comprising an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH 2 group, a SO group, and a SO 2 group.
- one may insert two or three sulfurs as X to induce a change in the degradation of the fatty acid and thus provide a modulated effect
- Multiple sulfur atoms would also modulate the polarity and stability. From a pharmacological viewpoint, it is generally desirable to present a spectrum of compounds rather than just one single compound to avoid or counteract problems with resistance.
- Embodiments of the technology define not only the identity of X, but also the position of X.
- the distance of X from the carboxylic end of the fatty acid is defined by how many CH 2 groups are positioned between X and the carboxylic end of the fatty acid, which is defined by (CH 2 ) 2+1 , where n is an integer from 0 to 11.
- CH 2 CH 2
- n an integer from 0 to 11.
- CH 2 groups there is an odd number of CH 2 groups; that is, the position of X relative to the carboxyl group is such that X blocks ⁇ -oxidation.
- the range of n is chosen to include all variations of the fatty acid analogue that have the desired biological effect. Since ⁇ -oxidation in theory can work on infinitely long molecules, n could be infinite, but in practice this is not so.
- fatty acids that normally undergo ⁇ -oxidation are usually 14 to 24 carbon atoms long, and this length is therefore most ideal for undergoing enzymatic ⁇ -oxidation.
- the ranges of n and R′ are thus given so that the fatty acid analogues cover this range.
- option ii of formulae I and II defines R to have from 1 to 25 carbon groups
- option i of formula II defines the alkyl group to contain from 1 to 23 carbon atoms to be analogous to naturally occurring compounds.
- the total number of carbon atoms in the fatty acid backbone is approximately between 8 and 30, e.g., in some embodiments between 12 and 26. This size range is also desirable for the uptake and transport through cell membranes of the fatty acid analogues described.
- fatty acid analogues as described with a block in the X position cannot undergo ⁇ -oxidation, they may still undergo ⁇ -oxidation.
- R′ methyl/hydrophobic head group
- the carbon atom at the ⁇ -end of the fatty acid is hydroxylated by a member of the cytochrome P450 enzyme family.
- This hydroxylated fatty acid is then converted into an aldehyde by an alcohol dehydrogenase, and subsequently this aldehyde is converted into a carboxyl group by an aldehyde dehydrogenase.
- the final product of the pathway is a dicarboxylic fatty acid, which can be degraded further by ⁇ -oxidation from the ⁇ -end.
- ⁇ -oxidation is believed to be the main pathway for degradation of the fatty acid analogues as described with a block in the X position.
- this modification resulted in the fatty acid analogue 3-thia-15-heptadecyne, which when tested showed a substantially increased degradation time in vivo.
- this modification finds use in embodiments of the technology to potentiate the effects of the ⁇ -oxidizable fa acid analogues by further slowing down their breakdown.
- fatty acid analogues comprising a double bond are also included in the definition of the methyl/hydrophobic head group end of the molecule, here termed R′. That is, it may be saturated or unsaturated.
- R′ is also defined as linear or branched.
- lipids e.g., monoglycerides, diglycerides, triglycerides, and/or phospholipids
- incorporating fatty acid analogues in naturally occurring lipids may also increase the bioavailability or stability.
- some embodiments of the technology relate to a triacylglycerol that includes a fatty acid that is not capable of being ⁇ -oxidized.
- a triacylglycerol that includes a fatty acid that is not capable of being ⁇ -oxidized.
- Such compounds are encompassed by formulas I and II. If such a triacylglycerol were taken orally, for instance in an animal food product, it would probably be transported like any triacylglycerol, e.g., from the small intestine in chylomicrons to the liver; then to the blood in lipoproteins to be stored in the adipose tissue or used by muscles, heart, or the liver; then by hydrolysis of the triacylglycerol into glycerol and three free fatty acids. The free fatty acids would at this point be the fatty acid analogue parent compound.
- Embodiments also encompass glycerophospholipid derivatives of the fatty acid analogues that block ⁇ -oxidation, including, but not limited to, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylserines, and phosphatidylglycerols.
- Additional embodiments include polar complexes such as, but not limited to, lysophospholipids, phosphatidic acids, alkoxy compounds, glycerocarbohydrates, gangliosides, and cerebrosides.
- polar complexes such as, but not limited to, lysophospholipids, phosphatidic acids, alkoxy compounds, glycerocarbohydrates, gangliosides, and cerebrosides.
- a non- ⁇ -oxidizable fatty acid analogue is incorporated into an archaeal phospholipid (e.g., as produced by members of the Archaea).
- the archaeal lipids are analogous to glycerolipids from Bacteria and Eukaryotes, but have some distinguishing features.
- archaeal lipids generally comprise a core lipid (e.g., archaeol or caldarchaeal) and polar head groups or glycosides that are linked to one of the core lipids.
- portions of archaeal lipid biosynthetic pathways e.g., genes encoding archaeal G-1-P dehydrogenase, GGPP synthase, GGGP synthase, and DGGGP synthase
- portions of archaeal lipid biosynthetic pathways have been reconstituted in Escherichia coli , thus providing a manipulable and tractable system for the production and isolation of archaeal lipids in a bacterium. See, e.g., Yokoi, et al. (2012), “Archaeal Phospholipid Biosynthetic Pathway Reconstructed in Escherichia coli ”, Archaea 2012.
- the technology relates to phospholipids, phospholipid derivatives, triacylglycerides (TAGs), and non-natural lipids, e.g., for use in therapeutic applications.
- these lipids and phospholipids incorporate the known sulfur fatty acid, tetradecylthioacetic acid (TTA) as well as its unsaturated analogues, dTTA and tTTA.
- Tetradecylthioacetic acid (TTA) is a fatty acid analogue of the technology according to formula I having a structure, in some embodiments, as shown below.
- TTA has properties very similar to natural fatty acids, it cannot be oxidized by mitochondrial ⁇ -oxidation. Importantly, though, TTA significantly increases the oxidation of other fatty acids. Finally, despite the fact that TTA is not catabolized by ⁇ -oxidation, it is metabolized in most ways as a normal saturated fatty acid. For example, it is incorporated into phospholipids.
- non- ⁇ -oxidizable fatty acid entities such as TTA modulate biological phospholipid levels, both alone and in compositions comprising various plant oil and/or fish oils.
- sunflower and/or fish oil in combination with TTA reduce phospholipid levels more than either TTA or the oils alone.
- soy oil and olive oil alone cause an increase in phospholipid levels
- these oils substantially potentiated the ability of TTA to decrease phospholipid levels.
- soy oil alone increased phospholipid levels by 10%, but a composition comprising both TTA and soy oil lowered phospholipid levels by an additional 40% compared to TTA alone. See, e.g., U.S. Pat. Appl. Pub. No. 2007009608.
- non ⁇ -oxidizable fatty acid entities such as TTA modulate biological cholesterol levels, both alone and in compositions comprising various plant oil and/or fish oils.
- TTA lowered cholesterol levels more than any plant or fish oil alone; compositions comprising both TTA and sunflower oil and/or fish oil lowers cholesterol levels more than TTA or either oil alone.
- olive and soy oil alone increase cholesterol levels, these oils substantially potentiated the ability of TTA to decrease cholesterol levels. This TTA potentiating effect was greatest with compositions comprising TTA and soy oil, which reduced the cholesterol level by 60% when compared with TTA alone.
- the fatty acid derivatives have one or more therapeutic effects.
- the fatty acid derivatives fund use in the treatment of hyperlipidemia conditions and in reducing the concentration of cholesterol and triglycerides in the blood of mammals.
- selenium analogues have the same properties as well as inhibiting the oxidative modification LDL (see, e.g., EP0345038; WO97/03663 (PCT/N095/00195)).
- the fatty acid analogues also find use for the treatment of and/or prevention of obesity, hypertension, fatty liver, and multi-metabolic syndrome (“Syndrome X”).
- WO99/58121 PCT/N099/00135
- diabetes Type I and II
- hyperglycaemia hyperinsulinemia
- hyperinsulinemia hyperinsulinemia
- reduced sensitivity to insulin see, e.g., WO99/58122 (PCT/N099/00136)
- primary stenosis secondary stenosis
- secondary stenosis and a disease caused by procedural vascular trauma and pathological proliferation of smooth muscle cells, and increase level of plasma homocystein
- cancer e.g., treatment and/or prevention of primary and secondary neoplasms (see, e.g., WO02/03983 (PCT/NO01/00301)
- proliferative skin disorders see, e.g., WO 02/26218
- the fatty acid lipid derivatives of the present technology have corresponding therapeutic effects and/or biological properties.
- the fatty acid derivatives modulate the activity of members of the peroxisome proliferator-activated receptor (PPAR) family.
- the PPAR are pleiotropic regulators of cellular functions such as cellular proliferation, differentiation, and lipid homeostasis (Ye, et al. (2001) Diabetes 50: 411-417).
- the PPAR family is comprised of three subtypes; PPAR ⁇ , PPAR ⁇ , and PPAR ⁇ .
- Forms of TTA are potent ligands of PPAR ⁇ .
- TTA stimulates the catabolism of fatty acids by increasing their cellular uptake. Lowering the plasma triglyceride levels with TTA caused a shift in liver cellular metabolism towards PPAR ⁇ -regulated fatty acid catabolism in mitochondria (Graf, et al. (2003) J Biol Chem 278: 30525-33). The effect of TTA on plasma triacylglycerol is direct by PPAR ⁇ activation, which is demonstrated by the abolishment of this effect in PPAR ⁇ knockout mice.
- PPAR ligands affect proliferation of various cancer cell lines. TTA in particular has been found to reduce proliferation of many cancer cell lines (Berge, et al. (2001) Carcinogenesis 22:1747-1755; Abdi-Dezfuli, et al. (1997) Breast Cancer Res Treat 45: 229-239; Tronstad, et al. (2001) Biochem Pharmacol 61: 639-649; Tronstad, et al. (2001) Lipids 36: 305-313). This reduction is related to reduction in triacylglycerol levels (Tronstad, et al.
- TTA may be used for the prevention and/or treatment of cancer including inhibition of: primary and secondary neoplasms, the growth of tumors, invasion of a primary tumor into connective tissue, and formation of secondary tumors (see, e.g., NO 2002 5930).
- PPAR agonists modulate the inflammatory response.
- TTA modulate inflammatory responses by depressing the release of inflammatory cytokine interleukin-2 and suppressing PHA stimulated proliferation of peripheral mononuclear cells (Aukrust, et al. (2003) Eur J Clin Invest 33: 426-33).
- the modulation of cytokines by TTA may be mediated by PPAR, through altering prostaglandin levels, or by modification of lipid mediated signal transduction, the latter which also is the proposed mechanism of action for polyunsaturated fatty acids, e.ge, as found in some oils.
- protein material, and optionally oil, in combination with non ⁇ -oxidizable fatty acid entities potentiates the effect of fatty acid entities on inflammatory disorders, including immune mediated disorders such as rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), various immune mediated neurological disorders (e.g. multiple sclerosis and myastenia gravis), various cardiovascular disorders (e.g.
- immune mediated disorders such as rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), various immune mediated neurological disorders (e.g. multiple sclerosis and myasteni
- myocarditis congestive heart failure, arteriosclerosis and stable and unstable angina, and Wegener's granulomatosis
- inflammatory bowel diseases Crohn's disease, non-specific colitis, pancreatitis, nephritis, cholestatis/fibrosis of the liver, and acute and chronic allograft rejection after organ transplantation, as well as proliferate skin disorders like psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact-dermatitis, allergic contact-dermatitis, lamellar ichthyosis, epidermolytic hyperkeratosis, pre-malignant sun-induced keratosis, and seborrhea, and diseases that have an inflammatory component such as, e.g., Alzheimer's disease or impaired/improvable cognitive function. See e.g., U.S. Pat. No. 7,659,242.
- compositions comprising TTA and an oil such as a fish oil and/or a protein such as a fermented soy protein material have a synergistic effect on lipid metabolism, e.g., the effect is more than the additive effects of TTA and an oil (e.g., a fish oil) and/or a protein product (e.g., a fermented soy product) alone. See, e.g., U.S. Pat. No. 7,659,242.
- Synthetic routes to TTA and molecules comprising TTA are provided in, e.g., U.S. Pat. Nos. 5,093,365; 6,046,237; 6,365,628; 6,417,232; 6,441,036; 7,026,356; 7,378,443; 7,902,399; 8,088,825; preparation of mono-, di-, and triglycerides and nitrogen comprising lipids according to the technology are disclosed in detail in U.S. Pat. No. 7,375,135; and the synthesis of phospholipids comprising TTA are provided in, e.g., 8,178,713.
- compositions of TTA produced for human consumption have been associated with side effects, including lethargy, muscle cramps, and muscle pain. It is likely that these side effects are due to contaminants in some commercially produced TTA products. Accordingly, provided herein are TTA preparations that eliminate or minimize side effects such as lethargy, muscle cramps, and muscle pain. One such improved synthesis is provided in the Examples.
- the TTA is used directly to provide a composition according to certain aspects of the technology and in some embodiments the TTA is incorporated into a phospholipid by a living organism.
- the technology relates to isolating phospholipids (e.g., a natural phospholipid and/or an oil) comprising a non-beta-oxidizable fatty acid analogue (e.g., TTA) from one or more living organisms such as a bacterium, alga, archaeon, yeast, etc.
- phospholipids make up approximately 10% of the dry weight of a cell.
- cultures of cells provide a source for the production and harvesting of phospholipids.
- the technology relates to feeding a living organism a non-beta-oxidizable fatty acid analogue (e.g., TTA), which is then incorporated into phospholipid by the living organism, and then isolating the phospholipid, e.g., by biochemical or other isolation and/or purification techniques.
- a non-beta-oxidizable fatty acid analogue e.g., TTA
- the phospholipid is co-isolated with other biological molecules, substances, entities, etc. that are produced by the living organism.
- the technology relates to a composition (e.g., an oil) and/or a method of producing a composition produced from a living organism, wherein the composition comprises a phospholipid (e.g., a natural phospholipid) having a non-beta-oxidizable fatty acid analogue (e.g., TTA) and at least one other biological molecule from the living organism.
- a phospholipid e.g., a natural phospholipid
- TTA non-beta-oxidizable fatty acid analogue
- the living organism may, in some embodiments, be grown in a controlled culture, e.g., in a defined medium, a semi-defined medium, an undefined medium, a synthetic medium, or a natural medium; under controlled temperature, pressure, volume, and agitation; and in a controlled atmosphere of gases (e.g., a particular mixture of oxygen, carbon dioxide, nitrogen, and other gases, etc.).
- the culture may comprise a single type of organism (e.g., a single species, sub-species, clone, subtype, isolate, etc.) or the culture may comprise more than one type of organism (e.g., more than one species, sub-species, clone, subtype, isolate, etc.).
- the living organism is a member of the Bacteria; in some embodiments, the living organism is a member of the Eukarya; and, in some embodiments, the living organism is a member of the Archaea, as defined by, e.g., Woese C, Fox G (1977). “Phylogenetic structure of the prokaryotic domain: the primary kingdoms.” Proc Natl Acad Sci USA 74: 5088-90; Woese C, Kandler O, Wheelis M (1990). “Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya.” Proc Natl Acad Sci USA 87: 4576-9.
- one or more phospholipids according to the technology is or are isolated from a composition of more than one living organism, e.g., a co-culture and/or living system and/or consortium of living organisms that may or may not be categorized in the same phylogenetic kingdom.
- any organism that can be grown in the presence of a non-beta-oxidizable fatty acid analogue such as TTA is encompassed by the present technology. It is contemplated that any organism that can incorporate a non-beta-oxidizable fatty acid analogue such as TTA into a phospholipid is encompassed by the present technology. As discussed elsewhere, it is contemplated that a non-beta-oxidizable fatty acid analogue is metabolized (e.g., anabolized) in the same manner as its natural counterpart save for its resistance to beta-oxidation.
- lipid extracts e.g., oils, fractions, etc. demonstrate high specific biological activities as isolated from microorganisms.
- furan fatty acids have biological activities such as scavenging free radicals (e.g., by reacting readily with peroxyl radicals to generate dioxoenes) and thus may contribute to the protective properties of fish and fish oil diets relative to heart disease.
- Furan fatty acids are tri- or tetra-substituted furan derivatives comprising either a C 3 or C 5 side chain in one of the alpha positions and a straight long-chain saturated acid with a carboxylate at its end in the other alpha position.
- Furan fatty acids have been found in fish, algae, bacteria, and fungi, and are generated in large amounts by algae and in small to moderate amounts by plants and other microorganisms. Marine organisms (such as fish) and mammals obtain furan fatty acids in food and metabolize them into phospholipids. Furan fatty acids are catabolized to dibasic urofuran acids and excreted in the urine. Due to their molecular structure, furan fatty acids are contemplated to be catabolized more slowly than other lipids in mammals, and thus potentially to be bioactive in relation to energy metabolism.
- unusual lipids e.g., phytanyl ether lipids
- Thermotoga spp. e.g., T. maritima
- the lipids found in Thermotoga spp. comprise a mixture of ether lipids and ester lipids, mainly polar. Liposomes produced from these lipids demonstrate high stability at high and low temperatures, are resistant to acids and bases, and are resistant to high pressure.
- these lipids affect membrane properties and thus may result in altered absorption and permeability of nutrients.
- the technology relates to isolating and characterizing bioactive fatty acids and/or lipids with specific and unusual molecular structures from living organisms such as marine organisms.
- lipids from one or more organisms are isolated, extracted, and/or fractionated, and the products are tested for biological activity, e.g., metabolic effects related to fatty acid and lipid metabolism.
- the testing is performed in relevant animal models or in cell culture. Models will be used to screen for effects related to energy metabolism and mitochondrial functions in addition to modulating membrane properties.
- living organisms have been provided (e.g., by feeding) a particular fatty acid, fatty acid analogue, or lipid, e.g., a non-beta-oxidizable fatty acid analogue such as TTA and/or a lipid, lipid extract mixture, isolate, oil, etc. isolated and characterized from a biological organism, system, or consortium.
- selected fractions are further processed in some embodiments for the formulation of nutritional products or products that improve the absorption or bioavailability of bioactive compounds.
- isolation and characterization are performed by analytical chromatography coupled to a flame ionization detector and/or mass spectrometry.
- analytical chromatography coupled to a flame ionization detector and/or mass spectrometry.
- embodiments of the technology use lipid extraction and isolation from biological samples. These techniques exploit the high solubility of hydrocarbon chains in organic solvents, for example, chloroform/methanol-based phase partitioning.
- the protocols are adapted for complex lipid chemistries and low-abundance and labile lipid metabolites.
- Lipid separation comprises use of, e.g., thin layer chromatography (TLC), solid-phase extraction (SPE) chromatography (e.g., using a column comprising silica or other stationary phases to separate glycerophospholipids, fatty acids, cholesteryl esters, glycerolipids, and sterols from crude lipid mixtures), and/or high performance liquid chromatography (e.g., normal-phase HPLC or reverse-phase HPLC).
- TLC thin layer chromatography
- SPE solid-phase extraction
- HPLC high performance liquid chromatography
- normal phase HPLC effectively separates glycerophospholipids on the basis of headgroup polarity
- reverse-phase HPLC effectively separates fatty acids such as eicosanoids on the basis of chain length, degree of unsaturation, and substitution.
- HPLC of lipids may either be performed offline or online where the eluate is integrated with the ionization source of a mass spectrometer.
- Lipid detection comprises use of spectrometric methods, e.g., and soft ionization techniques for mass spectrometry such as electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI).
- ESI electrospray ionization
- MALDI matrix-assisted laser desorption/ionization
- Soft ionization does not cause extensive fragmentation, so that comprehensive detection of an entire range of lipids within a complex mixture can be correlated to experimental conditions or disease state.
- APCI atmospheric pressure chemical ionization
- lipids are detected using ESI-MS, which depends on the formation of gaseous ions from lipids. It is a soft-ionization method that rarely disrupts the chemical nature of the analyte prior to mass analysis.
- ESI-MS methods have been developed for analysis of different classes, subclasses, and individual lipid species from biological extracts. Comprehensive reviews of the methods and their application have recently been published; see, e.g., Murphy et al. (2001) “Analysis of nonvolatile lipids by mass spectrometry” Chem Rev 101: 479-526.
- the major advantages of ESI-MS are high accuracy, sensitivity, reproducibility, and the applicability of the technique to complex solutions without prior derivatization.
- MALDI massive lipidomics
- MALDI mass spectrometry is a laser-based soft-ionization method often used for analysis of large proteins, but has been used successfully for lipids.
- the lipid is mixed with a matrix, such as 2,5-dihydroxybenzoic acid, and applied to a sample holder as a small spot.
- MALDI-Time-of-flight (MALDI-TOF) MS has become a very promising approach for lipidomics studies, particularly for the imaging of lipids from tissue slides. Schiller al. (2007). “MALDI-TOF MS in lipidomics” Front Biosci 12: 2568-79.
- APCI is used to detect lipids.
- the source for APCI is similar to ESI except that ions are formed by the interaction of the heated analyte solvent with a corona discharge needle set at a high electrical potential.
- APCI is particularly useful for the analysis of nonpolar lipids such as triacylglycerols, sterols, and fatty acid esters.
- lipid profiling is used to detect and/or characterize lipids.
- Lipid profiling is a targeted metabolomics platform that provides a comprehensive analysis of lipid species within a cell or tissue.
- Profiling based on electrospray ionization tandem mass spectrometry (ESI-MS/MS) is capable of providing quantitative data and is adaptable to high throughput analyses.
- ESI-MS/MS electrospray ionization tandem mass spectrometry
- lipid profiling techniques are applied to characterize the lipids of an organism such as a plants or a microorganism, e.g., a yeast or alga.
- a combination of quantitative lipidomic data in conjunction with the corresponding transcriptional data (using gene-array methods) and proteomic data (using tandem MS) enables a systems biology approach to a more in-depth understanding of the metabolic or signaling pathways of interest.
- lipid extracts, fractions, or lipid isolates are fed in some embodiments to a microorganism such as algae in culture. It is contemplated that the algae incorporate rare lipids in phospholipids and other non-neutral lipids, thus enriching the lipids in an esterified form.
- TTA will be used as a model compound to feed to microorganisms.
- Characterizing lipids comprises testing lipid extracts, fractions, isolates, oils, etc. for metabolic and other biological effects, e.g., using models such as a mouse model with diet-induced obesity or other transgenic mouse models of metabolic diseases. Diet composition is controlled and monitored as it affects metabolic status as a result of the macronutrients in the food source. Metabolic cages are used to control for gas exchange and food intake. In some testing, transcriptomics and proteomics are used to measure gene expression and protein levels of specific genes.
- mice are available (e.g., from Jackson Laboratories) for studying immune responses and metabolism diseases such as those involving lipid metabolism, e.g., problems with cholesterol levels (e.g., hypercholesterolemia, hypocholesterolemia), mitochondrial defects, sensitivity to cold, high blood pressure, insulin resistance, hyperlipidemia, diabetes, cardiovascular disease, steatosis, fasting, hyperglycemia, atherosclerosis, lipogenesis, glucose metabolism, glucose tolerance, oxidative stress, bile acid and lipid homeostasis, leptin, adipose tissue stores, wound healing, obesity, apolipoprotein function, statin treatment for hypercholesterolemia, Alzheimer's disease, fatty liver, effects of diet on skin and coat, appetite, hunger, and satiety, cardiac lipid metabolism, adipocyte physiology, fat metabolism and storage, inflammation, cancer, cholesterol gallstone formation, vitamin E deficiency, muscle lipotoxicity, low density lipoprotein receptor, hepatic clearance of alpha2-ma
- Phospholipids are ubiquitous in nature. In addition to serving as a primary component of cellular membranes and binding sites for intra- and intercellular proteins, some phospholipids in eukaryotic cells, such as phosphatidylinositols and phosphatidic acids are either precursors of or, themselves, membrane-derived second messengers. Most phospholipids contain a diglyceride, a phosphate group, and a simple organic molecule (e.g., choline). The lipid sphingomyelin, however, is derived from sphingosine instead of glycerol.
- the structure of the phospholipid molecule generally consists of hydrophobic tails (e.g., in some embodiments according to the technology, a hydrophobic tail is a TTA) and a hydrophilic head (e.g., a polar headgroup, e.g., a polar moiety). While, typically, one or both of the hydroxyl groups of the diglyceride are acylated with long-chain fatty acids, alkyl-linked and 1Z-alkenyl-linked (plasmalogen) phospholipids are known, and dialkylether variants are known in the archaea.
- Phospholipids are subdivided into classes based on the nature of the polar headgroup at the sn-3 position of the glycerol backbone in eukaryotes and eubacteria, or the sn-1 position in the case of archaea.
- Examples of phospholipids found in biological membranes are phosphatidylcholine (also known as PC, GPCho, or lecithin), phosphatidylethanolamine (PE or GPEtn), and phosphatidylserine (PS or GPSer).
- Sphingolipids are a complicated family of compounds that share a common structural feature, a sphingoid base backbone that is synthesized de novo from the amino acid serine and a long-chain fatty acyl CoA, then converted into ceramides, phosphosphingolipids, glycosphingolipids, and other compounds.
- the major sphingoid base of mammals is commonly referred to as sphingosine.
- Ceramides N-acyl-sphingoid bases
- the fatty acids are typically saturated or mono-unsaturated with chain lengths from 16 to 26 carbon atoms.
- the major phosphosphingolipids of mammals are sphingomyelins (ceramide phosphocholines), whereas insects contain mainly ceramide phosphoethanolamines and fungi have phytoceramide phosphoinositols and mannose-containing headgroups.
- the glycosphingolipids are a diverse family of molecules composed of one or more sugar residues linked via a glycosidic bond to the sphingoid base. Examples of these are the simple and complex glycosphingolipids such as cerebrosides and gangliosides.
- the enzymes of fatty acid biosynthesis are divided into two groups—in animals and fungi all the fatty acid synthase reactions are carried out by a single multifunctional fatty acid synthase protein, while in plant plastids and bacteria separate enzymes perform each step in the pathway.
- the fatty acids may be subsequently converted to triglycerides that are packaged in lipoproteins and secreted from the liver.
- the synthesis of unsaturated fatty acids involves a desaturation reaction, whereby a double bond is introduced into the fatty acyl chain.
- a desaturation reaction whereby a double bond is introduced into the fatty acyl chain.
- the desaturation of stearic acid by stearoyl-CoA desaturase-1 produces oleic acid.
- the doubly unsaturated fatty acid linoleic acid as well as the triply unsaturated ⁇ -linolenic acid cannot be synthesized in mammalian tissues, and are therefore essential fatty acids and must be obtained from the diet.
- triglyceride synthesis takes place in the endoplasmic reticulum by metabolic pathways in which acyl groups in fatty acyl-CoAs are transferred to the hydroxyl groups of glycerol-3-phosphate and diacylglycerol.
- Terpenes and isoprenoids are made by the assembly and modification of isoprene units donated from the reactive precursors isopentenyl pyrophosphate and dimethylallyl pyrophosphate. These precursors can be made in different ways. In animals and archaea, the mevalonate pathway produces these compounds from acetyl-CoA, while in plants and bacteria the non-mevalonate pathway uses pyruvate and glyceraldehyde 3-phosphate as substrates. One important reaction that uses these activated isoprene donors is steroid biosynthesis. Here, the isoprene units are joined together to make squalene and then folded up and formed into a set of rings to make lanosterol. Lanosterol can then be converted into other steroids such as cholesterol and ergosterol.
- the technology encompasses any biological molecule (e.g., a lipid, a protein, a small molecule, a hormone, etc.) comprising a non- ⁇ -oxidizable fatty acid.
- the technology encompasses a biological molecule that is covalently linked to a non- ⁇ -oxidizable fatty acid, that is bound to a non- ⁇ -oxidizable fatty acid, that is attached by a linker to a non- ⁇ -oxidizable fatty acid, or that is otherwise physically or chemically associated with a non- ⁇ -oxidizable fatty acid.
- the technology relates to biological molecules comprising a non- ⁇ -oxidizable fatty acid wherein the biological molecule is isolated from a living organism.
- the non- ⁇ -oxidizable fatty acid is TTA, e.g., that is provided in the culture medium (e.g., as an energy source, as a carbon source, as a nutrient, as an additive, etc.) in which the living organism is grown.
- the culture medium e.g., as an energy source, as a carbon source, as a nutrient, as an additive, etc.
- Particular embodiments relate to phospholipids comprising a non- ⁇ -oxidizable fatty acid such as TTA.
- Phospholipids according to the technology are not limited in the polar headgroup of the phospholipid.
- the polar head group may be the polar head group of any suitable lipid.
- the phospholipid is a neutral or anionic phospholipid.
- the polar head group is the polar head group of, or is derived from, a lipid such as a phospholipid, ceramide, triacylglycerol, lysophospholipid, phosphatidylserine, glycerol, alcohol, alkoxy compound, monoacylglycerol, ganglioside, sphingomyelin, cerebroside, phosphatidylcholine (e.g., dioleoylphosphatidylcholine (DOPC)), phosphatidylethanolamine (e.g., dioleoylphosphatidylethanolamine (DOPE)), phosphatidylinositol, diacylglycerol, phosphatidic acid, glycerocarbohydrate, polyalcohol, and/or phosphatidylglycerol.
- a lipid such as a phospholipid, ceramide,
- Exemplary polar headgroups are, e.g.:
- the polar head group is, or is derived from, a triacylglycerol, e.g., having the structure
- the polar head group comprises the group
- W is selected from CH 2 , O, NR 1 , and S, wherein R 1 is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.
- the head group (HG) may be polar or non-polar. When HG is non-polar it may be rendered polar by group —C(O)W-Linker-.
- Such head groups are encompassed by the present definition provided —C(O)W-Linker-HG is polar and HG is polar when attached to the —C(O)W-Linker-group.
- the head group (HG) may be an alkyl group, e.g., having at least 5 carbons. In some embodiments, it is a C 5-100 alkyl group, a C 5-80 alkyl group, a C 5-60 alkyl group, a C 5-50 alkyl group, a C 5-40 alkyl group, C 5-30 alkyl group, or a C 5-20 alkyl group.
- the HG is the head group of, or is derived from, a lipid such as a phospholipid, ceramide, triacylglycerol, lysophospholipid, phosphatidylserine, glycerol, alcohol, alkoxy compound, monoacylglycerol, ganglioside, sphingomyelin, cerebroside, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, diacylglycerol, phosphatidic acid, glycerocarbohydrate, polyalcohol, and/or a phosphatidylglycerol.
- a lipid such as a phospholipid, ceramide, triacylglycerol, lysophospholipid, phosphatidylserine, glycerol, alcohol, alkoxy compound, monoacylglycerol, ganglioside, sphingomyelin, cerebroside,
- Exemplary head groups are, e.g.:
- the Linker of may be any suitable group.
- a typical Linker group is a hydrocarbyl group.
- the term “hydrocarbyl group” as used herein means a group comprising at least C and H and that may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group, etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C, then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulfur, nitrogen, and oxygen.
- a non-limiting example of a hydrocarbyl group is an acyl group.
- a typical hydrocarbyl group is a hydrocarbon group.
- hydrocarbon means any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be linear, branched or cyclic, or an aryl group.
- the term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.
- the Linker is a C 1-30 , C 1-25 , C 1-20 , C 1-15 , C 1-10 , or C 1-5 hydrocarbyl group; a C 1-30 , C 1-25 , C 1-20 , C 1-15 , C 1-10 , or C 1-5 hydrocarbon group; a C 1-30 , C 1-25 , C 1-20 , C 1-15 , C 1-10 , or C 1-5 optionally substituted alkyl group; or a C 1-30 , C 1-25 , C 1-20 , C 1-15 , C 1-10 , or C 1-5 unsubstituted alkyl group.
- at least one optional Linker or no optional Linker groups are present.
- the group/compound from which the polar head group is derived is typically chosen to have one or more —OH groups. These allow a simple ester bond between the non-polar moiety and the polar moiety to be provided.
- two or more W groups may or may not be bonded to the same atom of the linker. It is envisaged that in some embodiments the two or more W groups are boned to different atoms of a linker.
- W is selected from CH 2 , O, NR 1 , and S, wherein R 1 is H, a hydrocarbyl group, a hydrocarbon group, an optionally substituted alkyl group, or an unsubstituted alkyl group, wherein the hydrocarbyl group, hydrocarbon group, optionally substituted alkyl group, and/or unsubstituted alkyl group may be a C 1-30 , C 1-25 , C 1-20 , C 1-15 , C 1-10 , C 1-5 , or C 5-15 group.
- lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO 2 , SO, or O; and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)] m PHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
- the lipids comprise more than one non-polar moiety, wherein at least one non-polar moiety is of the formula X—Y—Z—, (wherein X is a hydrocarbyl chain; Y is S, Se, SO 2 , SO, or O; and Z is an optional hydrocarbyl group) and one or more lipids which are not of this formula.
- X is a hydrocarbyl chain
- Y is S, Se, SO 2 , SO, or O
- Z is an optional hydrocarbyl group
- technology includes lipids which have multiple non-polar moieties of which only one has the structure X—Y—Z—.
- the lipids comprise at least two non-polar moieties and a polar moiety, wherein one non-polar moiety is of the formula X—Y—Z—, wherein one non-polar moiety is of the formula X—CH 2 —Z—, wherein each X is independently a hydrocarbyl chain; Y is S, Se, SO 2 , SO, or O; and each Z is independently an optional hydrocarbyl group, wherein the chain X—CH 2 —Z optionally contains an even number of atoms; wherein the polar moiety is of the formula —[C(O)] m PHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
- the chain length of X—CH 2 — is the longest chain of directly bonded atoms within moiety X—CH 2 .
- a chain and consequently the chain length do not include atoms of cyclic substituents or substituents of a terminal carbon.
- each non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO 2 , SO, or O; and Z is an optional hydrocarbyl group.
- X is a hydrocarbyl chain.
- hydrocarbyl chain it is meant a linear hydrocarbyl group.
- chain length it is meant the longest chain of directly bonded atoms within moiety X. A chain and consequently the chain length do not include atoms of cyclic substituents or substituents of a terminal carbon.
- X is an optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.
- X is an optionally substituted C 6 -C 24 alkyl, optionally substituted C 6 -C 24 alkenyl, or optionally substituted C 8 -C 24 alkynyl.
- X is an optionally substituted alkyl having a chain length of 6 to 24 atoms, optionally substituted alkenyl having a chain length of 6 to 24 atoms, or optionally substituted alkynyl having a chain length of 6 to 24 atoms. In some embodiments, X is an optionally substituted alkyl having a chain length of 10 to 18 atoms, optionally substituted alkenyl having a chain length of 10 to 18 atoms, or optionally substituted alkynyl having a chain length of 10 to 18 atoms.
- X is an optionally substituted alkyl having a chain length of 14 atoms, optionally substituted alkenyl having a chain length of 14 atoms, or an optionally substituted alkynyl having a chain length of 14 atoms, for example, in some embodiments X is an unsubstituted alkyl, unsubstituted alkenyl, or an unsubstituted alkynyl.
- X is an unsubstituted C 6 -C 24 alkyl, unsubstituted C 6 -C 24 alkenyl, or an unsubstituted C 6 -C 24 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 6 to 24 atoms, unsubstituted alkenyl having a chain length of 6 to 24 atoms, or an unsubstituted alkynyl having a chain length of 6 to 24 atoms.
- X is an unsubstituted C 10 -C 18 alkyl, unsubstituted C 10 -C 18 alkenyl, or an unsubstituted C 10 -C 18 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 10 to 18 atoms, unsubstituted alkenyl having a chain length of 10 to 18 atoms, or an unsubstituted alkynyl having a chain length of 10 to 18 atoms.
- X is an unsubstituted C 14 alkyl, unsubstituted C 14 alkenyl, or an unsubstituted C 14 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 14 atoms, unsubstituted alkenyl having a chain length of 14 atoms, or an unsubstituted alkynyl having a chain length of 14 atoms.
- X is a hydrocarbon chain
- hydrocarbon chain it is meant a linear hydrocarbon group.
- X a C 6 -C 24 alkenyl containing one or more double bonds and optionally one or more triple bonds, C 6 -C 24 alkynyl, C 6 -C 24 alkyl optionally substituted with at least one of F, C 1 , hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 2 -C 5 acyloxy, or C 1 -C 4 alkyl.
- alkynyl groups containing one or more alkenyl groups may be provided or alkenyl groups containing one or more alkynyl groups may be provided
- X contains one or more double bonds
- some embodiments provide that at least one double bond is in cis configuration. Some embodiments provide that all double bonds are in cis configuration.
- X is an acetylenic hydrocarbyl group.
- acetylenic hydrocarbyl as used herein means a group comprising at least C and H, having at least one —C ⁇ C— bond and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, a hydrocarbon group, an N-acyl group, a cyclic group, etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C, then those carbons need not necessarily be linked to each other.
- the carbons may be linked via a suitable element or group.
- the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulfur, nitrogen, and oxygen.
- X is an acetylenic hydrocarbyl group containing a single —C ⁇ C-bond, e.g., X contains one and only one —C ⁇ C-bond.
- the acetylenic hydrocarbyl group is an alkynyl group.
- X is an optionally substituted alkynyl group having a chain length of 6 to 24 atoms
- X is an optionally substituted alkynyl group having a chain length of 10 to 18 atoms
- X is an optionally substituted alkynyl groups having a chain length of 16 or 17 atoms
- X is an optionally unsubstituted alkynyl group.
- X is an unsubstituted C 6 -C 24 alkynyl group.
- X is an unsubstituted alkynyl group having a chain length of 6 to 24 atoms
- X is an unsubstituted C 10 -C 18 alkynyl group
- X is an unsubstituted alkynyl groups having a chain length of 10 to 18 atoms
- X is an unsubstituted C 16 or C 17 alkynyl group
- X is an unsubstituted alkynyl having a chain length of 16 or 17 atoms.
- the —C ⁇ C— of the acetylenic hydrocarbyl group is distanced from the terminal end of the acetylenic hydrocarbyl group by from 2 to 15 carbons, e.g., by 2 carbons, by 3 carbons, by 7 carbons, or by 13 carbons.
- At least one Y group is S or Se, e.g., in some embodiments each Y is selected from S and Se. Some embodiments provide that at least one Y group is S and some embodiments provide that each Y is S.
- the present invention provides structured phospholipid compositions comprising phospholipid molecules of the following structure:
- compositions of the present invention may comprise 99.5% 99.9% or 100% of the structured phospholipid, or may be compositions comprising a mixture of phospholipid molecules that can be characterized based on the molar percentage of fatty acid moieties present in the composition as a whole.
- the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R1. In some embodiments, the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moieties or combinations thereof at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moiety at position R1.
- the bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof.
- the composition comprises the bioactive fatty acid moiety is EPA.
- the composition comprises the bioactive fatty acid moiety is DHA.
- the composition comprises the bioactive fatty acid moiety is sciadonic acid.
- R3 is selected from a —H or nitrogen containing compound choline (HOCH 2 CH 2 N + (CH 3 ) 3 OH ⁇ ), ethanolamine (HOCH 2 CH 2 NH 2 ), serine, inositol such as cyclohexane polyolinositol and derivatives thereof.
- GPC sn-glycero-3-phosphocholine
- an activated fatty acid such as fatty acid imidazolides
- Sn-Glycero-3-phosphocholine, as cadmium (II) adduct can also be reacted with the imidazolide activated fatty acid in the presence of DBU (1,8-diazabicyclo[5.4.0]undec-7-ene] to prepare the phosphatidylcholine of the respective fatty acid (International application number PCT/GB2003/002582).
- Enzymatic transphosphatidylation can affect the transformation of phosphatidylcholine to phosphatidyletanolamine (Wang et al, J. Am. Chem. Soc., 1993, 115, 10487).
- a lysophospholipid with a desired bioactive fatty acid moiety e.g., omega-3 fatty acid moiety, conjugated linoleic acid moiety of sciadonic acid moiety
- a desired bioactive fatty acid moiety e.g., omega-3 fatty acid moiety, conjugated linoleic acid moiety of sciadonic acid moiety
- a non-beta-oxidizable fatty acid analogue moiety by combining desired omega-3 fatty acid non-beta-oxidizable fatty acid analogue moiety anhydride (e.g. from TTA) and 4-pyrrolidinopyridine as a catalyst (1.2 equivalents) in alcohol-free chloroform.
- Polyunsaturated fatty acids containing phospholipids may be prepared by various ways, mainly by chemical synthesis of phospholipids as described, by enzymatic esterification and transesterification of phospholipids or enzymatic transphosphatidylation of phospholipids. (Hosokawa, J. Am. Oil Chem. Soc. 1995, 1287, Lilja-Hallberg, Biocatalysis, 1994, 195).
- Z is an optional hydrocarbyl group. In some embodiments, Z is present and in some embodiments, Z is not present. In some embodiments, Z is an alkyl group such as C 1 -C 10 , C 1 -C 6 , or a C 1 -C 3 alkyl group such as, e.g., —CH 2 —.
- Y and Z together may be formed by a unit that repeats within the YZ moiety.
- Y—Z together represent the group [V—CH 2 ] n , wherein Y 1 is S, Se, SO 2 , SO, or O, and wherein n is an integer from 1 to 20.
- Y is Se or S, e.g., Y is S, and n is from 1 to 10, e.g., 1 to 5 or 1, 2 or 3, e.g., in some embodiments, n is 1.
- p is at least 1, such as 1 to 1000; 1 to 100; 1 to 50; 1 to 20; 1 to 10; 1 to 5; e.g., 1, 2 or 3; and wherein each W, X, Y, and Z is selected independently of each other.
- Table 1 Examples of compounds from which the polar head group may be derived for given values of p are provided in Table 1:
- embodiments of the technology provide compounds having formulas as follows:
- p is 1 to 10, e.g., 1 to 5; e.g., 1, 2 or 3, and wherein each W, X, Y, and Z is selected independently of each other.
- the compound comprises at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X—Y—Z—.
- each W, X, Y, and Z is selected independently of each other.
- the compound comprises at least three non-polar moieties wherein each is independently selected from non-polar moieties of the formula X—Y—Z—.
- some embodiments of the technology provide a compound having a structure of
- each W, X, Y and Z is selected independently of each other.
- Y 2 and Y 3 are independently S or Se (e.g., Y 2 and Y 3 are each S), and X 2 and X 3 are independently an unsubstituted C 10 -C 18 alkyl, unsubstituted C 10 -C 18 alkenyl, and/or an unsubstituted C 10 -C 18 alkynyl (e.g., X 2 and X 3 are independently an unsubstituted C 14 alkyl, unsubstituted C 14 alkenyl, and/or an unsubstituted C 14 alkynyl).
- Y 2 and Y 3 are each S and/or X 2 and X 3 are independently CH 3 (CH 2 ) 13 —, CH 3 (CH 2 ) 6 CH ⁇ CH(CH 2 ) 5 —, and/or CH 3 CH 2 CC(CH 2 ) 10 —; in some embodiments, X 2 and X 3 are both CH 3 (CH 2 ) 13 —; in some embodiments, X 2 and X 3 are both CH 3 (CH 2 ) 6 CH ⁇ CH(CH 2 ) 5 —; and in some embodiments, X 2 and X 3 are both CH 3 CH 2 CC(CH 2 ) 10 —.
- the PHG is derived from the polar head group of a phosphatidylcholine or a phosphatidylethanolamine
- the technology provides a compound having the structure
- Y 2 and Y 3 are independently S or Se and/or X 2 and X 3 are independently C 10 -C 18 alkyl, C 10 -C 18 alkenyl, and/or C 10 -C 18 alkynyl.
- Y 2 and Y 3 are independently S or Se and/or X 2 and X 3 are independently unsubstituted C 10 -C 18 alkyl, C 10 -C 18 alkenyl, or C 10 -C 18 alkynyl, e.g., Y 2 and Y 3 are independently S or Se and/or X 2 and X 3 are independently unsubstituted C 14 alkyl, C 14 alkenyl, and/or C 14 alkynyl.
- Y 2 and Y 3 are each S and/or X 2 and X 3 are both CH 3 (CH 2 ) 13 —, X 2 and X 3 are both CH 3 (CH 2 ) 6 CH ⁇ CH(CH 2 ) 5 —, or X 2 and X 3 are both CH 3 CH 2 CC(CH 2 ) 10 —.
- the compounds of the technology have a structure according to
- Y2, Y 3 , and Y 4 are independently S or Se and/or X 2 , X 3 , and X 4 are independently a C 10 -C 18 alkyl, C 10 -C 18 alkenyl, and/or a C 10 -C 18 alkynyl.
- Y2, Y 3 , and Y 4 are independently S or Se and/or X 2 , X 3 , and X 4 are independently a C 14 alkyl, C 14 alkenyl, and/or a C 14 alkynyl.
- Y2, Y 3 , and Y 4 are each S and/or X 2 , X 3 , and X 4 are independently a C 10 -C 18 alkyl, C 10 -C 18 alkenyl, and/or a C 10 -C 18 alkynyl.
- Y2, Y 3 , and Y 4 are each S and/or X 2 , X 3 , and X 4 are independently an unsubstituted C 10 -C 18 alkyl, an unsubstituted C 10 -C 18 alkenyl, and/or an unsubstituted C 10 -C 18 alkynyl.
- Y2, Y 3 , and Y 4 are each S and/or X 2 and X 3 are independently a C 14 alkyl, C 14 alkenyl, and/or a C 14 alkynyl. In some embodiments, Y2, Y 3 , and Y 4 are each S and/or X 2 , X 3 , and X 4 are each CH 3 (CH 2 ) 13 —; in some embodiments, Y2, Y 3 , and Y 4 are each S and/or X 2 , X 3 , and X 4 are each CH 3 (CH 2 ) 6 CH ⁇ CH(CH 2 ) 5 —; in some embodiments, Y2, Y 3 , and Y 4 are each S and/or X 2 , X 3 , and X 4 are each CH 3 CH 2 CC(CH 2 ) 10 ⁇ .
- ester linkages between lipid tails and the glycerol moiety are replaced by ether linkages.
- the compounds provided herein are combined with a liposome or formulated into a micellar form to assist in administration.
- compounds are formulated in a cochleate delivery vehicle.
- Cochleate delivery vehicles are a new technology platform for oral delivery of drugs.
- Cochleates are stable phospholipid-cation precipitates composed of simple, naturally occurring materials, for example, phosphatidylserine and calcium.
- Cochleates are a potential nanosized system that can encapsulate hydrophobic, amphiphilic, negatively, or positively charged moieties.
- the compound is an isolated form or purified form.
- the compound may be in a form or at a purity other than that found in a biological system such as in vivo.
- the compound is semi-isolated or semi-purified, e.g., the compound is an isolated form or purified form and is present in a composition with one or more other biological molecules that are not contaminants or impurities.
- the compounds provided are formulated to provide a pharmaceutical composition comprising a compound according to the technology and/or a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.
- embodiments provide compounds that are lipids comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO 2 , SO, O, or CH 2 ; and Z is an optional hydrocarbyl group.
- X is a hydrocarbyl chain
- Y is S, Se, SO 2 , SO, O, or CH 2
- Z is an optional hydrocarbyl group.
- the chain X—Y—Z contains an even number of atoms
- the polar moiety is —[C(O)] n PHG, wherein PHG is a polar head group and m is the number of non-polar moieties.
- compositions comprising a therapeutically effective amount of an agent according to the present technology and a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof).
- a composition according to the technology comprises or consists of a therapeutically effective amount of a pharmaceutically active agent.
- it includes a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof).
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
- the choice of pharmaceutical carrier, excipient, or diluent is selected with regard to the intended route of administration and standard pharmaceutical practice.
- the pharmaceutical comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
- This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.
- compositions within the scope of the present technology may include one or more of the following: preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, odorants, and/or salts.
- Compounds of the present technology may themselves be provided in the form of a pharmaceutically acceptable salt.
- embodiments may comprise buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients, and/or diluents. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.
- compositions of the present technology may also contain other therapeutically active agents in addition to compounds of the present technology. Where two or more therapeutic agents are used they may be administered separately (e.g., at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus, combination therapy is within the scope of the present technology.
- a pharmaceutical composition within the scope of the present technology may be adapted for administration by any appropriate route.
- it may be administered by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, or intradermal) routes.
- Such a composition may be prepared by any method known in the art of pharmacy, for example, by admixing one or more active ingredients with a suitable carrier.
- different drug delivery systems are used to administer pharmaceutical compositions of the present technology, depending upon the desired route of administration.
- Drug delivery systems are described, for example, by Langer ( Science 249:1527-1533 (1991)) and by Illum and Davis ( Current Opinions in Biotechnology 2: 254-259 (1991)).
- agents of the present technology may be administered alone but will generally be administered as a pharmaceutical composition—e.g., the agent is in admixture with a suitable pharmaceutical excipient, diluent, or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- a suitable pharmaceutical excipient e.g., orally or topically
- the agent is administered (e.g., orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions, or suspensions, which may contain flavoring or coloring agents, for immediate, delayed, modified, sustained, pulsed, and/or controlled-release applications.
- tablets contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and/orglycine; disintegrants such as starch (preferably corn, potato, or tapioca starch), sodium starch glycollate, croscarmellose sodium, and/or certain complex silicates; and/or granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin, and/or acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate, and talc may be included.
- excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and/orglycine
- disintegrants such as starch (preferably corn, potato, or tapioca starch), sodium starch glycollate, croscarmellose sodium,
- solid compositions of a similar type are also employed as fillers in gelatin capsules.
- excipients in this regard include lactose, starch, a cellulose, milk sugar, or high molecular weight polyethylene glycols.
- the agent is combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol, and glycerin, and combinations thereof.
- the routes for administration include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestable solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, via the penis, vaginal, epidural, sublingual.
- oral e.g. as a tablet, capsule, or as an ingestable solution
- mucosal e.g. as a nasal spray or aerosol for inhalation
- nasal parenteral (e.g. by an injectable form)
- gastrointestinal intraspinal
- composition comprises more than one active component, then those components may be administered by different routes.
- agents of the present technology are administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly, or subcutaneously administering the agent; and/or by using infusion techniques.
- compositions adapted for oral administration are provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions.
- Tablets or hard gelatine capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
- Solutions and syrups may comprise water, polyols and sugars.
- oils e.g., vegetable oils
- An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used).
- a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
- a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
- glyceryl monostearate or glyceryl distearate may be used.
- compositions adapted for transdermal administration may be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- the active ingredient may be delivered from the patch by iontophoresis, e.g., as described in Pharmaceutical Research, 3: 318 (1986)).
- the agent of the present technology can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
- the agent of the present technology may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route.
- the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride.
- a preservative such as a benzylalkonium chloride.
- they may be formulated in an ointment such as petrolatum.
- the agent of the present technology can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- compositions adapted for rectal administration may be provided as suppositories or enemas.
- compositions adapted for nasal administration may use solid carriers, e.g., powders (e.g., having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, e.g., by rapid inhalation through the nose from a container of powder held close to the nose.
- Compositions adopted for nasal administration may alternatively use liquid carriers, e.g., nasal sprays or nasal drops. These may comprise aqueous or oil solutions of the active ingredient.
- Compositions for administration by inhalation may be supplied in specially adapted devices, e.g., in pressurized aerosols, nebulizers, or insufflators. These devices can be constructed so as to provide predetermined dosages of the active ingredient
- compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- agents of the present technology are administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.
- the agent is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
- suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- Transdermal refers to the delivery of a compound by passage through the skin and into the blood stream.
- Transmucosal refers to delivery of a compound by passage of the compound through the mucosal tissue and into the blood stream.
- Transurethral or “intraurethral” refers to delivery of a drug into the urethra, such that the drug contacts and passes through the wall of the urethra and enters into the blood stream.
- Poration enhancement refers to an increase in the permeability of the skin or mucosal tissue to a selected pharmacologically active compound such that the rate at which the compound permeates through the skin or mucosal tissue is increased.
- Penetration enhancers may include, for example, dimethylsulfoxide (DMSO); dimethyl formamide (DMF); N,N-dimethylacetamide (DMA); decylmethylsulfoxide (CIOMSO); polyethyleneglycol monolaurate (PEGML); glyceral monolaurate; lecithin; 1-substituted azacycloheptanones, particularly 1-N-dodecylcyclaza-cycloheptanones (e.g., as available under the trademark AzoneTM from Nelson Research & Development Co., Irvine, Calif.), alcohols, and the like.
- DMSO dimethylsulfoxide
- DMF dimethyl formamide
- DMA N,N-dimethylacetamide
- CIOMSO decylmethylsulfoxide
- PEGML polyethyleneglycol monolaurate
- lecithin 1-substituted azacycloheptanones, particularly 1-N-dodecylcyclaza
- Carriers or “vehicles” refers to carrier materials suitable for compound administration and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner
- Examples of pharmaceutically acceptable carriers include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty add esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.
- Transfersomes (“carrying bodies”) are complex, most often vesicular, bi- or multi-component aggregates capable of crossing barriers and of transferring material between the application and the destination sites. Transfersomes are sold by IDEA Corporation, Kunststoff, Germany, and TRANSFERSOME is a trade mark of that company. Transfersome transdermal drug delivery technology may be used for controllable and non-invasive delivery of a wide variety of large molecules as well as for the improved delivery of small molecules, including the metabolic enzyme antagonists and/or drugs of the present technology.
- Transfersomes may be optimized to attain extremely flexible and self-regulating membranes. They are therefore deformable and consequently can cross microporous barriers efficiently, even when the available passages are much smaller than the average aggregate size.
- Transfersome formulations are typically composed of natural amphipathic compounds suspended in a water-based solution, optionally containing biocompatible surfactants.
- Vesicular Transfersomes consist of a lipid bilayer surrounding an aqueous core and further contain at least one component, capable of softening the membrane. The bilayer of a Transferosome is therefore more flexible than a liposome membrane, even metastable. Transfersome vesicles consequently change their shape easily by adjusting locally to ambient stress.
- Passage of transfersome aggregates across the skin is a function of vesicle membrane flexibility, hydrophilicity, and the ability to retain vesicle integrity, while the aggregate undergoes a significant change in shape.
- a suspension of Transfersome vesicles When a suspension of Transfersome vesicles is placed on the surface of the skin, water evaporates from the relatively arid skin surface and the vesicles start to dry out. Due to the strong polarity of major Transfersome ingredients, the large number of hydrophilic groups on the membrane, assisted by the softness of the membrane, the vesicles are attracted to the areas of higher water content in the narrow gaps between adjoining cells in the skin barrier, enabling skin penetration of the vehicle.
- BBB Blood Brain Barrier
- compositions may be designed to pass across the blood brain barrier (BBB).
- BBB blood brain barrier
- a carrier such as a fatty acid, inositol or cholesterol may be selected that is able to penetrate the BBB.
- the carrier may be a substance that enters the brain through a specific transport system in brain endothelial cells, such as insulin-like growth factor I or II.
- the carrier may be coupled to the active agent or may contain and/or be in admixture with the active agent. Liposomes can be used to cross the BBB.
- WO91/04014 describes a liposome delivery system in which an active agent can be encapsulated/embedded and in which molecules that are normally transported across the BBB (e.g., insulin or insulin-like growth factor I or II) are present on the liposome outer surface.
- BBB insulin or insulin-like growth factor I or II
- the agents may further be delivered attached to polymers.
- Polymer based therapeutics have been proposed to be effective delivery systems, and generally comprise one or more agents to be delivered attached to a polymeric molecule, which acts as a carrier. The agents are thus disposed on the polymer backbone, and are carried into the target cell together with the polymer.
- the agents may be coupled, fused, mixed, combined, or otherwise joined to a polymer.
- the coupling, etc. between the agent and the polymer may be permanent or transient, and may involve covalent or non-covalent interactions (including ionic interactions, hydrophobic forces, Van der Waals interactions, etc.).
- the exact mode of coupling is not important as long as the agent is taken into a target cell substantially together with the polymer.
- the entity comprising the agent attached to the polymer carrier is referred to here as a “polymer-agent conjugate”.
- High molecular weight macromolecules are unable to diffuse passively into cells and are instead engulfed as membrane-encircled vesicles.
- intracellular enzymes may act on the polymer-agent conjugate to effect release of the agent. Controlled intracellular release circumvents the toxic side effects associated with many drugs.
- polymer-agent conjugates for desirable properties.
- Advantages of using polymer-agent conjugates include economy of manufacture, stability (longer shelf life), and reduction of immunogenicity and side effects.
- polymer-agent conjugates are especially useful for the targeting of tumor cells because of the enhanced permeability and retention (EPR) effect, in which growing tumors are more “leaky” to circulating macromolecules and large particules, allowing them easy access to the interior of the tumor. Increased accumulation and low toxicity (typically 10-20% of the toxicity of the free agent) are also observed.
- EPR enhanced permeability and retention
- hyperbranched dendrimers for example, PAMAM dendrimers
- PAMAM dendrimers polyamindoamine polymers
- the pH responsiveness of polymer-agent conjugates may be tailored for particular intracellular environments. This enables the drug to be released only when the polymer therapeutic encounters a particular pH or range of pH, e.g., within a particular intracellular compartment.
- the polymer agent conjugates may further comprise a targeting means, such as an immunoglobulin or antibody, which directs the polymer-agent conjugate to certain tissues, organs or cells comprising a target, for example, a particular antigen. Other targeting means are described elsewhere in this document, and are also known in the art.
- polymer-agent conjugates include “Smancs”, comprising a conjugate of styrene-co-maleic anhydride and the antitumour protein neocarzinostatin, and a conjugate of PEG (polyethylene glycol) with L-asparaginase for treatment of leukaemia; PK1 (a conjugate of a HPMA copolymer with the anticancer drug doxorubicin); PK2 (similar to PK1, but furthermore including a galactose group for targeting primary and secondary liver cancer); a conjugate of HPMA copolymer with the anticancer agent captothecin; a conjugate of HPMA copolymer with the anticancer agent paclitaxel; HPMA copolymer-platinate, etc. Any of these polymer-agent conjugates are suitable for co-loading into the transgenic cells of the present technology.
- the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg or from 0.1 to 1 mg/kg body weight.
- the dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.
- the agent may be used in combination with one or more other pharmaceutically active agents.
- Other agents are sometimes referred to auxiliary agents.
- a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base, as appropriate.
- the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- Suitable acid addition salts are formed from acids that form non-toxic salts such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethane sulphonate, benzene sulphonate, p-toluenesulphonate, and pamoate salts.
- non-toxic salts such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethane sulphonate, benzene sulphonate
- the present technology relates to the use of a compound according to embodiments of the technology for the manufacture of a medicament for the treatment and/or prevention of a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia, and stenosis.
- the present technology provides use of a compound according to the technology for the manufacture of a medicament for lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein.
- the present technology provides a method for producing weigh loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound of the technology or a pharmaceutically acceptable salt thereof.
- the present technology provides a method for the modification of the fat distribution and content of animals in order to improve the quality of the meat, or product such as milk and eggs, comprising administering thereto an effective amount of a compound of the technology or a pharmaceutically acceptable salt thereof.
- said animal is an agricultural animal, such as gallinaceous birds, bovine, ovine, caprine or porcine mammals.
- the animal may be a fish or shellfish, such as salmon, cod, Tilapia, clams, oysters, lobster or crabs.
- the present technology provides use of a compound according to the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition and/or prevention of the growth of tumors.
- the present technology provides use of a compound according to the technology in the manufacture of a medicament for the inhibition and/or prevention of the invasion of a primary tumor into the connective tissue.
- the present technology provides use of a compound according to the technology for the manufacture of a medicament for the inhibition and/or prevention of the metastatic properties of a tumor, e.g., to inhibit the formation of secondary tumors.
- the use of the present compounds may increase the overall survival of mammals with tumors.
- the present technology provides a method for the treatment and/or inhibition of primary and secondary metastatic neoplasms, comprising administering a compound of the technology or a pharmaceutically acceptable salt thereof.
- the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of proliferative skin disorders such as psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, lamellar ichthyosis, epidermolytic hyperkeratosis, pre malignant sun induced keratosis, and seborrhea.
- proliferative skin disorders such as psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, lamellar ichthyosis, epidermolytic hyperkeratosis, pre malignant sun induced keratosis, and seborrhea.
- the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of proliferation and/or induction of differentiation of keratinocytes.
- the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of inflammatory disorders.
- the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of inflammatory disorders, wherein the inflammatory disorder is selected from the group comprising immune mediated disorders such as rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g.
- thyroiditis and adrenalitis various immune mediated neurological disorders (e.g. multiple sclerosis and myastenia gravis), various cardiovascular disorders (e.g. myocarditis, congestive heart failure, arteriosclerosis and stable and unstable angina, and Wegeners granulomatosis), inflammatory bowel diseases and colitis (e.g., Crohn's colitis), nephritis, various inflammatory skin disorders (e.g. psoriasis, atopic dermatitis and food allergy) and acute and chronic allograft rejection after organ transplantation.
- various immune mediated neurological disorders e.g. multiple sclerosis and myastenia gravis
- cardiovascular disorders e.g. myocarditis, congestive heart failure, arteriosclerosis and stable and unstable angina, and Wegeners granulomatosis
- inflammatory bowel diseases and colitis e.g., Crohn's colitis
- nephritis various inflammatory skin disorders (e.g.
- the present technology provides a method for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering a compound of the technology or a pharmaceutically acceptable salt thereof.
- IL-2 interleukin-2
- the mammal has developed or is susceptible to develop an autoimmune and/or inflammatory disorder.
- the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of proliferation of stimulated peripheral mononuclear cells (PBMC).
- PBMC peripheral mononuclear cells
- Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma, but also with decreased life span and numerous medical problems, including adverse psychological development, reproductive disorders such as polycystic ovarian disease, dermatological disorders such as infections, varicose veins, Acanthosis nigricans , and eczema, exercise intolerance, diabetes mellitus, insulin resistance, hypertension, hypercholesterolemia, cholelithiasis, osteoarthritis, orthopedic injury, thromboembolic disease, cancer, and coronary heart disease.
- the present technology provides a treatment regimen that is useful in returning the body weight of obese subjects toward a normal body weight. In some embodiments, the technology provides a therapy for obesity that results in maintenance of the lowered body weight for an extended period of time. Further, in some embodiments the present technology reduces or inhibits the weight gain normally induced by fat rich diets.
- the present technology prevents obesity and, once treatment has begun, to arrests progression or prevents the onset of diseases that are the consequence of, or secondary to, the obesity, such as hypertension and fatty liver.
- the obesity herein may be due to any cause, whether genetic or environmental.
- disorders that may result in obesity or be the cause of obesity include overeating and bulimia, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, Type II diabetes, GH-deficiency, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity.
- the present technology provides a treatment regimen that is useful in lowering the blood pressure. Further, in some embodiments the present technology provides a treatment regimen that is useful in lowering the concentration of triacylglycerols in the liver. It is anticipated that such a regimen provides an inhibiting effect on the development of a fatty liver condition and is suited as a method for the treatment of the manifested disease.
- the compounds of the present technology activate the oxidation, and also reduce the concentration, of triglycerides in the liver.
- metabolic syndrome is used to describe a multimetabolic syndrome that is inter alia characterized by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia, or hypertension.
- the compounds of the present technology provide a positive effect on all the conditions mentioned above, e.g., by regulating both glucose and lipid homeostasis, and thus it is anticipated that the compounds of the present technology are suitable agents for the regulation of the above defined metabolic disease (sometimes called syndrome X).
- IDDM insulin-dependent diabetes mellitus
- NIDDM noninsulin-dependent diabetes mellitus
- Type I diabetes severe diabetes mellitus, usually of abrupt onset prior to maturity, characterized by low plasma insulin levels, polydipsia, polyuria, increased appetite, weight loss and episodic ketoacidosis; also referred to as IDDM.
- Type II diabetes an often mild form of diabetes mellitus, often of gradual onset, usually in adults, characterized by normal to high absolute plasma insulin levels which are relatively low in relation to plasma glucose levels; also referred to as NIDDM.
- Type I and II diabetes are in accordance with an etiologic classification considered as primary diabetes respectively.
- Secondary diabetes comprises pancreatic, extrapancreatic and/or endocrine or drug-induced diabetes. Further, some types of diabetes are classified as exceptional forms. These include lipoatrophic, myatonic diabetes, and a type of diabetes caused by disturbance of insulin receptors.
- the present technology provides a treatment regimen that is useful in lowering the blood glucose and to treat a diabetic condition. Moreover, in some embodiments, the present technology provides a treatment regimen that is useful in lowering the concentration of insulin in the blood, and to increase the effect of the remaining insulin.
- pathological conditions have been found to be associated with smooth muscle cell proliferation. Such conditions include restenosis, arteriosclerosis, coronary heart disease, thrombosis, myocardial infarction, stroke, smooth muscle neoplasms such as leiomyoma, and leiomyosarcoma of the bowel and uterus and uterine fibroid or fibroma.
- interventional intravascular procedures Over half a million interventional intravascular procedures are performed each year. While such invasive procedures continue to improve over time, as many as 30% to 50% of the procedures performed each year fail as a result of restenosis, e.g., the formation of secondary stenosis. The reduction of restenosis is, therefore, often cited as the most critical factor in increasing the success realized in the treatment of cardiovascular disease through the use of interventional intravascular procedures, such as angioplasty, atherectomy, and procedures utilizing stents, and laser technology.
- a small incision is made to an artery in the patient's leg or arm and a long hollow tube, called a guide catheter, is inserted into the artery.
- a thick guide wire and deflated balloon catheter are then inserted into the guide catheter and are carefully advanced through the patient's blood vessels using X-ray visualization.
- the deflated balloon is advanced until it reaches the site of the luminal narrowing, at which point the physician inflates the balloon one or more times to a pressure of about 4-6 atm for about 60 seconds.
- the balloon When inflated, the balloon cracks and fractures the plaque and stretches the muscle fiber in the artery wall beyond its ability to recoil completely. Although no plaque is removed in this procedure, the fracturing of the plaque and the stretching of the arterial wall increase the vessel lumen, thereby allowing for increased blood flow.
- the restenosis that accompanies such procedures is characterized by platelet aggregation and adhesion, smooth muscle cell proliferation, narrowing of the vessel lumen, restricted vasodilatation, and an increase in blood pressure.
- Smooth muscle cells in the intimal layer of the artery have been reported to enter the growth cycle within about 2-3 days of these procedures and to proliferate for several days thereafter (intimal hyperplasia).
- Heparin is an example of one such compound, which reportedly inhibits smooth muscle cell proliferation in vitro but when used in vivo has the potential adverse side effect of inhibiting coagulation.
- chemotherapeutic agents for cancer treatment requires considering a variety of factors including cytotoxicity, tumor cell proliferation, invasion, and metastasis.
- Conventional anticancer agents have typically been identified on the basis of their cytotoxicity alone.
- Tumor progression is thought to occur when variant cells having selective growth properties arise within a tumor cell population, and one of the final stages of tumor progression is the appearance of the metastatic phenotype.
- the tumor cells During metastasis, the tumor cells invade the blood vessels, survive against circulating host immune defenses, and then extravasate, implant, and grow at sites distant from the primary tumor. This ability of tumor cells to invade neighboring tissues and to colonize other organs is among the leading causes of cancer related deaths.
- metastasis encompasses a number of phenotypic traits that together result in the clinical problem that most often leads to death from cancer.
- the cells lose their adherence and restrained position within an organized tissue, move into adjacent sites, develop the capacity both to invade and to egress from blood vessels, and become capable of proliferating in unnatural locations or environments. These changes in growth patterns are accompanied by an accumulation of biochemical alterations that have the capacity to promote the metastatic process.
- Cancer is a disease of inappropriate tissue accumulation. This derangement is most evident clinically when tumor tissue bulk compromises the function of vital organs. Contrary to what is generally thought, human malignant disorders are usually not diseases of rapid cell proliferation. In fact, the cells of most common cancers proliferate more slowly than many cells in normal tissues. It is a relatively slow accumulation of tumor tissue within vital organs that proves fatal to most patients who die of cancer.
- Chemotherapeutic agents share one characteristic: they are usually more effective in killing or damaging malignant cells than normal cells. However, the fact that they do harm normal cells indicates their potential for toxicity. Nearly all chemotherapeutic agents currently in use interfere with DNA synthesis, with the provision of precursors for DNA and RNA synthesis, or with mitosis. Such drugs are most effective against cycling cells. The mechanism of cell death after treatment with any single agent or combination of agents is complex and is likely to include more than one process. Because most clinically detectable tumors are composed mostly of non-cycling cells, it is not surprising that chemotherapy is not always effective in eradicating cancer.
- the strategy of cancer treatment is to shift tumor cells from a non-cycling compartment to a cycling compartment.
- Several methods that promote this shift form the basis for combined-modality treatment.
- Surgery is most commonly used to reduce tumor size and thus facilitate re-entry of cancer cells into the cell cycle.
- microscopic metastases may remain at distant sites. Because of their small size, the micrometastases are composed principally of cycling cells Small numbers of cells that remain at primary tumor site are also likely to re-enter the cell cycle. Thus, the remaining cancer cells are often susceptible to chemotherapy. Radiation therapy or chemotherapy alone can also be used to reduce tumor bulk and thus recruit cells into the cycling cell compartment.
- Combination drug therapy is, therefore, the basis for most chemotherapy employed at present.
- Combination chemotherapy uses the different mechanisms of action and cytotoxic potentials of multiple drugs.
- the chemotherapeutic agents are more effective in killing or damaging malignant cells than normal cells, the fact that they do harm normal cells indicates their great potential for toxicity.
- the patient must be in good physiologic condition.
- Cancer treatment requires inhibition of a variety of factors including tumor cell proliferation, metastatic dissemination of cancer cells to other parts of the body, invasion, tumor-induced neovascularization, and enhancement of host immunological responses and cytotoxicity.
- the present technology provides a method for the prevention and/or treatment of primary and metastatic neoplasms that involves using a fatty acid analogue, or a lipid comprising a fatty acid analogue, of the present technology to treat a patient suffering from a cancer.
- the two essential features of cancer are invasion and metastasis.
- microinvasion of the basement membrane characterizes the transition from neoplasia to cancer, and at the other extreme, metastases generally lead to death.
- Invasion into the underlying connective tissue by primary tumor proceeds in stages and is facilitated by various mediators produced by the tumor cells.
- Tumor cells that have not invaded the basement membrane and remain confined within the epithelium are termed carcinoma in situ.
- Metastases may form when circulating tumor cells with adherent lymphocytes and platelets are trapped in capillaries and the tumor cell membrane interacts with the capillary endothelium. The capillary endothelial junctions retract, and tumor cell ligands bind to receptors on the endothelial and basement membranes.
- Tumor cells then release collagenase IV, which destroys collagen IV, a major component of the underlying basement membrane. Invasion of the subcapillary connective tissue is aided by binding to the glycoproteins laminin and fibronectin, by the release of proteases that destroy the matrix, and by the secretion of motility and chemotactic factors. Tumor cells then may proliferate and synthesize platelet aggregatory factors such as thromboxanes and procoagulants, thereby leading to the deposition of a fibrin cocoon around the cells. Such a cocoon may protect the micrometastasis from attack by the host's immune system.
- Cancers that can be prevented and/or treated by the compositions and methods of the present technology include, but are not limited to, human sarcomas and carcinomas, e.g. carcinomas, e.g., colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma
- proliferative skin diseases are widespread throughout the world and afflict millions of humans and their domesticated animals.
- Proliferative skin diseases are characterized by keratinocyte cell proliferation, or division, and may also be associated with incomplete epidermal differentiation.
- Psoriasis is the most serious of the proliferative skin diseases with which this technology is concerned.
- Psoriasis is a genetically determined disease of the skin characterized by two biological hallmarks. First, there is a profound epidermal hyperproliferation related to accelerated and incomplete differentiation. Second, there is a marked inflammation of both epidermis and dermis with an increased recruitment of T lymphocytes, and in some cases, formation of neutrophil microabcesses. Many pathologic features of psoriasis can be attributed to alterations in the growth and maturation of epidermal keratinocytes, with increased proliferation of epidermal cells, occurring within 0.2 mm of the skin's surface.
- psoriasis vulgaris A common form of psoriasis, psoriasis vulgaris, is characterized by well-demarcated erythematous plaques covered by thick, silvery scales.
- a characteristic finding is the isomorphic response (Koebner phenomenon), in which new psoriatic lesions arise at sites of cutaneous trauma. Lesions are often localized to the extensor surfaces of the extremities, and the nails and scalp are also commonly involved.
- the retinoids are also an effective treatment for psoriasis.
- Etretinate is especially useful in the exfoliative and pustular varieties of psoriasis.
- several major potential complications must be monitored in patients placed on retinoids.
- the retinoids are potent teratogens and should not be given to women of childbearing age who are not using adequate contraception.
- Etretinate like other retinoids, can produce elevations in cholesterol and triglyceride levels; therefore dietary regulation may be necessary.
- etretinate can induce hepatotoxicity, liver function tests should be performed before and at regular intervals during use of the drug.
- Cytokines are a class of secreted soluble proteins normally present in very low concentration in a variety of cells. Lymphoid, inflammatory hemopoietic, and other cells such as connective tissue cells (e.g. fibroblasts, osteoblasts) secrete a variety of cytokines which regulate the immune, inflammatory, repair, and acute phase responses by controlling cell proliferation, differentiation, and effector functions. The effects of cytokines are mediated through binding to high affinity receptors on specific cell types.
- IL-10 An important cytokine is IL-10, a 35-40 kDa peptide produced by helper T-cells, B-cells, monocytes, macrophages, and other cell types.
- helper T-cells a 35-40 kDa peptide produced by helper T-cells, B-cells, monocytes, macrophages, and other cell types.
- IL-10 has demonstrated immunosuppressive properties as evidenced by its ability to suppress cytokine production including IL-1 and TNF ⁇ .
- IL-10 also inhibits activation of other inflammatory cytokines, and therefore has potent anti-inflammatory activity.
- Such diseases or conditions include loosening of prosthetic joint implants, inflammation, diabetes, cancer, graft versus host diseases, viral, fungal and bacterial infections, lipopolysaccharide endotoxin shock, diseases of depressed bone marrow function, thrombocytopenia, osteoporosis, spondyloarthropathies, Paget's disease, inflammatory bowel disease, arthritis, osteoarthritis, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and connective tissue diseases.
- IL-10 has been shown in vitro to suppress certain types of viral infections.
- U.S. Pat. No. 5,665,345 discloses a method for inhibiting replication of the human immunodeficiency virus, retro-viruses, and Kaposi sarcoma in human cells by administering IL-10.
- IL-10 has also been suggested for use in the treatment of certain cancers.
- U.S. Pat. No. 5,570,190 discloses administering exogenous IL-10 to treat mammals suffering from acute myelogenous leukemia and acute lymphocytic leukemia.
- IL-10 is said to be administered either in the purified or recombinant form and is believed to inhibit the proliferation of acute leukemia blast cells.
- IL-10 was shown to inhibit bone marrow metastasis in severe combined immunodeficient mice.
- IL-10 is a protein
- proteins often leach out of solution and bind to the plastic or glass used in intravenous administration sets.
- proteins are often incompatible and precipitate when mixed with physiological solutions such as dextrose or saline.
- oral and topical routes are unavailable for IL-10 administration. The oral route is unavailable because protein is degraded in the gastrointestinal tract. None of the above approaches suggests enhancing endogenous IL-10 production in mammals for prophylaxis and treatment of diseases or conditions.
- IL-10 is a powerful deactivator of macrophages and T cells, and inadequate production has been implicated in various autoimmune and inflammatory disorders.
- embodiments of the compounds provided herein enhance both LPS and PHA stimulated IL-10, and suppress PHA stimulated IL-2 production in PBMC from healthy blood donors.
- These findings suggested a marked anti-inflammatory net effect of the present compounds by both enhancing the release of the anti-inflammatory cytokine IL-10 and by suppressing the release of the inflammatory cytokine IL-2.
- the findings suggested that the present compounds may modulate both monocyte (e.g., LPS stimulation) and lymphocyte activation (e.g., PHA stimulation).
- the in vitro effect of the present compounds on activated PBMC from healthy blood donors may reflect the situation in various patient populations characterized by enhanced inflammatory activation in vivo. In fact, ex vivo activated PBMC from healthy controls, may represent the relevant target cells for therapeutically intervention in vivo in various inflammatory disorders.
- embodiments of the compound or composition of the present technology are useful in the treatment of the disorders listed in WO/1998/05635.
- cancer inflammation or inflammatory disease
- dermatological disorders fever, cardiovascular effects, hemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis
- cerebral ischemia ischemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurode generation, Alzheimer's disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis
- periodontitis, gingivitis psoriasis
- embodiments of the compound or composition of the present technology are useful in the treatment of disorders listed in WO/1998/07859.
- cytokine and cell proliferation/differentiation activity e.g., for treating immune deficiency, including infection with human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumor immunity); regulation of hematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g.
- follicle-stimulating hormone for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilizing specific cell types to sites of injury or infection); hemostatic and thrombolytic activity (e.g. for treating hemophilia and stroke); anti-inflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behavior; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.
- compositions of the present technology are useful in the treatment of disorders listed in WO/1998/09985.
- macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity e.g., anti-inflammatory activity
- anti-immune activity e.g., inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation
- unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with
- monocyte or leukocyte proliferative diseases e.g. leukaemia
- monocytes or lymphocytes for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.
- Embodiments of the technology include any therapeutic application that can benefit a human or non-human animal, for example a mammal. As such, both human and veterinary treatments are within the scope of the present technology.
- Treatment may be in respect of an existing condition or it may be prophylactic. It may be of an adult, a juvenile, an infant, a fetus, or a part of any of the aforesaid (e.g., an organ, tissue, cell, or nucleic acid molecule).
- an active agent for use in treatment is administered via any appropriate route and at any appropriate dosage. Dosages can vary between wide limits, depending upon the nature of the treatment, the age and condition of the individual to be treated, etc., and a physician will ultimately determine appropriate dosages to be used. However, without being bound by any particular dosages, a daily dosage of a compound of the present technology of from 1 ⁇ g to 1 mg/kg body weight may be suitable. The dosage may be repeated as often as appropriate. If side effects develop, the amount and/or frequency of the dosage can be reduced, in accordance with good clinical practice.
- Embodiments of compounds according to the present technology may exist in a polymorphic form.
- embodiments of compounds according to the present technology may contain one or more asymmetric carbon atoms and therefore exist in two or more stereoisomeric forms.
- an agent contains an alkenyl or alkenylene group
- cis (E) and trans (Z) isomerism may also occur.
- the present technology includes the individual stereoisomers of the agent and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
- Separation of diastereoisomers and/or cis and trans isomers may be achieved by conventional techniques, e.g., by fractional crystallization, chromatography, or H.P.L.C. of a stereoisomeric mixture of the agent or a suitable salt or derivative thereof.
- An individual enantiomer of a compound of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
- the present technology also includes all suitable isotopic variations of the agent or a pharmaceutically acceptable salt thereof.
- An isotopic variation of an agent of the present technology or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine such as 2 H, 3 H, 13 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, and 36 C 1 , respectively.
- isotopic variations of the agent and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies. Tritiated, e.g., 3 H, and carbon-14, e.g., 14 C, isotopes are particularly useful for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, e.g., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present technology and pharmaceutically acceptable salts thereof of this technology can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- compounds according to the technology are derived from a prodrug.
- Prodrugs are entities that may or may not possess pharmacological activity as such, but may be administered (such as orally or parenterally) and thereafter subject to bioactivation (for example metabolized) in the body to form the agent of the present technology which is pharmacologically active.
- Examples of prodrugs include entities that have certain protected group(s) and that may not possess pharmacological activity as such, but may, in certain instances, be administered (such as orally or parenterally) and thereafter metabolized in the body to form the agent of the present technology that are pharmacologically active.
- the technology encompasses certain moieties known as “pro-moieties”, for example as described in “Design of Prodrugs” by H. Bundgaard, Elsevier, 1985 (the disclosure of which is hereby incorporated by reference).
- a pro-moiety may be placed on appropriate functionalities of the agents. Such prodrugs are also included within the scope of the technology.
- derivative or “derivatized” as used herein includes chemical modification of an agent. Illustrative of such chemical modifications would be replacement of hydrogen by a halo group, an alkyl group, an acyl group, or an amino group.
- the agent may be a chemically modified agent.
- the chemical modification of an agent of the present technology may either enhance or reduce hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction, or dipole interaction between the agent and the target.
- the identified agent may act as a model (for example, a template) for the development of other compounds.
- the lipid compositions described above may be used in combination with one or more sialic acid analogs.
- sialic acid analogs include sialic acids and sialic acid precursors.
- sialic acids or sialic acid precursors are selected from the group consisting of n-glycolylneuraminic acid, n-acetylneuraminic acid and N-Acetyl-D-mannosamine.
- the composition may comprise two or more of the following sialic acids: Neuraminic acid, 5-N-Acetyl-4-O-acetyl-neuraminic acid, 5-N-Acetyl-7-O-acetyl-neuraminic acid, 5-N-Acetyl-8-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-neuraminic acid, 5-N-Acetyl-4,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-8,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,8,9-tri-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-L-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-7
- compositions may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sialic acid analogs.
- sialic acid analogs have a purity selected from the group consisting of greater than 90%, 95%, 99%, and 99.5% pure.
- the sialic acid precursor may be co-formulated in the same delivery vehicle as the lipid composition, or may be provided in a separated delivery vehicle.
- the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day.
- the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 0.1 to 10 mg/150 kg subject/day, 0.3 to 5 mg/150 kg subject/day, and 0.5 to 2 mg/150 kg subject/day.
- the administering is selected from the group consisting of enteral administration, parenteral administration, oral administration, sublingual administration, subcutaneous administration, intramuscular administration, and intravenous administration.
- the lipid composition/sialic acid compositions may be provided in a single dosage form or a part of treatment regime where the lipid composition and sialic acid are co-administered. It is contemplated that these compositions may be utilized for the uses described above.
- TTA has shown promise as an agent for the treatment of various metabolic conditions and related conditions, including metabolic syndrome, diabetes, obesity, fatty liver, and hypertension. TTA also shows promise as a nutritional supplement that can be used to reduce weight and improve body composition. See e.g., U.S. Pat. Nos. 7,902,399; 7,659,242; 7,378,443; 7,230,029; 7,026,356; 6,441,036; 6,417,232; and 6; 365; 628, all of which are incorporated by reference herein in their entirety.
- TTA has properties very similar to natural fatty acids, the main difference being that TTA is not oxidized by the mitochondrial beta-oxidation system. However, the presence of non-beta-oxidizable fatty acid analogues has been shown to increase the beta-oxidation of other fatty acids.
- TTA modifies the composition of lipids in various tissues.
- TTA also modifies fat content and it is anticipated that TTA also modifies fat distribution.
- TTA Tetradecylselenoacetic
- TTA compositions that have been marketed in the United States and Europe for human consumption have been associated with side effects, including lethargy, muscle cramps and muscle pain. It is likely that these side effects are due to contaminants in the commercially produced TTA. Accordingly, during the development of embodiments of the technology, experiments were performed to provide a synthesis of TTA that has reduced side effects and to test the use of such TTA compositions in human nutrition.
- a method for the synthesis of TTA comprises distillation of bromotetradecane-1 to provide a reagent for the synthesis.
- a mass of 29.5 kg of commercial bromotetradecane-1 was distilled in two steps at 79° C. under reduced pressure; the two distillates were combined and totaled 25.0 kg. A dark residue of 2.7 kg was removed.
- Crystallization The liquid TTA (20 kg) was mixed at approximately 70° C. with 100 of kg room-temperature acetone. After cooling to 30 to 35° C. 145 kg of fresh acetone were added to the mix to provide a total of 245 kg acetone added. The mixture was then cooled to ⁇ 30° C. and filtered. After drainage of the liquid, the crystal phase was dried under vacuum and heated to about 40° C. The yield was 19.9 kg.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
Abstract
Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids.
Description
- The present application is a continuation of U.S. patent application Ser. No. 15/725,431, filed Oct. 5, 2017, now allowed as U.S. Pat. No. 10,259,833, which is a continuation of U.S. patent application Ser. No. 14/774,434, filed Sep. 10, 2015, which is a 371 U.S. National Phase Entry of International Application No. PCT/IB2014/001254, filed Mar. 10, 2014, which claims priority to U.S. Provisional Patent Application No. 61/775,834, filed Mar. 11, 2013, the contents of which are incorporated by reference in their entireties.
- Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids.
- By introducing particular atoms into a fatty acid, fatty acid analogues are produced that are not catabolized by β-oxidation. For example, European Patent Specification No. 0345038 described the preparation of non-β-oxidizable fatty acid analogues having the general formula
-
Alkyl-X—CH2COOR - wherein Alkyl represents a saturated or unsaturated hydrocarbon group of from 8 to 22 carbon atoms; X represents O, S, SO, and SO2; and R represents hydrogen or a C1-C4 alkyl. Subsequently, PCT/N099/00135, PCT/N099/00136, and PCT/N099/00149 described similar non-β-oxidizable fatty acid analogues having the formula
-
CH3—[CH2]w—[Xi—CH2]n—COOR - wherein n is an integer from 1 to 12; m is an integer from 0 to 23; i is an odd number that indicates the position of Xi relative to COOR; Xi are independently selected from the group comprising O, S, SO, SO2, Se, and CH2; and R represents hydrogen or C1-C4 alkyl; with the proviso that at least one of the Xi is not CH2. As indicated by these two formulae, these compounds comprise one or several X groups (e.g., selenium or sulfur) at positions 3, 5, 7, 9, etc.
- Due to the X atom (e.g., sulfur or selenium) that is substituted in the carbon chain of these fatty acid analogues, the compounds are not β-oxidized in the mitochondria beyond the position of the X atom. Thus, the degradation of these molecules must start from the methyl end of the fatty acid, which is a rather slow metabolic process. As such, the catabolism of these fatty acid analogues includes ω-oxidation and chain shortening of the dicarboxylic acid by peroxisomes. Enzymes in the endoplasmic reticulum ω-hydroxylate and further oxidize the hydroxylated fatty acid to a dicarboxylic acid. This acid may then be chain shortened by β-oxidation in the peroxisomes.
- These substituted analogues have been demonstrated to have general antioxidant properties due to the presence of the heteroatom (see, e.g., WO/1997/03663). In addition, the biochemical characteristics of non-β-oxidizable fatty acid analogues provide particular beneficial activities, for example, to treat and/or prevent obesity (NO 2000 5461); diabetes (NO 2000 5462); primary and secondary stenosis (NO 2000 5463); cancer (NO 2002 5930); proliferate skin disorders (NO 2003 1080); and inflammatory and autoimmune disorders (NO 2003 2054). See also Int'l App. Nos. WO/1999/058123, WO/2001/N000301, WO/2001/N000393, and WO/2001/N000470; U.S. Pat. Nos. 6,365,628; 6,441,036; 6,417,232; and 7,026,356; and U.S. Pat. App. Pub. No. 2002198259.
- Additional work described synthetic phospholipid compounds containing non-β-oxidizable fatty acid analogues. (see, e.g., U.S. Pat. No. 8,178,713). These phospholipids (e.g., phosphatidylcholine and triacylglycerol compounds) increased fatty acid oxidation and decreased hepatic lipid levels in vivo. Due to similarities in molecular structure with the fatty acid analogues from which they are synthesized, these phospholipids are anticipated to have similar biological activities as the fatty acid analogues, e.g., as agents to treat hyperinsulinemia, hyperglycemia, fatty liver, and obesity. However, the in vitro synthesis of these lipid compounds lacks efficiency. Moreover, the synthetic phospholipid preparations may contain non-natural substances that are not desirable or appropriate for administration to a subject.
- As such, provided herein is technology related to producing natural phospholipids in an in vivo system. In particular, embodiments of the technology relate to providing a non-β-oxidizable fatty acid analogue as a nutrient to a living organism (e.g., a yeast, a bacterium, an alga, an archaeon, etc.) that produces a phospholipid incorporating the non-β-oxidizable fatty acid analogue and then isolating the phospholipid containing the non-β-oxidizable fatty acid analogue from the living organism. The technology also encompasses embodiments related to compositions comprising a phospholipid incorporating the non-β-oxidizable fatty acid analogue and uses of such compositions.
- In some embodiments, the present invention provides composition comprising a natural lipid and a natural biomolecule, wherein the natural lipid comprises a non-beta-oxidizable fatty acid analogue. In some embodiments, the natural biomolecule is a second lipid. In some embodiments, the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film. In some embodiments, the non-beta-oxidizable fatty acid analogue is tetradecylthioacetic acid (TTA). In some embodiments, the non-beta-oxidizable fatty acid analogue is tetradecylselenoacetic acid (TSA). In some embodiments, the natural lipid is a phospholipid. In some embodiments, the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a headgroup. In some embodiments, the natural lipid has a biological activity in a mammal. In some embodiments, the biomolecule has a biological activity in a mammal. In some embodiments, the natural lipid is a sphingolipid. In some embodiments, the biomolecule is a protein, nucleic acid, steroid, cofactor, or vitamin. In some embodiments, the natural lipid is an omega-3 fatty acid moiety. In some embodiments, the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA. In some embodiments, the natural lipid is an omega-6 fatty acid moiety. In some embodiments, the natural lipid is a conjugated linoleic acid moiety.
- In some embodiments, the present invention provides a composition comprising a natural lipid, the composition obtainable by a process comprising the steps of: 1) providing a biologically active biomolecule to a living organism in vitro; and 2) isolating the composition comprising the natural lipid from the living organism. In some embodiments, the biologically active biomolecule is a non-beta-oxidizable fatty acid analogue. In some embodiments, the biologically active biomolecule is TTA or a furan fatty acid. In some embodiments, the lipid comprises a non-beta-oxidizable fatty acid analogue. In some embodiments, the lipid comprises TTA or a furan fatty acid. In some embodiments, the living organism is an alga. In some embodiments, the living organism is a bacterium or an archaeon. In some embodiments, the living organism is a yeast. In some embodiments, the process further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a second living organism. In some embodiments, the process further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a marine organism. In some embodiments, the compositions further comprise a second biomolecule. In some embodiments, the second biomolecule is a lipid, protein, nucleic acid, steroid, cofactor, or vitamin. In some embodiments, the living organism is in a culture. In some embodiments, the culture comprises a plurality of living organisms, wherein each living organism is characterized by a type and the culture comprises a plurality of the types. In some embodiments, the type is a species, subspecies, isolate, clone, genus, family, division, kingdom, or other taxonomic classification. In some embodiments, the living organism is a thermophile. In some embodiments, the second living organism is a thermophile. In some embodiments, the TTA is produced by reacting thioglycolic acid with bromotetradecane. In some embodiments, the TTA is produced by a method comprising dissolving sodium hydroxide in methanol to produce a reaction solution, adding thioglycolic acid to the reaction solution, adding 1-bromotetradecane to the reaction solution, adding citric acid to the reaction solution, and isolating TTA from the reaction solution. In some embodiments, the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film. In some embodiments, the natural lipid is a phospholipid. In some embodiments, the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a headgroup. In some embodiments, the natural lipid has a biological activity in a mammal. In some embodiments, the second biomolecule has a biological activity in a mammal. In some embodiments, the natural lipid is a sphingolipid. In some embodiments, the natural lipid further comprises an omega-3 fatty acid moiety. In some embodiments, the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA. In some embodiments, the natural lipid further comprises an omega-6 fatty acid moiety. In some embodiments, the natural lipid further comprises a conjugated linoleic acid moiety.
- In some embodiments, the present invention provides methods for producing a composition comprising a natural lipid, the method comprising: 1) providing a biologically active biomolecule to a living organism in vitro; and 2) isolating the composition comprising the natural lipid from the living organism. In some embodiments, the biologically active biomolecule is a non-beta-oxidizable fatty acid analogue. In some embodiments, the biologically active biomolecule is TTA. In some embodiments, the natural lipid comprises a non-beta-oxidizable fatty acid analogue. In some embodiments, the natural lipid comprises TTA. In some embodiments, the living organism is an alga. In some embodiments, the living organism is a bacterium or an archaeon. In some embodiments, the living organism is a yeast. In some embodiments, the method further comprises producing an extract, fraction, or composition comprising the biologically active molecule from a second living organism. In some embodiments, the method further comprise producing an extract, fraction, or composition comprising the biologically active molecule from a marine organism. In some embodiments, the composition comprising the natural lipid further comprises a second biomolecule. In some embodiments, the second biomolecule is a lipid, protein, nucleic acid, steroid, cofactor, or vitamin. In some embodiments, the living organism is in a culture. In some embodiments, the culture comprises a plurality of living organisms, wherein each living organism is characterized by a type and the culture comprises a plurality of the types. In some embodiments, the type is a species, subspecies, isolate, clone, genus, family, division, kingdom, or other taxonomic classification. In some embodiments, the living organism is a thermophile. In some embodiments, the second living organism is a thermophile. In some embodiments, the TTA is produced by reacting thioglycolic acid with bromotetradecane. In some embodiments, the TTA is produced by a method comprising dissolving sodium hydroxide in methanol to produce a reaction solution, adding thioglycolic acid to the reaction solution, adding 1-bromotetradecane to the reaction solution, adding citric acid to the reaction solution, and isolating TTA from the reaction solution. In some embodiments, the composition comprises an oil, powder, crystal, wax, emulsion, micelle, vesicle, or film. In some embodiments, the natural lipid is a phospholipid. In some embodiments, the natural lipid comprises a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol headgroup. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a headgroup. In some embodiments, natural lipid has a biological activity in a mammal. In some embodiments, the biomolecule has a biological activity in a mammal. In some embodiments, the natural lipid is a sphingolipid. In some embodiments, the methods further comprise
- testing the composition comprising the natural lipid in a mouse model of a metabolic disease. In some embodiments, the natural lipid further comprises an omega-3 fatty acid moiety. In some embodiments, the omega-3 fatty acid moiety is selected from the group consisting of EPA and DHA. In some embodiments, the natural lipid further comprises an omega-6 fatty acid moiety. In some embodiments, the natural lipid further comprises a conjugated linoleic acid moiety.
- In some embodiments, the present invention provides structured phospholipid compositions comprising phospholipid molecules of the following structure:
- wherein one of R1 and R2 is a non-beta-oxidizable fatty acid analogue moiety and the other of R1 and R2 is a bioactive fatty acid moiety selected from the group consisting of an omega-3 fatty acid moiety, on omega-6 fatty acid moiety, a polyunsaturated fatty acid moiety, a conjugated linoleic fatty acid moiety, and combinations thereof. In some embodiments, the composition comprises greater than 10%, 20%, 30%, 40%, 50%, 80%, 90% or 99% on a molar basis of the non-beta-oxidizable fatty acid analogue moiety at position R1. In some embodiments, the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of the non-beta-oxidizable fatty acid analogue moiety at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of the bioactive fatty acid moieties or combinations thereof at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of the bioactive fatty acid moiety at position R1. In some embodiments, the bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof. In some embodiments, the bioactive fatty acid moiety is EPA. In some embodiments, the bioactive fatty acid moiety is DHA. In some embodiments, the bioactive fatty acid moiety is conjugated linoleic acid.
- In some embodiments, the present invention provides for the use of a composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a medicament.
- In some embodiments, the present invention provides for the use of a composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a food product. In some embodiments, the food product has a biological activity in a human.
- In some embodiments, the present invention provides for the use of a composition for ameliorating a metabolic disease in a subject, the composition comprising a natural lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue or a furan fatty acid. In some embodiments, the non-beta-oxidizable fatty acid analogue is TTA.
- In some embodiments, the present invention provides for the use of a composition comprising a lipid and a natural biomolecule or a structured phospholipid, wherein the lipid or structured phospholipid comprises a non-beta-oxidizable fatty acid analogue, for the preparation of a medicament to treat a disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the metabolic disease is obesity, diabetes, hypercholesterolemia, hyperlipidemia, glucose intolerance, aberrant adipose tissue storage and/or distribution, syndrome X, hypertension, fatty liver, hyperglycemia, hyperinsulinemia, or stenosis. In some embodiments, the disease is cancer, vascular disease, skin condition, or an inflammatory disorder.
- In some embodiments, the present invention provides a combination comprising a liposome and a composition as described above.
- In some embodiments, a cosmetic formulation comprising a lipid composition as described above.
- In some embodiments, the present invention provides methods of treating a condition chosen from syndrome X, obesity or an overweight condition, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia, insulin resistance, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia (HTG), and stenosis, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof. In some embodiments, the method provides for producing weight loss or a reduction of fat mass in a human or non-human animal in need thereof.
- In some embodiments, the present invention provides methods for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods of lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the modification of the fat distribution and content of animals, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods of inhibiting the growth of tumors, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the treatment or inhibition of primary and secondary metastatic neoplasms, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the treatment of proliferative skin disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the inhibition of proliferation or induction of differentiation of keratinocytes, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides methods for the inhibition of proliferation of stimulated peripheral mononuclear cells (PBMC), comprising administering to a subject in need thereof an effective amount of a composition as described above, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present invention provides a pharmaceutical composition comprising a natural lipid as described above, a natural biomolecule, and a pharmaceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition comprising a structured phospholipid as described above. In some embodiments, the natural lipid comprises TTA or a furan fatty acid. In some embodiments, the natural lipid comprises an ether link between a lipid tail and a lipid headgroup. In some embodiments, the pharmaceutical composition is admixed with at least one of a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant. In some embodiments, the pharmaceutical composition is topically administrable. In some embodiments, the pharmaceutical composition is parenterally administrable. In some embodiments, the pharmaceutical composition is intravenously administrable.
- In some embodiments, the present invention provides a composition comprising a physiologically effective amount of TTA or a derivative thereof, the composition characterized in by a substantial lack of side effects when administered to a human subject, the side effects selected from the group consisting of lethargy, muscle cramps, and muscle pain. In some embodiments, the physiologically effective amount is from about 10 mg to 5 g TTA. In some embodiments, the physiologically effective amount is from about 100 mg to 3 g TTA. In some embodiments, the substantial lack of side effects is characterized by the presence of the side effects in less than 5% of a population. In some embodiments, the substantial lack of side effects is characterized by the presence of the side effects in less than 1% of a population. In some embodiments, the composition comprises at least one fatty acid in addition to the TTA or a derivative thereof. In some embodiments, the derivative of TTA is an ester, triglyceride, or phospholipid comprising a TTA moiety. In some embodiments, the composition is produced by distilling 1-bromotetradecane to remove contaminants and provide distilled 1-bromotetradecane, and reacting the distilled 1-bromotetradecane with a chemical moiety to provide TTA.
- In some embodiments, the lipid compositions described above (e.g., the natural lipid compositions and structured lipid compositions) may be used in combination with one or more sialic acid analogs. As used herein sialic acid analogs include sialic acids and sialic acid precursors. Preferably, sialic acids or sialic acid precursors are selected from the group consisting of n-glycolylneuraminic acid, n-acetylneuraminic acid and N-Acetyl-D-mannosamine. In some embodiments, the composition may comprise two or more of the following sialic acids: Neuraminic acid, 5-N-Acetyl-4-O-acetyl-neuraminic acid, 5-N-Acetyl-7-O-acetyl-neuraminic acid, 5-N-Acetyl-8-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-neuraminic acid, 5-N-Acetyl-4,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-8,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,8,9-tri-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-L-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-4-O-acetyl-9-O-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-8-O-methyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-8-O-methyl-neuraminic acid, 5-N-Acetyl-8-O-sulpho-neuraminic acid, 5-N-Acetyl-9-O-phosphoro-neuraminic acid, 5-N-Acetyl-2-deoxy-2,3-didehydro-neuraminic acid, 5-N-Acetyl-9-O-acetyl-2-deoxy-2,3-didehydro-neuraminic acid, 5-N-Acetyl-2-deoxy-2,3-didehydro-9-O-lactyl-neuraminic acid, 5-N-Acetyl-2,7-anhydro-neuraminic acid, 4-O-Acetyl-5-N-glycolyl-neuraminic acid, 7-O-Acetyl-5-N-glycolyl-neuraminic acid, 8-O-Acetyl-5-N-glycolyl-neuraminic acid, 9-O-Acetyl-5-N-glycolyl-neuraminic acid, 7,9-Di-O-acetyl-5-N-glycolyl-neuraminic acid, 8,9-Di-O-acetyl-5-N-glycolyl-neuraminic acid, 7,8,9-Tri-O-acetyl-5-N-glycolyl-neuraminic acid, 5-N-glycolyl-9-O-lactyl-neuraminic acid, 5-N-glycolyl-8-O-methyl-neuraminic acid, 9-O-Acetyl-5-N-glycolyl-8-O-methyl-neuraminic acid, 7,9-di-O-Acetyl-5-N-glycolyl-8-O-methyl-neuraminic acid, 5-N-glycolyl-8-O-sulpho-neuraminic acid, N—(O-acetyl)glycolylneuraminic acid, N—(O-Methyl)glycolylneuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-neuraminic acid, 9-O-Acetyl-2-deoxy-2,3-didehydo-5-N-glycolyl-neuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-9-0-lactyl-neuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-8-O-methyl-neuraminic acid, 2,7-Anhydro-5-N-glycolyl-neuraminic acid, 2,7-Anhydro-5-N-glycolyl-8-O-methyl-neuraminic acid, 2-Keto-3-deoxynononic acid, and 9-O-Acetyl-2-keto-3-deoxynononic acid. In some embodiments, the compositions may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sialic acid analogs. In some embodiments, the sialic acid analogs have a purity selected from the group consisting of greater than 90%, 95%, 99%, and 99.5% pure.
- The sialic acid precursor may be co-formulated in the same delivery vehicle as the lipid composition, or may be provided in a separated delivery vehicle. In some embodiments, the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day. In some embodiments, the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 0.1 to 10 mg/150 kg subject/day, 0.3 to 5 mg/150 kg subject/day, and 0.5 to 2 mg/150 kg subject/day. In some embodiments, the administering is selected from the group consisting of enteral administration, parenteral administration, oral administration, sublingual administration, subcutaneous administration, intramuscular administration, and intravenous administration.
- Additional embodiments will be apparent to persons skilled in the relevant art based on the teachings contained herein.
- Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and therapeutic use of natural lipids containing non-β-oxidizable fatty acids. This technology is described below, wherein the section headings are for organizational purposes only and are not to be construed as limiting the described subject matter in any way.
- In this detailed description of the various embodiments, for purposes of explanation, numerous specific details are set forth to provide a thorough understanding of the embodiments disclosed. One skilled in the art will appreciate, however, that these various embodiments may be practiced with or without these specific details. In other instances, structures and devices are shown in block diagram form. Furthermore, one skilled in the art can readily appreciate that the specific sequences in which methods are presented and performed are illustrative and it is contemplated that the sequences can be varied and still remain within the spirit and scope of the various embodiments disclosed herein.
- All literature and similar materials cited in this application, including but not limited to, patents, patent applications, articles, books, treatises, and internet web pages are expressly incorporated by reference in their entirety for any purpose. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which the various embodiments described herein belongs. When definitions of terms in incorporated references appear to differ from the definitions provided in the present teachings, the definition provided in the present teachings shall control.
- To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.
- Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the technology may be readily combined, without departing from the scope or spirit of the technology.
- In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”
- As used herein, “feeding” refers to providing a substance, compound, composition, etc. to a living organism. For example, the substance, compound, composition, etc. may be an energy source, a carbon source, a nutrient, or a source of other elements, molecules, and/or precursors of biological molecules that are used by the living organism and/or are metabolized (e.g., catabolized, anabolized) by the living organism. The substance, compound, composition, etc. is not necessarily a substance, compound, composition, etc. that the living organism encounters in its native milieu, but may be a synthetic substance, compound, composition, etc. or a natural substance, compound, composition, etc. that is nevertheless used by the living organism for metabolism. The substance, compound, composition, etc. may be added to a culture medium or a substrate in which or on which the living organism lives and/or grows.
- As used herein, “active” or “activity” refers to native or naturally occurring biological and/or immunological activity.
- As used herein the term, “in vitro” refers to an artificial environment and to processes or reactions that occur within an artificial environment. In vitro environments may include, but are not limited to, test tubes and cell cultures. The term “in vivo” refers to the natural environment (e.g., an animal or a cell) and to processes or reactions that occur within a natural environment.
- As used herein, the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g., a human with a disease such as obesity, diabetes, or insulin resistance).
- As used herein, the term “individual” refers to vertebrates, particularly members of the mammalian species. The term includes but is not limited to domestic animals, sports animals, primates, and humans.
- As used herein, the term “effective amount” refers to the amount of a composition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
- As used herein, the term “administration” refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment to a subject. Exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (transdermal, topical), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.), and the like.
- As used herein, the term “co-administration” refers to the administration of at least two agents or therapies to a subject. In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy. Those of skill in the art understand that the formulations and/or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent.
- As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for therapeutic use.
- The terms “pharmaceutically acceptable” or “pharmacologically acceptable”, as used herein, refer to compositions that do not substantially produce adverse reactions, e.g., toxic, allergic, or immunological reactions, when administered to a subject.
- As used herein, the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a disease or disorder through introducing in any way a therapeutic composition of the present technology into or onto the body of a subject. “Treatment” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
- As used herein, the term “sample” is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like. Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples. Such examples are not however to be construed as limiting the sample types applicable to the present technology.
- As used herein, the terms “alkyl” and the prefix “alk-” are inclusive of both straight chain and branched chain saturated or unsaturated groups, and of cyclic groups, e.g., cycloalkyl and cycloalkenyl groups. Unless otherwise specified, acyclic alkyl groups are from 1 to 6 carbons. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 8 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl, and adamantyl groups. Alkyl groups may be substituted with one or more substituents or unsubstituted. Exemplary substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halogen, alkylsilyl, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups. When the prefix “alk” is used, the number of carbons contained in the alkyl chain is given by the range that directly precedes this term, with the number of carbons contained in the remainder of the group that includes this prefix defined elsewhere herein. For example, the term “C1-C4 alkaryl” exemplifies an aryl group of from 6 to 18 carbons (e.g., see below) attached to an alkyl group of from 1 to 4 carbons.
- As used herein, the term “aryl” refers to a carbocyclic aromatic ring or ring system. Unless otherwise specified, aryl groups are from 6 to 18 carbons. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl, and indenyl groups.
- As used herein, the term “heteroaryl” refers to an aromatic ring or ring system that contains at least one ring heteroatom (e.g., O, S, Se, N, or P). Unless otherwise specified, heteroaryl groups are from 1 to 9 carbons. Heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, oxatriazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazyl, triazyl, benzofuranyl, isobenzofuranyl, benzothienyl, indole, indazolyl, indolizinyl, benzisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphtyridinyl, phthalazinyl, phenanthrolinyl, purinyl, and carbazolyl groups.
- As used herein, the term “heterocycle” refers to a non-aromatic ring or ring system that contains at least one ring heteroatom (e.g., O, S, Se, N, or P). Unless otherwise specified, heterocyclic groups are from 2 to 9 carbons. Heterocyclic groups include, for example, dihydropyrrolyl, tetrahydropyrrolyl, piperazinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophene, tetrahydrothiophene, and morpholinyl groups.
- Aryl, heteroaryl, or heterocyclic groups may be unsubstituted or substituted by one or more substituents selected from the group consisting of C1-6 alkyl, hydroxy, halo, nitro, C1-6 alkoxy, C1-6 alkylthio, trifluoromethyl, C1-6 acyl, arylcarbonyl, heteroarylcarbonyl, nitrile, C1-6 alkoxycarbonyl, alkaryl (where the alkyl group has from 1 to 4 carbon atoms), and alkheteroaryl (where the alkyl group has from 1 to 4 carbon atoms).
- As used herein, the term “alkoxy” refers to a chemical substituent of the formula —OR, where R is an alkyl group. By “aryloxy” is meant a chemical substituent of the formula —OR′, where R′ is an aryl group.
- As used herein, the term “Cx-y alkaryl” refers to a chemical substituent of formula —RR′, where R is an alkyl group of x to y carbons and R′ is an aryl group as defined elsewhere herein.
- As used herein, the term “Cx-y alkheteraryl” refers to a chemical substituent of formula RR″, where R is an alkyl group of x to y carbons and R″ is a heteroaryl group as defined elsewhere herein.
- As used herein, the term “halide” or “halogen” or “halo” refers to bromine, chlorine, iodine, or fluorine.
- As used herein, the term “non-vicinal O, S, or N” refers to an oxygen, sulfur, or nitrogen heteroatom substituent in a linkage, where the heteroatom substituent does not form a bond to a saturated carbon that is bonded to another heteroatom.
- For structural representations where the chirality of a carbon has been left unspecified it is to be presumed by one skilled in the art that either chiral form of that stereocenter is possible.
- The compounds according to the technology are analogues of naturally occurring compounds and as such are recognized by the same systems that process the natural compounds, including the enzymes that β- and in some cases ω-oxidize natural long chain fatty acids. The analogues differ from their naturally occurring counterparts in that they cannot be completely oxidized in this manner.
- Non-β-Oxidizable Analogues
- The compounds according to the technology comprise non-β-oxidizable fa acid analogues as represented by the formula
-
R″CCO—(CH2)2n+1—X—R′ - wherein X is a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, or a SO2 group; n is an integer of 0 to 11; R′ is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of the R′ contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, and a SO2 group; and R″ is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms.
- Embodiments of the technology relate to phospholipids comprising a non-β-oxidizable fatty acid analogues. That is, in some embodiments the compounds are structures derived from one or more of said non-β-oxidizable fatty acid analogues, as represented by the general formulae I or II
- wherein in I, R1, R2, and R3 represent:
- i) a hydrogen atom;
- ii) a group having the formula CO—R or R in which R is a linear or branched alkyl group, saturated or unsaturated, optionally substituted; and the main chain of R contains from 1 to 25 carbon atoms;
- iii) a group having the formula CO—(CH2)2n+1—X—R′ or (CH2)2n-+1—X—R′, wherein X is a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, or a SO2 group; n is an integer from 0 to 11; and R′ is a linear or branched alkyl group, saturated or unsaturated, optionally substituted; and the main chain of R′ contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, and a SO2 group; or
- iv) an entity that is a PO3CH2CHNH3COOH (serine), PO3CH2CH2NH3 (ethanolamine), PO3CH2CH2N(CH3)3 (choline), PO3CH2CHOHCH2OH (glycerol), or PO3(CHOH)6 (inositol),
wherein R1, R2, and R3 are chosen independently from i), ii), iii), or iv), but at least one of R1, R2, or R3 is defined by iii); and/or, wherein in II, A1, A2 and A3 are chosen independently and represent an oxygen atom, a sulfur atom, or an N—R4 group in which R4 is a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, and contains from 1 to 5 carbon atoms; and R1, R2, and R3 represent - i) a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, containing from 1 to 23 carbon atoms; or
- ii) a group having the formula CO—R in which R is a linear or branched alkyl group, saturated or unsaturated, optionally substituted; and the main chain of said R contains from 1 to 25 carbon atoms;
- iii) a group having the formula CO—(CH2)2+1—X—R′, wherein X is a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, or a SO2 group; n is an integer from 0 to 11; and R′ is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of R′ contains from 13 to 23 carbon atoms and optionally one or more heterogroups that is an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, or a SO2 group; or
- iv) an entity that is a PO3CH2CHNH3COOH (serine), PO3CH2CH2NH3 (ethanolamine), PO3CH2CH2N(CH3)3 (choline), PO3CH2CHOHCH2OH (glycerol), or PO3(CHOH)6 (inositol), wherein R1, R2, and R3 are chosen independently from i), ii), iii), or iv), but at least one of R1, R2, or R3 is defined by iii).
- These compounds are analogues of naturally occurring monoacylglycerols, diacylglycerols, or triacylglycerols; or phospholipids including phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, and diphosphatidyl glycerol. Said compounds may also comprise a substitution in the glycerol backbone, as shown in formula II. Said substitution of the oxygen(s) is achieved by replacing the oxygen(s) with sulfur or a nitrogen containing group. This may block hydrolysis before uptake by the intestines, thus increasing the bioavailability of the compounds.
- These structures derived from one or more non-β-oxidizable fatty acid entities have their effect because the fatty acid analogues are not capable of being fully β-oxidized. The structures may have an effect as complete structures and/or as naturally resulting degradation products comprising the fatty acid analogues. Because the compounds are not fully β-oxidized, they will build up and trigger an increase in the β-oxidation of naturally occurring fatty acids. Many of the effects of the compounds according to the technology relate to this increase in β-oxidation.
- During β-oxidation, a fatty acid is enzymatically cleaved between carbons 2 and 3 (relative to the carboxylic end of the fatty acid), resulting in the removal of two carbon atoms as acetic acid. This step is then repeated on the resulting shorter fatty acid and repeated again until the fatty acid is fully oxidized. β-oxidation is the usual way in which the majority of fatty acids is catabolized in vivo. The compounds according to the technology block β-oxidation due to the presence of a non-oxidizable group (e.g., S, O, SO, SO2, CH2 or Se) in the X position in the structural formula of the present technology. These compounds all block β-oxidation in the same manner.
- Furthermore, the compounds may contain more than one block. For example, the R′ comprising X may also optionally comprise one or more additional heterogroups selected from the group comprising an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, and a SO2 group. As an example, one may insert two or three sulfurs as X to induce a change in the degradation of the fatty acid and thus provide a modulated effect Multiple sulfur atoms would also modulate the polarity and stability. From a pharmacological viewpoint, it is generally desirable to present a spectrum of compounds rather than just one single compound to avoid or counteract problems with resistance.
- Embodiments of the technology define not only the identity of X, but also the position of X. The distance of X from the carboxylic end of the fatty acid is defined by how many CH2 groups are positioned between X and the carboxylic end of the fatty acid, which is defined by (CH2)2+1, where n is an integer from 0 to 11. Thus, there is an odd number of CH2 groups; that is, the position of X relative to the carboxyl group is such that X blocks β-oxidation. The range of n is chosen to include all variations of the fatty acid analogue that have the desired biological effect. Since β-oxidation in theory can work on infinitely long molecules, n could be infinite, but in practice this is not so. The fatty acids that normally undergo β-oxidation are usually 14 to 24 carbon atoms long, and this length is therefore most ideal for undergoing enzymatic β-oxidation. The ranges of n and R′ are thus given so that the fatty acid analogues cover this range. Likewise, option ii of formulae I and II defines R to have from 1 to 25 carbon groups, and option i of formula II defines the alkyl group to contain from 1 to 23 carbon atoms to be analogous to naturally occurring compounds. The total number of carbon atoms in the fatty acid backbone is approximately between 8 and 30, e.g., in some embodiments between 12 and 26. This size range is also desirable for the uptake and transport through cell membranes of the fatty acid analogues described.
- Although β-oxidation is blocked by fatty acid analogues wherein the β-oxidation blocker X is an odd number of positions from the carboxylic end block, the biological effect varies as a function of the position of X due to the difference in biological degradation time of the various compounds. Experiments show the effect of moving X further from the carboxylic fatty acid end. In particular, these experiments show that mitochondrial β-oxidation of fatty acid analogues in the liver varied as a function of sulfur position, e.g., in the 3, 5 and 7 positions relative to the carboxyl ends. The activities were 0.81 for sulfur in the 3rd position, 0.61 for sulfur in the 5th position, 0.58 for sulfur in the 7th position, and 0.47 for the non β-oxidation blocking control palmitic acid (see, e.g., U.S. Pat. No. 8,178,713). Thus, β-oxidation is indeed blocked to varying degrees depending on the position of the block. The blocking effect lessens as the blocking group is moved further away from the carboxylic end because the β-oxidation takes longer to reach the block and more of the fatty acid analogue is degraded. However, as the relative decline is great for moving the block from the 3rd to 5th position and the relative decline is smaller for moving the block from the 5th to the 7th position, it is reasonable to assume that the relative decline between positions will continue to lessen as the block is placed further down the chain. It is thus expected that no effect (compared to the control) will be seen at very far distances from the carboxyl end.
- Accordingly, the technology encompasses fatty acid analogues and other compounds represented by the general formulas I and II comprising fatty acid analogues that block β-oxidation. In some embodiments, different compounds have a block at different distances from the carboxylic end of the analogues to modulate the effect on β-oxidation. In some embodiments, the modulation differs under varying conditions, in different tissues, with varying dosages, and by changing the fatty acid analogue, e.g., to one that is resistant to metabolisis. Thus, the technology includes all embodiments of the compositions in which the distance of the β-oxidation blocker from the carboxylic end provides a fatty acid analogue that is biologically relevant.
- Although fatty acid analogues as described with a block in the X position cannot undergo β-oxidation, they may still undergo ω-oxidation. This is a much less common and slower biological process that oxidizes the fatty acid from the methyl/hydrophobic head group, here termed R′. In this pathway, the carbon atom at the ω-end of the fatty acid is hydroxylated by a member of the cytochrome P450 enzyme family. This hydroxylated fatty acid is then converted into an aldehyde by an alcohol dehydrogenase, and subsequently this aldehyde is converted into a carboxyl group by an aldehyde dehydrogenase. As a consequence, the final product of the pathway is a dicarboxylic fatty acid, which can be degraded further by ω-oxidation from the ω-end.
- ω-oxidation is believed to be the main pathway for degradation of the fatty acid analogues as described with a block in the X position. Fatty acid analogues in which R′ was changed by introducing a triple bond at the methyl end of the fatty acid analogue block ω-oxidation. In particular, this modification resulted in the fatty acid analogue 3-thia-15-heptadecyne, which when tested showed a substantially increased degradation time in vivo. Thus, this modification finds use in embodiments of the technology to potentiate the effects of the β-oxidizable fa acid analogues by further slowing down their breakdown.
- Based upon knowledge of how ω-oxidation occurs, a double bond will also block co-oxidation. Thus, fatty acid analogues comprising a double bond are also included in the definition of the methyl/hydrophobic head group end of the molecule, here termed R′. That is, it may be saturated or unsaturated. A branch may also block oxidation, so R′ is also defined as linear or branched.
- To block ω-oxidation by the insertion of a substitute in R′, the R′ may be substituted in one or several positions with heterogroups such as an oxygen atom, a sulfur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group, or a SO2 group. R′ may also be substituted with one or more compounds of a fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy, or C1-C4 alkyl.
- Thus, the compounds according to the present technology are either fatty acids analogous to naturally occurring fatty acids, which are not capable of being β-oxidized, or naturally occurring lipids comprising said fatty acid analogues. In vivo, the fatty acid analogues show a strong preference for being incorporated into phospholipids. Incorporating fatty acid analogues in naturally occurring lipids (e.g., monoglycerides, diglycerides, triglycerides, and/or phospholipids) produces a compound with different absorption characteristics compared to the fatty acids. In addition, it is contemplated that incorporating fatty acid analogues in naturally occurring lipids (e.g., monoglycerides, diglycerides, triglycerides, and/or phospholipids) may also increase the bioavailability or stability.
- For example, some embodiments of the technology relate to a triacylglycerol that includes a fatty acid that is not capable of being β-oxidized. Such compounds are encompassed by formulas I and II. If such a triacylglycerol were taken orally, for instance in an animal food product, it would probably be transported like any triacylglycerol, e.g., from the small intestine in chylomicrons to the liver; then to the blood in lipoproteins to be stored in the adipose tissue or used by muscles, heart, or the liver; then by hydrolysis of the triacylglycerol into glycerol and three free fatty acids. The free fatty acids would at this point be the fatty acid analogue parent compound.
- Embodiments also encompass glycerophospholipid derivatives of the fatty acid analogues that block β-oxidation, including, but not limited to, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylserines, and phosphatidylglycerols.
- In some embodiments, the fatty acid analogues that block β-oxidation are incorporated into a sphingolipid derivative such as ceramide or a sphingomyelin. Like glycerophospholipids complexes, these compounds would be water insoluble and hydrophobic, and thus pass through biological membranes.
- Additional embodiments include polar complexes such as, but not limited to, lysophospholipids, phosphatidic acids, alkoxy compounds, glycerocarbohydrates, gangliosides, and cerebrosides.
- In some embodiments, a non-β-oxidizable fatty acid analogue is incorporated into an archaeal phospholipid (e.g., as produced by members of the Archaea). The archaeal lipids are analogous to glycerolipids from Bacteria and Eukaryotes, but have some distinguishing features. For example, archaeal lipids generally comprise a core lipid (e.g., archaeol or caldarchaeal) and polar head groups or glycosides that are linked to one of the core lipids. In addition, the hydrocarbon chains (e.g., a non-β-oxidizable fatty acid analogue) are bound at the sn-2 and sn-3 positions of the glycerol moiety and thus the glycerophosphate backbone of archaeal phospholipids is sn-glycerol-1-phosphate. The hydrocarbon chains are bound to the glycerol by ether linkages. In some of these lipids, the hydrophobic tails are methyl-branched isoprenoids, e.g., derived from (all-E) geranylgeranyl diphosphate (GGPP). Archaeal lipids comprise polar phospholipid head groups such as ethanolamine, L-serine, glycerol, myo-inositol, choline, dimethylaminopentanetetrol, trimethylaminopentanetetrol, glucosaminyl-myo-inositol, and glucosyl-myo-inositol. See, e.g., Koga and Morii (2005), “Recent Advances in Structural Research on Ether Lipids from Archaea Including Comparative and Physiological Aspects”, Biosci Biotechnol Biochem 69: 2019-34; Koga and Morii (2007), “Biosynthesis of Ether-Type Polar Lipids in Archaea and Evolutionary Considerations”, Microbiol Mol Biol Rev, 71: 97. Archaeal lipid biosynthetic pathways are well characterized. Indeed, portions of archaeal lipid biosynthetic pathways (e.g., genes encoding archaeal G-1-P dehydrogenase, GGPP synthase, GGGP synthase, and DGGGP synthase) have been reconstituted in Escherichia coli, thus providing a manipulable and tractable system for the production and isolation of archaeal lipids in a bacterium. See, e.g., Yokoi, et al. (2012), “Archaeal Phospholipid Biosynthetic Pathway Reconstructed in Escherichia coli”, Archaea 2012.
- Although there can be large structural differences between different compounds comprising non β-oxidizable fatty acid entities according to the technology, the biological functions of all the compounds are expected to be very similar because they all block β-oxidation in the same manner. This inability of the fatty acid analogues to be β-oxidized (and in some embodiments, ω-oxidized) causes the analogues to build up in the mitochondria, which triggers the β-oxidation of the in vivo naturally occurring fatty acids. This in turn leads to the biological effects associated with the compounds provided herein according to the present technology. See, e.g., Berge R K et al. (2002) Curr Opin Lipidol 13(3):295-304.
- Tetradecylthioacetic Acid (TTA)
- The technology relates to phospholipids, phospholipid derivatives, triacylglycerides (TAGs), and non-natural lipids, e.g., for use in therapeutic applications. In particular, these lipids and phospholipids incorporate the known sulfur fatty acid, tetradecylthioacetic acid (TTA) as well as its unsaturated analogues, dTTA and tTTA. Tetradecylthioacetic acid (TTA) is a fatty acid analogue of the technology according to formula I having a structure, in some embodiments, as shown below.
- It is understood that analogues that contain one of Se, SO, SO2, O, or CH2 in place of sulfur also provide useful pharmaceutical activity. In addition, the length and degrees of saturation of the alkyl chains can also be varied.
- The sulfur atom is more electronegative than carbon. Hence, the 3-thia acid is slightly more acidic than its corresponding fatty acid. Thia fatty acids are also more polar and slightly more soluble in water than fatty acids of corresponding chain length.
- Biological Effects of Tetradecylthioacetic Acid (TTA)
- TTA is a modified fatty acid that has a number of powerful effects demonstrable both in vivo and in vitro on living organisms (see, e.g., Int'l Pat. App. Nos WO01/68582 (PCT/NO01/00082), WO99/58121 (PCT/N099/00135), WO99/58122 (PCT/N099/00136), and WO99/58123 (PCT/N099/00149); Berg, R. K. and Hvattuu, E. (1994), Pharmac Ther 61: 345; Skrede, S. et al (1997), Biochim Biophys Acta 1344: 115). While TTA has properties very similar to natural fatty acids, it cannot be oxidized by mitochondrial β-oxidation. Importantly, though, TTA significantly increases the oxidation of other fatty acids. Finally, despite the fact that TTA is not catabolized by β-oxidation, it is metabolized in most ways as a normal saturated fatty acid. For example, it is incorporated into phospholipids.
- TTA affects antioxidant status at different levels, e.g., by changing the antioxidant defense system in addition to being an antioxidant itself through its free radical scavenging capacity. Addition of TTA may prevent the oxidative modification of LDL particles in plasma and reduce the generation of lipid peroxides.
- The fatty acid β-oxidation pathway is the main pathway for the metabolism of fats. The initial and rate limiting reaction is carried out in the peroxisomes of the liver by acyl-CoA oxidase. Acyl-CoA oxidase catalyzes the dehydrogenation of acyl-CoA thioesters to the corresponding trans-2-enoyl CoA.
- Compositions comprising TTA and particular plant and animal oils have biological effects on acyl-CoA oxidase. For example, TTA alone effects a large increase in acyl-CoA oxidase activity. When combined with fish and/or olive oil, the composition showed a slight potentiation of the increased acyl-CoA oxidase activity effected by TTA. In contrast, sunflower oil does not increase the activity of TTA when the sunflower oil and TTA were administered together. Soy oil without TTA had negligible effects on acyl-CoA oxidase activity, but combined with TTA it exhibited a 60% increase when compared to the effects of TTA alone. See, e.g., U.S. Pat. Appl. Pub. No. 2007009608.
- In addition, non-β-oxidizable fatty acid entities such as TTA modulate biological phospholipid levels, both alone and in compositions comprising various plant oil and/or fish oils. For example, sunflower and/or fish oil in combination with TTA reduce phospholipid levels more than either TTA or the oils alone. While soy oil and olive oil alone cause an increase in phospholipid levels, these oils substantially potentiated the ability of TTA to decrease phospholipid levels. In particular, soy oil alone increased phospholipid levels by 10%, but a composition comprising both TTA and soy oil lowered phospholipid levels by an additional 40% compared to TTA alone. See, e.g., U.S. Pat. Appl. Pub. No. 2007009608.
- Furthermore, non β-oxidizable fatty acid entities such as TTA modulate biological cholesterol levels, both alone and in compositions comprising various plant oil and/or fish oils. For example, TTA lowered cholesterol levels more than any plant or fish oil alone; compositions comprising both TTA and sunflower oil and/or fish oil lowers cholesterol levels more than TTA or either oil alone. While olive and soy oil alone increase cholesterol levels, these oils substantially potentiated the ability of TTA to decrease cholesterol levels. This TTA potentiating effect was greatest with compositions comprising TTA and soy oil, which reduced the cholesterol level by 60% when compared with TTA alone.
- TTA reduces plasma triacylglycerol level by increasing the number of mitochondria and stimulating mitochondrial β-oxidation of normal saturated and unsaturated fatty acids to ketone bodies (Froyland L et al. (1997), J Lipid Res 38: 1851-1858). This effect is potentiated by the addition of plant and fish oils to compositions comprising TTA. Olive, sunflower, and fish oil alone all lower triacylglycerol levels. While sunflower and fish oils lower triacylglycerol levels more than TTA alone, these oils further potentiate the effect of TTA beyond that seen for either the oils or TTA alone. Furthermore, while soy oil increases triacylglycerol levels by 15%, compositions comprising both TTA and soy oil lower triacylglycerol levels more than TTA or soy oil alone, e.g., by a factor of 130%.
- According to embodiments of the technology, the fatty acid derivatives have one or more therapeutic effects. For example, the fatty acid derivatives fund use in the treatment of hyperlipidemia conditions and in reducing the concentration of cholesterol and triglycerides in the blood of mammals. In addition, selenium analogues have the same properties as well as inhibiting the oxidative modification LDL (see, e.g., EP0345038; WO97/03663 (PCT/N095/00195)). 2). The fatty acid analogues also find use for the treatment of and/or prevention of obesity, hypertension, fatty liver, and multi-metabolic syndrome (“Syndrome X”). (see, e.g., WO99/58121 (PCT/N099/00135)); for the treatment and/or the prevention of diabetes (Type I and II), hyperglycaemia, hyperinsulinemia, and reduced sensitivity to insulin (see, e.g., WO99/58122 (PCT/N099/00136)); for the treatment and/or prevention of primary stenosis, secondary stenosis, and a disease caused by procedural vascular trauma and pathological proliferation of smooth muscle cells, and increase level of plasma homocystein (see, e.g., WO99/58123 (PCT/N099/00149)); for the treatment and/or prevention of cancer (e.g., treatment and/or prevention of primary and secondary neoplasms (see, e.g., WO02/03983 (PCT/NO01/00301)), for the treatment and/or prevention of proliferative skin disorders (see, e.g., WO 02/26218), and for the treatment and/or prevention of inflammatory disorders (see, e.g., WO 02/43728).
- Accordingly, the fatty acid lipid derivatives of the present technology have corresponding therapeutic effects and/or biological properties.
- TTA Modulation of PPAR
- In particular, the fatty acid derivatives modulate the activity of members of the peroxisome proliferator-activated receptor (PPAR) family. The PPAR are pleiotropic regulators of cellular functions such as cellular proliferation, differentiation, and lipid homeostasis (Ye, et al. (2001) Diabetes 50: 411-417). The PPAR family is comprised of three subtypes; PPARα, PPARβ, and PPARγ. Forms of TTA are potent ligands of PPARα. (Forman, et al. (1997) Proc Natl Acad Sci 94:4312-4317; Gottlicher, et al. (1993) Biochem Pharmacol 46: 2177-2184; Berge, et al. (1999) Biochem J 343: 191-197) and activate PPARβ and PPARγ as well (Raspe, et al. (1999) J Lipid Res 40: 2099-2110). As a PPARα activator, TTA stimulate the catabolism of fatty acids by increasing their cellular uptake. Lowering the plasma triglyceride levels with TTA caused a shift in liver cellular metabolism towards PPARα-regulated fatty acid catabolism in mitochondria (Graf, et al. (2003) J Biol Chem 278: 30525-33). The effect of TTA on plasma triacylglycerol is direct by PPARα activation, which is demonstrated by the abolishment of this effect in PPARα knockout mice.
- PPAR ligands affect proliferation of various cancer cell lines. TTA in particular has been found to reduce proliferation of many cancer cell lines (Berge, et al. (2001) Carcinogenesis 22:1747-1755; Abdi-Dezfuli, et al. (1997) Breast Cancer Res Treat 45: 229-239; Tronstad, et al. (2001) Biochem Pharmacol 61: 639-649; Tronstad, et al. (2001) Lipids 36: 305-313). This reduction is related to reduction in triacylglycerol levels (Tronstad, et al. (2001) Biochem Pharmacol 61: 639-649) and is mediated by both PPAR dependent and independent pathways (Berge, et al. (2001) Carcinogenesis 22: 1747-1755). It has also been shown that fermented soy protein improves TTA's ability to lower triacylglycerol levels; it is therefore contemplated that fermented soy protein also improves the anti-proliferative effects of TTA, thus improving TTA's cancer prevention and treatment abilities. For example, TTA may be used for the prevention and/or treatment of cancer including inhibition of: primary and secondary neoplasms, the growth of tumors, invasion of a primary tumor into connective tissue, and formation of secondary tumors (see, e.g., NO 2002 5930).
- In general, PPAR agonists modulate the inflammatory response. TTA modulate inflammatory responses by depressing the release of inflammatory cytokine interleukin-2 and suppressing PHA stimulated proliferation of peripheral mononuclear cells (Aukrust, et al. (2003) Eur J Clin Invest 33: 426-33). The modulation of cytokines by TTA may be mediated by PPAR, through altering prostaglandin levels, or by modification of lipid mediated signal transduction, the latter which also is the proposed mechanism of action for polyunsaturated fatty acids, e.ge, as found in some oils.
- According to embodiments of the technology, protein material, and optionally oil, in combination with non β-oxidizable fatty acid entities potentiates the effect of fatty acid entities on inflammatory disorders, including immune mediated disorders such as rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), various immune mediated neurological disorders (e.g. multiple sclerosis and myastenia gravis), various cardiovascular disorders (e.g. myocarditis, congestive heart failure, arteriosclerosis and stable and unstable angina, and Wegener's granulomatosis), inflammatory bowel diseases, Crohn's disease, non-specific colitis, pancreatitis, nephritis, cholestatis/fibrosis of the liver, and acute and chronic allograft rejection after organ transplantation, as well as proliferate skin disorders like psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact-dermatitis, allergic contact-dermatitis, lamellar ichthyosis, epidermolytic hyperkeratosis, pre-malignant sun-induced keratosis, and seborrhea, and diseases that have an inflammatory component such as, e.g., Alzheimer's disease or impaired/improvable cognitive function. See e.g., U.S. Pat. No. 7,659,242.
- Substances such as oils, e.g., fish oils, and proteins, e.g., fermented soy protein, potentiate the modulatory effects of TTA on lipid metabolism. That is, compositions comprising TTA and an oil such as a fish oil and/or a protein such as a fermented soy protein material have a synergistic effect on lipid metabolism, e.g., the effect is more than the additive effects of TTA and an oil (e.g., a fish oil) and/or a protein product (e.g., a fermented soy product) alone. See, e.g., U.S. Pat. No. 7,659,242.
- Synthesis of TTA and TTA Compounds
- Synthetic routes to TTA and molecules comprising TTA are provided in, e.g., U.S. Pat. Nos. 5,093,365; 6,046,237; 6,365,628; 6,417,232; 6,441,036; 7,026,356; 7,378,443; 7,902,399; 8,088,825; preparation of mono-, di-, and triglycerides and nitrogen comprising lipids according to the technology are disclosed in detail in U.S. Pat. No. 7,375,135; and the synthesis of phospholipids comprising TTA are provided in, e.g., 8,178,713.
- Some compositions of TTA produced for human consumption have been associated with side effects, including lethargy, muscle cramps, and muscle pain. It is likely that these side effects are due to contaminants in some commercially produced TTA products. Accordingly, provided herein are TTA preparations that eliminate or minimize side effects such as lethargy, muscle cramps, and muscle pain. One such improved synthesis is provided in the Examples. In some embodiments, the TTA is used directly to provide a composition according to certain aspects of the technology and in some embodiments the TTA is incorporated into a phospholipid by a living organism.
- Isolation of Phospholipids from a Living Organism, Consortium, or System
- In some embodiments, the technology relates to isolating phospholipids (e.g., a natural phospholipid and/or an oil) comprising a non-beta-oxidizable fatty acid analogue (e.g., TTA) from one or more living organisms such as a bacterium, alga, archaeon, yeast, etc. Phospholipids make up approximately 10% of the dry weight of a cell. Thus, cultures of cells provide a source for the production and harvesting of phospholipids. Accordingly, in some embodiments, the technology relates to feeding a living organism a non-beta-oxidizable fatty acid analogue (e.g., TTA), which is then incorporated into phospholipid by the living organism, and then isolating the phospholipid, e.g., by biochemical or other isolation and/or purification techniques. In some embodiments, the phospholipid is co-isolated with other biological molecules, substances, entities, etc. that are produced by the living organism. That is, in some embodiments, the technology relates to a composition (e.g., an oil) and/or a method of producing a composition produced from a living organism, wherein the composition comprises a phospholipid (e.g., a natural phospholipid) having a non-beta-oxidizable fatty acid analogue (e.g., TTA) and at least one other biological molecule from the living organism.
- The living organism may, in some embodiments, be grown in a controlled culture, e.g., in a defined medium, a semi-defined medium, an undefined medium, a synthetic medium, or a natural medium; under controlled temperature, pressure, volume, and agitation; and in a controlled atmosphere of gases (e.g., a particular mixture of oxygen, carbon dioxide, nitrogen, and other gases, etc.). The culture may comprise a single type of organism (e.g., a single species, sub-species, clone, subtype, isolate, etc.) or the culture may comprise more than one type of organism (e.g., more than one species, sub-species, clone, subtype, isolate, etc.).
- In some embodiments, the living organism is a member of the Bacteria; in some embodiments, the living organism is a member of the Eukarya; and, in some embodiments, the living organism is a member of the Archaea, as defined by, e.g., Woese C, Fox G (1977). “Phylogenetic structure of the prokaryotic domain: the primary kingdoms.” Proc Natl Acad Sci USA 74: 5088-90; Woese C, Kandler O, Wheelis M (1990). “Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya.” Proc Natl Acad Sci USA 87: 4576-9. In some embodiments, one or more phospholipids according to the technology is or are isolated from a composition of more than one living organism, e.g., a co-culture and/or living system and/or consortium of living organisms that may or may not be categorized in the same phylogenetic kingdom.
- It is contemplated that any organism that can be grown in the presence of a non-beta-oxidizable fatty acid analogue such as TTA is encompassed by the present technology. It is contemplated that any organism that can incorporate a non-beta-oxidizable fatty acid analogue such as TTA into a phospholipid is encompassed by the present technology. As discussed elsewhere, it is contemplated that a non-beta-oxidizable fatty acid analogue is metabolized (e.g., anabolized) in the same manner as its natural counterpart save for its resistance to beta-oxidation.
- Other Natural Lipids and/or Fatty Acids
- While the structure and biological function of many of the major lipids from marine organisms have been studied, less is known of the properties of the structure and function of lipids present in marine organisms in small amounts. Microorganisms such as marine bacteria and algae are the primary source for lipids and/or lipid precursors in marine food chains. Many potentially bioactive compounds are detectable in fish and other marine animals in low amounts, e.g., due to losses in the food chain. These bioactive lipids may be present in a larger amount in microorganisms nearer the base of the food chain That is, it is contemplated that lipid extracts (e.g., oils, fractions, etc.) demonstrate high specific biological activities as isolated from microorganisms.
- For example, furan fatty acids have biological activities such as scavenging free radicals (e.g., by reacting readily with peroxyl radicals to generate dioxoenes) and thus may contribute to the protective properties of fish and fish oil diets relative to heart disease. Furan fatty acids are tri- or tetra-substituted furan derivatives comprising either a C3 or C5 side chain in one of the alpha positions and a straight long-chain saturated acid with a carboxylate at its end in the other alpha position.
- Furan fatty acids have been found in fish, algae, bacteria, and fungi, and are generated in large amounts by algae and in small to moderate amounts by plants and other microorganisms. Marine organisms (such as fish) and mammals obtain furan fatty acids in food and metabolize them into phospholipids. Furan fatty acids are catabolized to dibasic urofuran acids and excreted in the urine. Due to their molecular structure, furan fatty acids are contemplated to be catabolized more slowly than other lipids in mammals, and thus potentially to be bioactive in relation to energy metabolism.
- As discussed elsewhere, unusual lipids (e.g., phytanyl ether lipids) are present in the Archaea, particularly in thermophiles and hyperthermophiles, some of which grow optimally at temperatures higher than 80° C. In addition, unusual lipids have been found in some thermophilic members of the Bacteria. For example, the lipids found in Thermotoga spp. (e.g., T. maritima) comprise a mixture of ether lipids and ester lipids, mainly polar. Liposomes produced from these lipids demonstrate high stability at high and low temperatures, are resistant to acids and bases, and are resistant to high pressure. In addition, these lipids affect membrane properties and thus may result in altered absorption and permeability of nutrients.
- Isolating, Characterizing, and Testing Fatty Acids and/or Lipids from Biological Organisms
- In some embodiments, the technology relates to isolating and characterizing bioactive fatty acids and/or lipids with specific and unusual molecular structures from living organisms such as marine organisms.
- In some embodiments, lipids from one or more organisms (e.g., one or more marine organisms) are isolated, extracted, and/or fractionated, and the products are tested for biological activity, e.g., metabolic effects related to fatty acid and lipid metabolism.
- In some embodiments, the testing is performed in relevant animal models or in cell culture. Models will be used to screen for effects related to energy metabolism and mitochondrial functions in addition to modulating membrane properties. In some embodiments, living organisms have been provided (e.g., by feeding) a particular fatty acid, fatty acid analogue, or lipid, e.g., a non-beta-oxidizable fatty acid analogue such as TTA and/or a lipid, lipid extract mixture, isolate, oil, etc. isolated and characterized from a biological organism, system, or consortium.
- Based on the results of the characterization and the potential for human applications, selected fractions are further processed in some embodiments for the formulation of nutritional products or products that improve the absorption or bioavailability of bioactive compounds.
- In some embodiments, isolation and characterization are performed by analytical chromatography coupled to a flame ionization detector and/or mass spectrometry. For example, see Ivanova, et al. (2009) “Lipidomics: a mass spectrometry based systems level analysis of cellular lipids.”, Curr Opin Chem Biol 13: 526-31; Albert et al. (2009) “Chromatographic methods for the analyses of 2-halofatty aldehydes and chlorohydrin molecular species of lysophosphatidylcholine.” J Chromatogr B Analyt Technol Biomed Life Sci 877: 2768-77; Suzuki (2011) “Mass spectrometry-based quantitative analysis and biomarker discovery” Yakugaku Zasshi 131: 1305-9.
- For example, embodiments of the technology use lipid extraction and isolation from biological samples. These techniques exploit the high solubility of hydrocarbon chains in organic solvents, for example, chloroform/methanol-based phase partitioning. In some embodiments, the protocols are adapted for complex lipid chemistries and low-abundance and labile lipid metabolites. Lipid separation comprises use of, e.g., thin layer chromatography (TLC), solid-phase extraction (SPE) chromatography (e.g., using a column comprising silica or other stationary phases to separate glycerophospholipids, fatty acids, cholesteryl esters, glycerolipids, and sterols from crude lipid mixtures), and/or high performance liquid chromatography (e.g., normal-phase HPLC or reverse-phase HPLC). For example, normal phase HPLC effectively separates glycerophospholipids on the basis of headgroup polarity, whereas reverse-phase HPLC effectively separates fatty acids such as eicosanoids on the basis of chain length, degree of unsaturation, and substitution. HPLC of lipids may either be performed offline or online where the eluate is integrated with the ionization source of a mass spectrometer. Lipid detection, in some embodiments, comprises use of spectrometric methods, e.g., and soft ionization techniques for mass spectrometry such as electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI). “Soft” ionization does not cause extensive fragmentation, so that comprehensive detection of an entire range of lipids within a complex mixture can be correlated to experimental conditions or disease state. In addition to ESI and MALDI, the technique of atmospheric pressure chemical ionization (APCI) is used in some embodiments for the analysis of nonpolar lipids.
- In some embodiments, lipids are detected using ESI-MS, which depends on the formation of gaseous ions from lipids. It is a soft-ionization method that rarely disrupts the chemical nature of the analyte prior to mass analysis. Various ESI-MS methods have been developed for analysis of different classes, subclasses, and individual lipid species from biological extracts. Comprehensive reviews of the methods and their application have recently been published; see, e.g., Murphy et al. (2001) “Analysis of nonvolatile lipids by mass spectrometry” Chem Rev 101: 479-526. The major advantages of ESI-MS are high accuracy, sensitivity, reproducibility, and the applicability of the technique to complex solutions without prior derivatization. Han and coworkers have developed a method known as “shotgun lipidomics”, which involves direct infusion of a crude lipid extract into an ESI source optimized for intrasource separation of lipids based on their intrinsic electrical properties. Gross and Han (2007). “Lipidomics in diabetes and the metabolic syndrome” Meth Enzymol 433: 73-90. In some embodiments, MALDI is used. MALDI mass spectrometry is a laser-based soft-ionization method often used for analysis of large proteins, but has been used successfully for lipids. The lipid is mixed with a matrix, such as 2,5-dihydroxybenzoic acid, and applied to a sample holder as a small spot. A laser is fired at the spot, and the matrix absorbs the energy, which is then transferred to the analyte, resulting in ionization of the molecule. MALDI-Time-of-flight (MALDI-TOF) MS has become a very promising approach for lipidomics studies, particularly for the imaging of lipids from tissue slides. Schiller al. (2007). “MALDI-TOF MS in lipidomics” Front Biosci 12: 2568-79. In some embodiments, APCI is used to detect lipids. The source for APCI is similar to ESI except that ions are formed by the interaction of the heated analyte solvent with a corona discharge needle set at a high electrical potential. Primary ions are formed immediately surrounding the needle, and these interact with the solvent to form secondary ions that ultimately ionize the sample. APCI is particularly useful for the analysis of nonpolar lipids such as triacylglycerols, sterols, and fatty acid esters.
- In some embodiments, lipid profiling is used to detect and/or characterize lipids. Lipid profiling is a targeted metabolomics platform that provides a comprehensive analysis of lipid species within a cell or tissue. Profiling based on electrospray ionization tandem mass spectrometry (ESI-MS/MS) is capable of providing quantitative data and is adaptable to high throughput analyses. Klose, et al. (2012). “Flexibility of a Eukaryotic Lipidome-Insights from Yeast Lipidomics” PLoS ONE 7: e35063. In some embodiments, lipid profiling techniques are applied to characterize the lipids of an organism such as a plants or a microorganism, e.g., a yeast or alga. A combination of quantitative lipidomic data in conjunction with the corresponding transcriptional data (using gene-array methods) and proteomic data (using tandem MS) enables a systems biology approach to a more in-depth understanding of the metabolic or signaling pathways of interest.
- To enrich identified lipids, lipid extracts, fractions, or lipid isolates are fed in some embodiments to a microorganism such as algae in culture. It is contemplated that the algae incorporate rare lipids in phospholipids and other non-neutral lipids, thus enriching the lipids in an esterified form. For these studies, in some embodiments TTA will be used as a model compound to feed to microorganisms.
- Characterizing lipids comprises testing lipid extracts, fractions, isolates, oils, etc. for metabolic and other biological effects, e.g., using models such as a mouse model with diet-induced obesity or other transgenic mouse models of metabolic diseases. Diet composition is controlled and monitored as it affects metabolic status as a result of the macronutrients in the food source. Metabolic cages are used to control for gas exchange and food intake. In some testing, transcriptomics and proteomics are used to measure gene expression and protein levels of specific genes.
- Mouse models are available (e.g., from Jackson Laboratories) for studying immune responses and metabolism diseases such as those involving lipid metabolism, e.g., problems with cholesterol levels (e.g., hypercholesterolemia, hypocholesterolemia), mitochondrial defects, sensitivity to cold, high blood pressure, insulin resistance, hyperlipidemia, diabetes, cardiovascular disease, steatosis, fasting, hyperglycemia, atherosclerosis, lipogenesis, glucose metabolism, glucose tolerance, oxidative stress, bile acid and lipid homeostasis, leptin, adipose tissue stores, wound healing, obesity, apolipoprotein function, statin treatment for hypercholesterolemia, Alzheimer's disease, fatty liver, effects of diet on skin and coat, appetite, hunger, and satiety, cardiac lipid metabolism, adipocyte physiology, fat metabolism and storage, inflammation, cancer, cholesterol gallstone formation, vitamin E deficiency, muscle lipotoxicity, low density lipoprotein receptor, hepatic clearance of alpha2-macroglobulin and plasma accumulation of remnant lipoproteins, HDL, VLDL, LDL, sitosterolemia, fatty acid and triglyceride biosynthesis, Tangier disease, and life span.
- Biological Anabolisis of Lipids
- Phospholipids are ubiquitous in nature. In addition to serving as a primary component of cellular membranes and binding sites for intra- and intercellular proteins, some phospholipids in eukaryotic cells, such as phosphatidylinositols and phosphatidic acids are either precursors of or, themselves, membrane-derived second messengers. Most phospholipids contain a diglyceride, a phosphate group, and a simple organic molecule (e.g., choline). The lipid sphingomyelin, however, is derived from sphingosine instead of glycerol. The structure of the phospholipid molecule generally consists of hydrophobic tails (e.g., in some embodiments according to the technology, a hydrophobic tail is a TTA) and a hydrophilic head (e.g., a polar headgroup, e.g., a polar moiety). While, typically, one or both of the hydroxyl groups of the diglyceride are acylated with long-chain fatty acids, alkyl-linked and 1Z-alkenyl-linked (plasmalogen) phospholipids are known, and dialkylether variants are known in the archaea. Phospholipids are subdivided into classes based on the nature of the polar headgroup at the sn-3 position of the glycerol backbone in eukaryotes and eubacteria, or the sn-1 position in the case of archaea. Examples of phospholipids found in biological membranes are phosphatidylcholine (also known as PC, GPCho, or lecithin), phosphatidylethanolamine (PE or GPEtn), and phosphatidylserine (PS or GPSer).
- Sphingolipids are a complicated family of compounds that share a common structural feature, a sphingoid base backbone that is synthesized de novo from the amino acid serine and a long-chain fatty acyl CoA, then converted into ceramides, phosphosphingolipids, glycosphingolipids, and other compounds. The major sphingoid base of mammals is commonly referred to as sphingosine. Ceramides (N-acyl-sphingoid bases) are a major subclass of sphingoid base derivatives with an amide-linked fatty acid. The fatty acids are typically saturated or mono-unsaturated with chain lengths from 16 to 26 carbon atoms. The major phosphosphingolipids of mammals are sphingomyelins (ceramide phosphocholines), whereas insects contain mainly ceramide phosphoethanolamines and fungi have phytoceramide phosphoinositols and mannose-containing headgroups. The glycosphingolipids are a diverse family of molecules composed of one or more sugar residues linked via a glycosidic bond to the sphingoid base. Examples of these are the simple and complex glycosphingolipids such as cerebrosides and gangliosides.
- In animals, when there is an oversupply of dietary carbohydrate, excess carbohydrate is converted to triglycerides. This involves the synthesis of fatty acids from acetyl-CoA and the esterification of fatty acids in the production of triglycerides, a process called lipogenesis. Fatty acids are made by fatty acid synthases that polymerize and then reduce acetyl-CoA units. The acyl chains in the fatty acids are extended by a cycle of reactions that add the acetyl group, reduce it to an alcohol, dehydrate it to an alkene group and then reduce it again to an alkane group.
- The enzymes of fatty acid biosynthesis are divided into two groups—in animals and fungi all the fatty acid synthase reactions are carried out by a single multifunctional fatty acid synthase protein, while in plant plastids and bacteria separate enzymes perform each step in the pathway. The fatty acids may be subsequently converted to triglycerides that are packaged in lipoproteins and secreted from the liver.
- The synthesis of unsaturated fatty acids involves a desaturation reaction, whereby a double bond is introduced into the fatty acyl chain. For example, in humans, the desaturation of stearic acid by stearoyl-CoA desaturase-1 produces oleic acid. The doubly unsaturated fatty acid linoleic acid as well as the triply unsaturated α-linolenic acid cannot be synthesized in mammalian tissues, and are therefore essential fatty acids and must be obtained from the diet.
- In eukaryotes, triglyceride synthesis takes place in the endoplasmic reticulum by metabolic pathways in which acyl groups in fatty acyl-CoAs are transferred to the hydroxyl groups of glycerol-3-phosphate and diacylglycerol.
- Terpenes and isoprenoids, including the carotenoids, are made by the assembly and modification of isoprene units donated from the reactive precursors isopentenyl pyrophosphate and dimethylallyl pyrophosphate. These precursors can be made in different ways. In animals and archaea, the mevalonate pathway produces these compounds from acetyl-CoA, while in plants and bacteria the non-mevalonate pathway uses pyruvate and glyceraldehyde 3-phosphate as substrates. One important reaction that uses these activated isoprene donors is steroid biosynthesis. Here, the isoprene units are joined together to make squalene and then folded up and formed into a set of rings to make lanosterol. Lanosterol can then be converted into other steroids such as cholesterol and ergosterol.
- The technology encompasses any biological molecule (e.g., a lipid, a protein, a small molecule, a hormone, etc.) comprising a non-β-oxidizable fatty acid. For example, the technology encompasses a biological molecule that is covalently linked to a non-β-oxidizable fatty acid, that is bound to a non-β-oxidizable fatty acid, that is attached by a linker to a non-β-oxidizable fatty acid, or that is otherwise physically or chemically associated with a non-β-oxidizable fatty acid. In particular, the technology relates to biological molecules comprising a non-β-oxidizable fatty acid wherein the biological molecule is isolated from a living organism. In some embodiments, the non-β-oxidizable fatty acid is TTA, e.g., that is provided in the culture medium (e.g., as an energy source, as a carbon source, as a nutrient, as an additive, etc.) in which the living organism is grown.
- Polar Moiety
- Particular embodiments relate to phospholipids comprising a non-β-oxidizable fatty acid such as TTA. Phospholipids according to the technology are not limited in the polar headgroup of the phospholipid. For example, the polar head group may be the polar head group of any suitable lipid.
- In some embodiments, the phospholipid is a neutral or anionic phospholipid. For example, in some embodiments the polar head group is the polar head group of, or is derived from, a lipid such as a phospholipid, ceramide, triacylglycerol, lysophospholipid, phosphatidylserine, glycerol, alcohol, alkoxy compound, monoacylglycerol, ganglioside, sphingomyelin, cerebroside, phosphatidylcholine (e.g., dioleoylphosphatidylcholine (DOPC)), phosphatidylethanolamine (e.g., dioleoylphosphatidylethanolamine (DOPE)), phosphatidylinositol, diacylglycerol, phosphatidic acid, glycerocarbohydrate, polyalcohol, and/or phosphatidylglycerol.
- Exemplary polar headgroups are, e.g.:
- In some embodiments, the polar head group is, or is derived from, a triacylglycerol, e.g., having the structure
- In some embodiments, the polar head group (PHG) comprises the group
-
—W-Linker-HG - wherein W is selected from CH2, O, NR1, and S, wherein R1 is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.
- The head group (HG) may be polar or non-polar. When HG is non-polar it may be rendered polar by group —C(O)W-Linker-. Such head groups are encompassed by the present definition provided —C(O)W-Linker-HG is polar and HG is polar when attached to the —C(O)W-Linker-group.
- In some embodiments, the head group (HG) may be an alkyl group, e.g., having at least 5 carbons. In some embodiments, it is a C5-100 alkyl group, a C5-80 alkyl group, a C5-60 alkyl group, a C5-50 alkyl group, a C5-40 alkyl group, C5-30 alkyl group, or a C5-20 alkyl group.
- For example, in some embodiments the HG is the head group of, or is derived from, a lipid such as a phospholipid, ceramide, triacylglycerol, lysophospholipid, phosphatidylserine, glycerol, alcohol, alkoxy compound, monoacylglycerol, ganglioside, sphingomyelin, cerebroside, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, diacylglycerol, phosphatidic acid, glycerocarbohydrate, polyalcohol, and/or a phosphatidylglycerol.
- Exemplary head groups are, e.g.:
- In embodiments comprising a Linker group, the Linker of may be any suitable group. A typical Linker group is a hydrocarbyl group. The term “hydrocarbyl group” as used herein means a group comprising at least C and H and that may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group, etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C, then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulfur, nitrogen, and oxygen. A non-limiting example of a hydrocarbyl group is an acyl group.
- A typical hydrocarbyl group is a hydrocarbon group. Here the term “hydrocarbon” means any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.
- In some embodiments, the Linker is a C1-30, C1-25, C1-20, C1-15, C1-10, or C1-5 hydrocarbyl group; a C1-30, C1-25, C1-20, C1-15, C1-10, or C1-5 hydrocarbon group; a C1-30, C1-25, C1-20, C1-15, C1-10, or C1-5 optionally substituted alkyl group; or a C1-30, C1-25, C1-20, C1-15, C1-10, or C1-5 unsubstituted alkyl group. In some embodiments, at least one optional Linker or no optional Linker groups are present. When one or more or all optional linker groups are not present, the group/compound from which the polar head group is derived is typically chosen to have one or more —OH groups. These allow a simple ester bond between the non-polar moiety and the polar moiety to be provided.
- It will be appreciated by one skilled in the art that when an optional Linker is present, two or more W groups may or may not be bonded to the same atom of the linker. It is envisaged that in some embodiments the two or more W groups are boned to different atoms of a linker.
- W is selected from CH2, O, NR1, and S, wherein R1 is H, a hydrocarbyl group, a hydrocarbon group, an optionally substituted alkyl group, or an unsubstituted alkyl group, wherein the hydrocarbyl group, hydrocarbon group, optionally substituted alkyl group, and/or unsubstituted alkyl group may be a C1-30, C1-25, C1-20, C1-15, C1-10, C1-5, or C5-15 group.
- The technology provides in some embodiments a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO2, SO, or O; and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
- In some embodiments, the lipids comprise more than one non-polar moiety, wherein at least one non-polar moiety is of the formula X—Y—Z—, (wherein X is a hydrocarbyl chain; Y is S, Se, SO2, SO, or O; and Z is an optional hydrocarbyl group) and one or more lipids which are not of this formula. In other words, technology includes lipids which have multiple non-polar moieties of which only one has the structure X—Y—Z—.
- In some embodiments, the lipids comprise at least two non-polar moieties and a polar moiety, wherein one non-polar moiety is of the formula X—Y—Z—, wherein one non-polar moiety is of the formula X—CH2—Z—, wherein each X is independently a hydrocarbyl chain; Y is S, Se, SO2, SO, or O; and each Z is independently an optional hydrocarbyl group, wherein the chain X—CH2—Z optionally contains an even number of atoms; wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
- The chain length of X—CH2— is the longest chain of directly bonded atoms within moiety X—CH2. A chain and consequently the chain length do not include atoms of cyclic substituents or substituents of a terminal carbon.
- In some embodiments, each non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO2, SO, or O; and Z is an optional hydrocarbyl group.
- As discussed above X is a hydrocarbyl chain. By “hydrocarbyl chain” it is meant a linear hydrocarbyl group. In the following definitions of chain length it is meant the longest chain of directly bonded atoms within moiety X. A chain and consequently the chain length do not include atoms of cyclic substituents or substituents of a terminal carbon. In some embodiments, X is an optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In some embodiments, X is an optionally substituted C6-C24 alkyl, optionally substituted C6-C24 alkenyl, or optionally substituted C8-C24 alkynyl. In some embodiments, X is an optionally substituted alkyl having a chain length of 6 to 24 atoms, optionally substituted alkenyl having a chain length of 6 to 24 atoms, or optionally substituted alkynyl having a chain length of 6 to 24 atoms. In some embodiments, X is an optionally substituted alkyl having a chain length of 10 to 18 atoms, optionally substituted alkenyl having a chain length of 10 to 18 atoms, or optionally substituted alkynyl having a chain length of 10 to 18 atoms. In some embodiments, X is an optionally substituted alkyl having a chain length of 14 atoms, optionally substituted alkenyl having a chain length of 14 atoms, or an optionally substituted alkynyl having a chain length of 14 atoms, for example, in some embodiments X is an unsubstituted alkyl, unsubstituted alkenyl, or an unsubstituted alkynyl.
- In some embodiments, X is an unsubstituted C6-C24 alkyl, unsubstituted C6-C24 alkenyl, or an unsubstituted C6-C24 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 6 to 24 atoms, unsubstituted alkenyl having a chain length of 6 to 24 atoms, or an unsubstituted alkynyl having a chain length of 6 to 24 atoms.
- In some embodiments, X is an unsubstituted C10-C18 alkyl, unsubstituted C10-C18 alkenyl, or an unsubstituted C10-C18 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 10 to 18 atoms, unsubstituted alkenyl having a chain length of 10 to 18 atoms, or an unsubstituted alkynyl having a chain length of 10 to 18 atoms. In some embodiments, X is an unsubstituted C14 alkyl, unsubstituted C14 alkenyl, or an unsubstituted C14 alkynyl, e.g., X is an unsubstituted alkyl having a chain length of 14 atoms, unsubstituted alkenyl having a chain length of 14 atoms, or an unsubstituted alkynyl having a chain length of 14 atoms.
- In some embodiments, X is a hydrocarbon chain By “hydrocarbon chain” it is meant a linear hydrocarbon group. For example, in some embodiments X a C6-C24 alkenyl containing one or more double bonds and optionally one or more triple bonds, C6-C24 alkynyl, C6-C24 alkyl optionally substituted with at least one of F, C1, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy, or C1-C4 alkyl. One skilled in the art will appreciate that alkynyl groups containing one or more alkenyl groups may be provided or alkenyl groups containing one or more alkynyl groups may be provided
- When X contains one or more double bonds, some embodiments provide that at least one double bond is in cis configuration. Some embodiments provide that all double bonds are in cis configuration.
- In one preferred aspect X is an acetylenic hydrocarbyl group. The term “acetylenic hydrocarbyl” as used herein means a group comprising at least C and H, having at least one —C≡C— bond and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, a hydrocarbon group, an N-acyl group, a cyclic group, etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C, then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulfur, nitrogen, and oxygen.
- In some embodiments, X is an acetylenic hydrocarbyl group containing a single —C≡C-bond, e.g., X contains one and only one —C≡C-bond. In some embodiments, the acetylenic hydrocarbyl group is an alkynyl group. In some embodiments, X is an optionally substituted alkynyl group having a chain length of 6 to 24 atoms, X is an optionally substituted alkynyl group having a chain length of 10 to 18 atoms, X is an optionally substituted alkynyl groups having a chain length of 16 or 17 atoms, or X is an optionally unsubstituted alkynyl group. For example, in some embodiments, X is an unsubstituted C6-C24 alkynyl group. In some embodiments, X is an unsubstituted alkynyl group having a chain length of 6 to 24 atoms, X is an unsubstituted C10-C18 alkynyl group, X is an unsubstituted alkynyl groups having a chain length of 10 to 18 atoms; X is an unsubstituted C16 or C17 alkynyl group, X is an unsubstituted alkynyl having a chain length of 16 or 17 atoms. In some embodiments, the —C≡C— of the acetylenic hydrocarbyl group is distanced from the terminal end of the acetylenic hydrocarbyl group by from 2 to 15 carbons, e.g., by 2 carbons, by 3 carbons, by 7 carbons, or by 13 carbons.
- In some embodiments, at least one Y group is S or Se, e.g., in some embodiments each Y is selected from S and Se. Some embodiments provide that at least one Y group is S and some embodiments provide that each Y is S.
- In some embodiments, the present invention provides structured phospholipid compositions comprising phospholipid molecules of the following structure:
- wherein one of R1 and R2 is a non-beta-oxidizable fatty acid analogue moiety and the other of R1 and R2 is a bioactive fatty acid moiety selected from the group consisting of an omega-3 fatty acid moiety, on omega-6 fatty acid moiety, a conjugated linoleic fatty acid moiety, a sciadonic fatty acid moiety, and combinations thereof. The compositions of the present invention may comprise 99.5% 99.9% or 100% of the structured phospholipid, or may be compositions comprising a mixture of phospholipid molecules that can be characterized based on the molar percentage of fatty acid moieties present in the composition as a whole. In some embodiments, the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R1. In some embodiments, the composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moieties or combinations thereof at position R2. In some embodiments, the composition comprises greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moiety at position R1. In some embodiments, the bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof. In some embodiments, the composition comprises the bioactive fatty acid moiety is EPA. In some embodiments, the composition comprises the bioactive fatty acid moiety is DHA. In some embodiments, the composition comprises the bioactive fatty acid moiety is conjugated linoleic acid. In some embodiments, the composition comprises the bioactive fatty acid moiety is sciadonic acid. In some embodiments, R3 is selected from a —H or nitrogen containing compound choline (HOCH2CH2N+(CH3)3OH−), ethanolamine (HOCH2CH2NH2), serine, inositol such as cyclohexane polyolinositol and derivatives thereof.
- Acylation of sn-glycero-3-phosphocholine (GPC) with an activated fatty acid, such as fatty acid imidazolides, is a standard procedure in phosphatidylcholine synthesis. It is usually carried out in the presence of DMSO anion with DMSO as solvent (Hermetter; Chemistry and Physics of lipids, 1981, 28, 111). Sn-Glycero-3-phosphocholine, as cadmium (II) adduct can also be reacted with the imidazolide activated fatty acid in the presence of DBU (1,8-diazabicyclo[5.4.0]undec-7-ene] to prepare the phosphatidylcholine of the respective fatty acid (International application number PCT/GB2003/002582). Enzymatic transphosphatidylation can affect the transformation of phosphatidylcholine to phosphatidyletanolamine (Wang et al, J. Am. Chem. Soc., 1993, 115, 10487). In other embodiments, a lysophospholipid with a desired bioactive fatty acid moiety (e.g., omega-3 fatty acid moiety, conjugated linoleic acid moiety of sciadonic acid moiety) at the SN-1 or SN-2 position is acylated with a non-beta-oxidizable fatty acid analogue moiety by combining desired omega-3 fatty acid non-beta-oxidizable fatty acid analogue moiety anhydride (e.g. from TTA) and 4-pyrrolidinopyridine as a catalyst (1.2 equivalents) in alcohol-free chloroform. Polyunsaturated fatty acids containing phospholipids may be prepared by various ways, mainly by chemical synthesis of phospholipids as described, by enzymatic esterification and transesterification of phospholipids or enzymatic transphosphatidylation of phospholipids. (Hosokawa, J. Am. Oil Chem. Soc. 1995, 1287, Lilja-Hallberg, Biocatalysis, 1994, 195).
- Examples of embodiments according to the technology are:
- wherein groups X and Z are selected independently of each other;
- wherein groups X and Z are selected independently of each other.
- Z is an optional hydrocarbyl group. In some embodiments, Z is present and in some embodiments, Z is not present. In some embodiments, Z is an alkyl group such as C1-C10, C1-C6, or a C1-C3 alkyl group such as, e.g., —CH2—.
- In some embodiments, Y and Z together may be formed by a unit that repeats within the YZ moiety. For example, in some embodiments Y—Z together represent the group [V—CH2]n, wherein Y1 is S, Se, SO2, SO, or O, and wherein n is an integer from 1 to 20. In some embodiments, Y is Se or S, e.g., Y is S, and n is from 1 to 10, e.g., 1 to 5 or 1, 2 or 3, e.g., in some embodiments, n is 1.
- Some embodiments provide a compound having the structure
- wherein p is at least 1, such as 1 to 1000; 1 to 100; 1 to 50; 1 to 20; 1 to 10; 1 to 5; e.g., 1, 2 or 3; and wherein each W, X, Y, and Z is selected independently of each other. Examples of compounds from which the polar head group may be derived for given values of p are provided in Table 1:
-
TABLE 1 P 1 glycerols alcohols alkoxy compounds lysophospholipids monoacylglycerols gangliosides sphingomyelins cerebrosides 2 phosphatidylcholines (PC) phosphatidylethanelamines (PE), phosphatidylserines (PS) phosphatidylinositols (PI) diacylglycerols Phosphatidic acids glycerocarbohydrates phosphatidylglycerols 3 triacylglycerols 1 or more polyalcohols - For example, embodiments of the technology provide compounds having formulas as follows:
- Some embodiments provide a compound having the structure
- wherein p is 1 to 10, e.g., 1 to 5; e.g., 1, 2 or 3, and wherein each W, X, Y, and Z is selected independently of each other.
- Embodiments provide compounds having a structure such as
- In some embodiments, the compound comprises at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X—Y—Z—.
- Some embodiments provide a compound having a formula as follows
- wherein each W, X, Y, and Z is selected independently of each other.
- In some embodiments, the compound comprises at least three non-polar moieties wherein each is independently selected from non-polar moieties of the formula X—Y—Z—. For example, some embodiments of the technology provide a compound having a structure of
- wherein each W, X, Y and Z is selected independently of each other.
- Some embodiments provide a compound having a structure defined as
- wherein Y2 and Y3 are independently S or Se (e.g., Y2 and Y3 are each S), and X2 and X3 are independently an unsubstituted C10-C18 alkyl, unsubstituted C10-C18 alkenyl, and/or an unsubstituted C10-C18 alkynyl (e.g., X2 and X3 are independently an unsubstituted C14 alkyl, unsubstituted C14 alkenyl, and/or an unsubstituted C14 alkynyl). In some embodiments, Y2 and Y3 are each S and/or X2 and X3 are independently CH3(CH2)13—, CH3(CH2)6CH═CH(CH2)5—, and/or CH3CH2CC(CH2)10—; in some embodiments, X2 and X3 are both CH3(CH2)13—; in some embodiments, X2 and X3 are both CH3(CH2)6CH═CH(CH2)5—; and in some embodiments, X2 and X3 are both CH3CH2CC(CH2)10—. In some embodiments, the PHG is derived from the polar head group of a phosphatidylcholine or a phosphatidylethanolamine
- In some embodiments, the technology provides a compound having the structure
- wherein Y2 and Y3 are independently S or Se and/or X2 and X3 are independently C10-C18 alkyl, C10-C18 alkenyl, and/or C10-C18 alkynyl. In some embodiments, Y2 and Y3 are independently S or Se and/or X2 and X3 are independently unsubstituted C10-C18 alkyl, C10-C18 alkenyl, or C10-C18 alkynyl, e.g., Y2 and Y3 are independently S or Se and/or X2 and X3 are independently unsubstituted C14 alkyl, C14 alkenyl, and/or C14 alkynyl. In some embodiments, Y2 and Y3 are each S and/or X2 and X3 are both CH3(CH2)13—, X2 and X3 are both CH3(CH2)6CH═CH(CH2)5—, or X2 and X3 are both CH3CH2CC(CH2)10—.
- In some embodiments, the compounds of the technology have a structure according to
- wherein Y2, Y3, and Y4 are independently S or Se and/or X2, X3, and X4 are independently a C10-C18 alkyl, C10-C18 alkenyl, and/or a C10-C18 alkynyl. For example, in some embodiments, Y2, Y3, and Y4 are independently S or Se and/or X2, X3, and X4 are independently a C14 alkyl, C14 alkenyl, and/or a C14 alkynyl. In some embodiments, Y2, Y3, and Y4 are each S and/or X2, X3, and X4 are independently a C10-C18 alkyl, C10-C18 alkenyl, and/or a C10-C18 alkynyl. In some embodiments, Y2, Y3, and Y4 are each S and/or X2, X3, and X4 are independently an unsubstituted C10-C18 alkyl, an unsubstituted C10-C18 alkenyl, and/or an unsubstituted C10-C18 alkynyl. In some embodiments, Y2, Y3, and Y4 are each S and/or X2 and X3 are independently a C14 alkyl, C14 alkenyl, and/or a C14 alkynyl. In some embodiments, Y2, Y3, and Y4 are each S and/or X2, X3, and X4 are each CH3(CH2)13—; in some embodiments, Y2, Y3, and Y4 are each S and/or X2, X3, and X4 are each CH3(CH2)6CH═CH(CH2)5—; in some embodiments, Y2, Y3, and Y4 are each S and/or X2, X3, and X4 are each CH3CH2CC(CH2)10−.
- In some embodiments, in any of these compounds ester linkages between lipid tails and the glycerol moiety are replaced by ether linkages.
- Further Aspects
- In some embodiments, the compounds provided herein are combined with a liposome or formulated into a micellar form to assist in administration. In some embodiments, compounds are formulated in a cochleate delivery vehicle. Cochleate delivery vehicles are a new technology platform for oral delivery of drugs. Cochleates are stable phospholipid-cation precipitates composed of simple, naturally occurring materials, for example, phosphatidylserine and calcium. Cochleates are a potential nanosized system that can encapsulate hydrophobic, amphiphilic, negatively, or positively charged moieties.
- In some embodiments, the compound is an isolated form or purified form. For example, the compound may be in a form or at a purity other than that found in a biological system such as in vivo. In some embodiments, the compound is semi-isolated or semi-purified, e.g., the compound is an isolated form or purified form and is present in a composition with one or more other biological molecules that are not contaminants or impurities. In some embodiments, the compounds provided are formulated to provide a pharmaceutical composition comprising a compound according to the technology and/or a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.
- An addition, embodiments provide compounds that are lipids comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain; Y is S, Se, SO2, SO, O, or CH2; and Z is an optional hydrocarbyl group. Furthermore, when Y is CH2, the chain X—Y—Z contains an even number of atoms, the polar moiety is —[C(O)]nPHG, wherein PHG is a polar head group and m is the number of non-polar moieties.
- Pharmaceutical Compositions
- Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of an agent according to the present technology and a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof).
- A composition according to the technology comprises or consists of a therapeutically effective amount of a pharmaceutically active agent. In some embodiments, it includes a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof). Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient, or diluent is selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
- This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.
- Pharmaceutical compositions within the scope of the present technology may include one or more of the following: preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, odorants, and/or salts. Compounds of the present technology may themselves be provided in the form of a pharmaceutically acceptable salt. In addition, embodiments may comprise buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients, and/or diluents. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.
- They may also contain other therapeutically active agents in addition to compounds of the present technology. Where two or more therapeutic agents are used they may be administered separately (e.g., at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus, combination therapy is within the scope of the present technology.
- Route of Administration
- A pharmaceutical composition within the scope of the present technology may be adapted for administration by any appropriate route. For example, it may be administered by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, or intradermal) routes. Such a composition may be prepared by any method known in the art of pharmacy, for example, by admixing one or more active ingredients with a suitable carrier.
- In various embodiments, different drug delivery systems are used to administer pharmaceutical compositions of the present technology, depending upon the desired route of administration. Drug delivery systems are described, for example, by Langer (Science 249:1527-1533 (1991)) and by Illum and Davis (Current Opinions in Biotechnology 2: 254-259 (1991)).
- The agents of the present technology may be administered alone but will generally be administered as a pharmaceutical composition—e.g., the agent is in admixture with a suitable pharmaceutical excipient, diluent, or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, in some embodiments the agent is administered (e.g., orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions, or suspensions, which may contain flavoring or coloring agents, for immediate, delayed, modified, sustained, pulsed, and/or controlled-release applications.
- In some embodiments, tablets contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and/orglycine; disintegrants such as starch (preferably corn, potato, or tapioca starch), sodium starch glycollate, croscarmellose sodium, and/or certain complex silicates; and/or granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin, and/or acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate, and talc may be included.
- In some embodiments, solid compositions of a similar type are also employed as fillers in gelatin capsules. Examples of excipients in this regard include lactose, starch, a cellulose, milk sugar, or high molecular weight polyethylene glycols. For some embodiments of aqueous suspensions and/or elixirs, the agent is combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol, and glycerin, and combinations thereof.
- The routes for administration (delivery) include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestable solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, via the penis, vaginal, epidural, sublingual.
- It is to be understood that not all of the agent need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.
- If the agent of the present technology is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly, or subcutaneously administering the agent; and/or by using infusion techniques.
- Oral Administration
- In some embodiments, pharmaceutical compositions adapted for oral administration are provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions. Tablets or hard gelatine capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars. For the preparation of suspensions, oils (e.g., vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions. An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used). Thus, the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.
- Transdermal Administration
- Pharmaceutical compositions adapted for transdermal administration may be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis, e.g., as described in Pharmaceutical Research, 3: 318 (1986)).
- Topical Administration
- Alternatively, the agent of the present technology can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The agent of the present technology may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
- For application topically to the skin, the agent of the present technology can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- Rectal Administration
- Pharmaceutical compositions adapted for rectal administration may be provided as suppositories or enemas.
- Nasal Administration
- Pharmaceutical compositions adapted for nasal administration may use solid carriers, e.g., powders (e.g., having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, e.g., by rapid inhalation through the nose from a container of powder held close to the nose. Compositions adopted for nasal administration may alternatively use liquid carriers, e.g., nasal sprays or nasal drops. These may comprise aqueous or oil solutions of the active ingredient. Compositions for administration by inhalation may be supplied in specially adapted devices, e.g., in pressurized aerosols, nebulizers, or insufflators. These devices can be constructed so as to provide predetermined dosages of the active ingredient
- Vaginal Administration
- Pharmaceutical compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- Parenteral Administration
- If the agent of the present technology is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.
- For parenteral administration, the agent is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- Transdermal; Transmucosal; Transurethral or Intraurethral
- “Transdermal” refers to the delivery of a compound by passage through the skin and into the blood stream. “Transmucosal” refers to delivery of a compound by passage of the compound through the mucosal tissue and into the blood stream. “Transurethral” or “intraurethral” refers to delivery of a drug into the urethra, such that the drug contacts and passes through the wall of the urethra and enters into the blood stream.
- Penetration Enhancement or Permeation Enhancement
- “Penetration enhancement” or “permeation enhancement” refers to an increase in the permeability of the skin or mucosal tissue to a selected pharmacologically active compound such that the rate at which the compound permeates through the skin or mucosal tissue is increased.
- Penetration enhancers may include, for example, dimethylsulfoxide (DMSO); dimethyl formamide (DMF); N,N-dimethylacetamide (DMA); decylmethylsulfoxide (CIOMSO); polyethyleneglycol monolaurate (PEGML); glyceral monolaurate; lecithin; 1-substituted azacycloheptanones, particularly 1-N-dodecylcyclaza-cycloheptanones (e.g., as available under the trademark Azone™ from Nelson Research & Development Co., Irvine, Calif.), alcohols, and the like.
- Carriers or Vehicles
- “Carriers” or “vehicles” refers to carrier materials suitable for compound administration and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner
- Examples of pharmaceutically acceptable carriers include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty add esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.
- Epidermal Drug Delivery (Transfersomes)
- Transfersomes (“carrying bodies”) are complex, most often vesicular, bi- or multi-component aggregates capable of crossing barriers and of transferring material between the application and the destination sites. Transfersomes are sold by IDEA Corporation, Munich, Germany, and TRANSFERSOME is a trade mark of that company. Transfersome transdermal drug delivery technology may be used for controllable and non-invasive delivery of a wide variety of large molecules as well as for the improved delivery of small molecules, including the metabolic enzyme antagonists and/or drugs of the present technology.
- Transfersomes may be optimized to attain extremely flexible and self-regulating membranes. They are therefore deformable and consequently can cross microporous barriers efficiently, even when the available passages are much smaller than the average aggregate size. Transfersome formulations are typically composed of natural amphipathic compounds suspended in a water-based solution, optionally containing biocompatible surfactants. Vesicular Transfersomes consist of a lipid bilayer surrounding an aqueous core and further contain at least one component, capable of softening the membrane. The bilayer of a Transferosome is therefore more flexible than a liposome membrane, even metastable. Transfersome vesicles consequently change their shape easily by adjusting locally to ambient stress.
- Skin is one of the best biological barriers. Its outermost part reaches less than 10% into the depth of the skin but contributes over 80% to the skin permeability barrier. This body protecting layer consists of overlapping, flaccid corneocytes, organized in columnar clusters, sealed with multilamellar lipid sheets that are covalently attached to the cell membranes and very tightly packed. Generally, the average number of, and the degree of order in, the intercellular lipid lamellae increases toward the skin surface. This is accompanied by a continuous, but nonlinear, decrease in local water content near the surface. Notwithstanding this, the peak skin barrier is located in the inner half of the outermost layer, where the intercellular lipid seals are already formed, but not yet compromised by the skin cells detachment.
- Passage of transfersome aggregates across the skin is a function of vesicle membrane flexibility, hydrophilicity, and the ability to retain vesicle integrity, while the aggregate undergoes a significant change in shape. When a suspension of Transfersome vesicles is placed on the surface of the skin, water evaporates from the relatively arid skin surface and the vesicles start to dry out. Due to the strong polarity of major Transfersome ingredients, the large number of hydrophilic groups on the membrane, assisted by the softness of the membrane, the vesicles are attracted to the areas of higher water content in the narrow gaps between adjoining cells in the skin barrier, enabling skin penetration of the vehicle. This, together with the vesicle's extreme ability to deform, enables Transfersome aggregates to open, temporarily, the tiny “cracks” through which water normally evaporates out of the skin Channels between the skin cells, two orders of magnitude wider than the original micropores, are thus created. Such newly activated passages can accommodate sufficiently deformable vesicles, which maintain their integrity but change their shape to fit the channel Along the resulting “virtual pathways”, or “virtual channels” in the outermost layer, Transfersomes reach regions of high water content in the deeper skin layers. There, the vesicles (re)distribute. Since Transfersomes are too large to enter the blood vessels locally, they bypass the capillary bed and get to subcutaneous tissue, where they accumulate.
- Although small molecules that have crossed the outermost layer of the skin (stratum corneum) are normally cleared from the skin through the blood circulation, delivery of drugs by means of Transfersome vesicles allows accumulation of drug deep under the skin. Due to their large size, the vesicles are cleared slowly from the skin and associated drugs can accumulate at the site. Transfersome mediated administration of weight drugs, consequently, tends to shift the drug distribution towards the deep tissue under the application site.
- Blood Brain Barrier (BBB)
- Pharmaceutical compositions may be designed to pass across the blood brain barrier (BBB). For example, a carrier such as a fatty acid, inositol or cholesterol may be selected that is able to penetrate the BBB. The carrier may be a substance that enters the brain through a specific transport system in brain endothelial cells, such as insulin-like growth factor I or II. The carrier may be coupled to the active agent or may contain and/or be in admixture with the active agent. Liposomes can be used to cross the BBB. WO91/04014 describes a liposome delivery system in which an active agent can be encapsulated/embedded and in which molecules that are normally transported across the BBB (e.g., insulin or insulin-like growth factor I or II) are present on the liposome outer surface. Liposome delivery systems are also discussed in U.S. Pat. No. 4,704,355.
- Polymer Delivery/Therapeutics
- The agents may further be delivered attached to polymers. Polymer based therapeutics have been proposed to be effective delivery systems, and generally comprise one or more agents to be delivered attached to a polymeric molecule, which acts as a carrier. The agents are thus disposed on the polymer backbone, and are carried into the target cell together with the polymer.
- The agents may be coupled, fused, mixed, combined, or otherwise joined to a polymer. The coupling, etc. between the agent and the polymer may be permanent or transient, and may involve covalent or non-covalent interactions (including ionic interactions, hydrophobic forces, Van der Waals interactions, etc.). The exact mode of coupling is not important as long as the agent is taken into a target cell substantially together with the polymer. For simplicity, the entity comprising the agent attached to the polymer carrier is referred to here as a “polymer-agent conjugate”.
- Any suitable polymer, for example, a natural or synthetic polymer, may be used, e.g., the carrier polymer is a synthetic polymer such as PEG. In some embodiments, the carrier polymer is a biologically inert molecule. Particular examples of polymers include polyethylene glycol (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers, polyamidoamine (PAMAM) dendrimers, HEMA, linear polyamidoamine polymers, etc. Any suitable linker for attaching the agent to the polymer may be used. In some embodiments, the linker is a biodegradable linker. Use of biodegradable linkers enables controlled release of the agent on exposure to the extracellular or intracellular environment. High molecular weight macromolecules are unable to diffuse passively into cells and are instead engulfed as membrane-encircled vesicles. Once inside the vesicle, intracellular enzymes may act on the polymer-agent conjugate to effect release of the agent. Controlled intracellular release circumvents the toxic side effects associated with many drugs.
- Furthermore, agents may be conjugated, attached, etc. by methods known in the art to any suitable polymer and delivered. The agents may in particular comprise any of the molecules referred to as “second agents”, such as polypeptides, nucleic acids, macromolecules, etc., as described in the section below. In particular, the agent may comprise a pro-drug as described elsewhere.
- The ability to choose the starting polymer enables the engineering of polymer-agent conjugates for desirable properties. The molecular weight of the polymer (and thus the polymer-agent conjugate), as well as its charge and hydrophobicity properties, may be precisely tailored. Advantages of using polymer-agent conjugates include economy of manufacture, stability (longer shelf life), and reduction of immunogenicity and side effects. Furthermore, polymer-agent conjugates are especially useful for the targeting of tumor cells because of the enhanced permeability and retention (EPR) effect, in which growing tumors are more “leaky” to circulating macromolecules and large particules, allowing them easy access to the interior of the tumor. Increased accumulation and low toxicity (typically 10-20% of the toxicity of the free agent) are also observed. Use of hyperbranched dendrimers, for example, PAMAM dendrimers, is particularly advantageous in that they enable monodisperse compositions to be made and also flexibility of attachment sites (within the interior or the exterior of the dendrimer). The pH responsiveness of polymer-agent conjugates, for example, those conjugated to polyamindoamine polymers, may be tailored for particular intracellular environments. This enables the drug to be released only when the polymer therapeutic encounters a particular pH or range of pH, e.g., within a particular intracellular compartment. The polymer agent conjugates may further comprise a targeting means, such as an immunoglobulin or antibody, which directs the polymer-agent conjugate to certain tissues, organs or cells comprising a target, for example, a particular antigen. Other targeting means are described elsewhere in this document, and are also known in the art.
- Particular examples of polymer-agent conjugates include “Smancs”, comprising a conjugate of styrene-co-maleic anhydride and the antitumour protein neocarzinostatin, and a conjugate of PEG (polyethylene glycol) with L-asparaginase for treatment of leukaemia; PK1 (a conjugate of a HPMA copolymer with the anticancer drug doxorubicin); PK2 (similar to PK1, but furthermore including a galactose group for targeting primary and secondary liver cancer); a conjugate of HPMA copolymer with the anticancer agent captothecin; a conjugate of HPMA copolymer with the anticancer agent paclitaxel; HPMA copolymer-platinate, etc. Any of these polymer-agent conjugates are suitable for co-loading into the transgenic cells of the present technology.
- Dose Levels
- Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of that compound; the age, body weight, general health, sex, diet, mode and time of administration; rate of excretion; drug combination; the severity of the particular condition; and the individual undergoing therapy. The agent and/or the pharmaceutical composition of the present technology may be administered in accordance with a regimen of from 1 to 10 times per day, such as once or twice per day. For oral and parenteral administration to human patients, the daily dosage level of the agent may be in single or divided doses.
- Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg or from 0.1 to 1 mg/kg body weight. Naturally, the dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.
- Therapeutically Effective Amount
- “Therapeutically effective amount” refers to the amount of the therapeutic agent that is effective to achieve its intended purpose. While individual patient needs may vary, determination of optimal ranges for effective amounts of the compounds related to the technology is within the skill of the art. Generally, the dosage regimen for treating a condition with the compounds and/or compositions of this technology is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient; the severity of the dysfunction; the route of administration; pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used; whether a drug delivery system is used; and whether the compound is administered as part of a drug combination and can be adjusted by one skilled in the art. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the exemplary dosage regimens set forth herein.
- Pharmaceutical Combinations
- In general, the agent may be used in combination with one or more other pharmaceutically active agents. Other agents are sometimes referred to auxiliary agents.
- Pharmaceutically Acceptable Salt
- The agent may be in the form of, and/or may be administered as, a pharmaceutically acceptable salt, e.g., an acid addition salt or a base salt, or a solvate thereof, including a hydrate thereof. For a review on suitable salts see Berge et al, J. (1977) Pharm. Sci. 66: 1-19.
- Typically, a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- Suitable acid addition salts are formed from acids that form non-toxic salts such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethane sulphonate, benzene sulphonate, p-toluenesulphonate, and pamoate salts.
- Suitable base salts are formed from bases that form non-toxic salts and examples are sodium, potassium, aluminum, calcium, magnesium, zinc, and diethanolamine salts.
- Disease States
- The present technology relates to the use of a compound according to embodiments of the technology for the manufacture of a medicament for the treatment and/or prevention of a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia, and stenosis.
- In some embodiments, the present technology provides use of a compound according to the technology for the manufacture of a medicament for lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein.
- In some embodiments, the present technology provides a method for producing weigh loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound of the technology or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present technology provides a method for the modification of the fat distribution and content of animals in order to improve the quality of the meat, or product such as milk and eggs, comprising administering thereto an effective amount of a compound of the technology or a pharmaceutically acceptable salt thereof. Preferably said animal is an agricultural animal, such as gallinaceous birds, bovine, ovine, caprine or porcine mammals. The animal may be a fish or shellfish, such as salmon, cod, Tilapia, clams, oysters, lobster or crabs.
- In some embodiments, the present technology provides use of a compound according to the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition and/or prevention of the growth of tumors.
- In some embodiments, the present technology provides use of a compound according to the technology in the manufacture of a medicament for the inhibition and/or prevention of the invasion of a primary tumor into the connective tissue.
- In some embodiments, the present technology provides use of a compound according to the technology for the manufacture of a medicament for the inhibition and/or prevention of the metastatic properties of a tumor, e.g., to inhibit the formation of secondary tumors. For example, the use of the present compounds may increase the overall survival of mammals with tumors.
- In some embodiments, the present technology provides a method for the treatment and/or inhibition of primary and secondary metastatic neoplasms, comprising administering a compound of the technology or a pharmaceutically acceptable salt thereof.
- In some embodiments, the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of proliferative skin disorders such as psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, lamellar ichthyosis, epidermolytic hyperkeratosis, pre malignant sun induced keratosis, and seborrhea.
- In some embodiments, the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of proliferation and/or induction of differentiation of keratinocytes.
- In some embodiments, the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of inflammatory disorders. For example, in some embodiments, the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of inflammatory disorders, wherein the inflammatory disorder is selected from the group comprising immune mediated disorders such as rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, various autoimmune endocrine disorders (e.g. thyroiditis and adrenalitis), various immune mediated neurological disorders (e.g. multiple sclerosis and myastenia gravis), various cardiovascular disorders (e.g. myocarditis, congestive heart failure, arteriosclerosis and stable and unstable angina, and Wegeners granulomatosis), inflammatory bowel diseases and colitis (e.g., Crohn's colitis), nephritis, various inflammatory skin disorders (e.g. psoriasis, atopic dermatitis and food allergy) and acute and chronic allograft rejection after organ transplantation.
- In some embodiments, the present technology provides a method for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering a compound of the technology or a pharmaceutically acceptable salt thereof. In some embodiments, the mammal has developed or is susceptible to develop an autoimmune and/or inflammatory disorder.
- In some embodiments, the present technology provides a method for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering a compound of the technology or a pharmaceutically acceptable salt thereof. In some embodiments, the mammal has developed or is susceptible to develop an autoimmune and/or inflammatory disorder.
- In some embodiments, the present technology provides use of a compound of the technology or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of proliferation of stimulated peripheral mononuclear cells (PBMC).
- Further description of these and other diseases is provided below.
- Obesity and Related Diseases
- Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma, but also with decreased life span and numerous medical problems, including adverse psychological development, reproductive disorders such as polycystic ovarian disease, dermatological disorders such as infections, varicose veins, Acanthosis nigricans, and eczema, exercise intolerance, diabetes mellitus, insulin resistance, hypertension, hypercholesterolemia, cholelithiasis, osteoarthritis, orthopedic injury, thromboembolic disease, cancer, and coronary heart disease.
- In some embodiments, the present technology provides a treatment regimen that is useful in returning the body weight of obese subjects toward a normal body weight. In some embodiments, the technology provides a therapy for obesity that results in maintenance of the lowered body weight for an extended period of time. Further, in some embodiments the present technology reduces or inhibits the weight gain normally induced by fat rich diets.
- In some embodiments, the present technology prevents obesity and, once treatment has begun, to arrests progression or prevents the onset of diseases that are the consequence of, or secondary to, the obesity, such as hypertension and fatty liver.
- The obesity herein may be due to any cause, whether genetic or environmental. Examples of disorders that may result in obesity or be the cause of obesity include overeating and bulimia, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, Type II diabetes, GH-deficiency, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity.
- In some embodiments, the present technology provides a treatment regimen that is useful in lowering the blood pressure. Further, in some embodiments the present technology provides a treatment regimen that is useful in lowering the concentration of triacylglycerols in the liver. It is anticipated that such a regimen provides an inhibiting effect on the development of a fatty liver condition and is suited as a method for the treatment of the manifested disease.
- In some embodiments, the compounds of the present technology activate the oxidation, and also reduce the concentration, of triglycerides in the liver.
- The term “metabolic syndrome” is used to describe a multimetabolic syndrome that is inter alia characterized by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia, or hypertension.
- As indicated above it is anticipated that the compounds of the present technology provide a positive effect on all the conditions mentioned above, e.g., by regulating both glucose and lipid homeostasis, and thus it is anticipated that the compounds of the present technology are suitable agents for the regulation of the above defined metabolic disease (sometimes called syndrome X).
- Diabetes
- There are two major forms of diabetes mellitus. One is type I diabetes, which is also known as insulin-dependent diabetes mellitus (IDDM), and the other is type II diabetes, which is also known as noninsulin-dependent diabetes mellitus (NIDDM). Most patients with IDDM have a common pathological picture; the nearly total disappearance of insulin-producing pancreatic beta cells which results in hyperglycemia.
- Considerable evidence has been accumulated showing that most IDDM is the consequence of progressive beta-cell destruction during an asymptomatic period often extending over many years. The prediabetic period is recognized usually by the detection of circulating islet-cell autoantibodies and insulin autoantibodies.
- As such, there is a need for a compound that is nontoxic and has no or minimal side effects but that would prevent clinical IDDM and NIDDM.
- Type I diabetes: severe diabetes mellitus, usually of abrupt onset prior to maturity, characterized by low plasma insulin levels, polydipsia, polyuria, increased appetite, weight loss and episodic ketoacidosis; also referred to as IDDM.
- Type II diabetes: an often mild form of diabetes mellitus, often of gradual onset, usually in adults, characterized by normal to high absolute plasma insulin levels which are relatively low in relation to plasma glucose levels; also referred to as NIDDM.
- Type I and II diabetes are in accordance with an etiologic classification considered as primary diabetes respectively.
- Secondary diabetes comprises pancreatic, extrapancreatic and/or endocrine or drug-induced diabetes. Further, some types of diabetes are classified as exceptional forms. These include lipoatrophic, myatonic diabetes, and a type of diabetes caused by disturbance of insulin receptors.
- Considering the high prevalence of diabetes in our society and the serious consequences associated therewith as discussed above, any therapeutic drug potentially useful for the treatment and prevention of this disease would have a profound beneficial effect on their health. There is a need in the art for a drug that reduces the concentration of glucose in the blood of diabetic subjects without significant adverse side effects.
- Accordingly, in some embodiments, the present technology provides a treatment regimen that is useful in lowering the blood glucose and to treat a diabetic condition. Moreover, in some embodiments, the present technology provides a treatment regimen that is useful in lowering the concentration of insulin in the blood, and to increase the effect of the remaining insulin.
- Stenosis
- Many pathological conditions have been found to be associated with smooth muscle cell proliferation. Such conditions include restenosis, arteriosclerosis, coronary heart disease, thrombosis, myocardial infarction, stroke, smooth muscle neoplasms such as leiomyoma, and leiomyosarcoma of the bowel and uterus and uterine fibroid or fibroma.
- Over half a million interventional intravascular procedures are performed each year. While such invasive procedures continue to improve over time, as many as 30% to 50% of the procedures performed each year fail as a result of restenosis, e.g., the formation of secondary stenosis. The reduction of restenosis is, therefore, often cited as the most critical factor in increasing the success realized in the treatment of cardiovascular disease through the use of interventional intravascular procedures, such as angioplasty, atherectomy, and procedures utilizing stents, and laser technology.
- In balloon angioplasty, e.g. Percutaneous Transluminal Coronary Angioplasty (PTCA), a small incision is made to an artery in the patient's leg or arm and a long hollow tube, called a guide catheter, is inserted into the artery. A thick guide wire and deflated balloon catheter are then inserted into the guide catheter and are carefully advanced through the patient's blood vessels using X-ray visualization. The deflated balloon is advanced until it reaches the site of the luminal narrowing, at which point the physician inflates the balloon one or more times to a pressure of about 4-6 atm for about 60 seconds. When inflated, the balloon cracks and fractures the plaque and stretches the muscle fiber in the artery wall beyond its ability to recoil completely. Although no plaque is removed in this procedure, the fracturing of the plaque and the stretching of the arterial wall increase the vessel lumen, thereby allowing for increased blood flow.
- The restenosis that accompanies such procedures is characterized by platelet aggregation and adhesion, smooth muscle cell proliferation, narrowing of the vessel lumen, restricted vasodilatation, and an increase in blood pressure. Smooth muscle cells in the intimal layer of the artery have been reported to enter the growth cycle within about 2-3 days of these procedures and to proliferate for several days thereafter (intimal hyperplasia).
- Compounds that reportedly suppress smooth muscle proliferation in vitro may have undesirable pharmacological side effects when used in vivo. Heparin is an example of one such compound, which reportedly inhibits smooth muscle cell proliferation in vitro but when used in vivo has the potential adverse side effect of inhibiting coagulation.
- As is apparent from the foregoing, many problems remain to be solved in the use of inhibitory drugs to effectively treat smooth muscle cell mobilization and proliferation. It would be highly advantageous to develop new compositions or methods for inhibiting stenosis, restenosis or related disorders due to proliferation and mobilization of vascular smooth muscle cells following, for example, traumatic injury to vessels rendered during vascular surgery.
- Accordingly, it is anticipated that embodiments of compounds in accordance with the present technology are effective in the treatment of these diseases.
- Tumors
- As discussed in WO 02/03983, the development of new and more effective chemotherapeutic agents for cancer treatment requires considering a variety of factors including cytotoxicity, tumor cell proliferation, invasion, and metastasis. Conventional anticancer agents have typically been identified on the basis of their cytotoxicity alone.
- Tumor progression is thought to occur when variant cells having selective growth properties arise within a tumor cell population, and one of the final stages of tumor progression is the appearance of the metastatic phenotype.
- During metastasis, the tumor cells invade the blood vessels, survive against circulating host immune defenses, and then extravasate, implant, and grow at sites distant from the primary tumor. This ability of tumor cells to invade neighboring tissues and to colonize other organs is among the leading causes of cancer related deaths.
- The term metastasis encompasses a number of phenotypic traits that together result in the clinical problem that most often leads to death from cancer. The cells lose their adherence and restrained position within an organized tissue, move into adjacent sites, develop the capacity both to invade and to egress from blood vessels, and become capable of proliferating in unnatural locations or environments. These changes in growth patterns are accompanied by an accumulation of biochemical alterations that have the capacity to promote the metastatic process.
- So far, little is known about the intrinsic mechanism involved in the metastatic cascade. It is likely that in some cases the augmented metastatic potential of certain tumor cells may be due to an increased expression of oncogenes, which normally are responsible for control of various cellular functions, including differentiation, proliferation, cell motility, and communication. Further, it has been shown that substances that modulate signal transduction pathways can inhibit the metastatic behavior of a tumor, and it is also speculated that compounds with surface related effects, e.g., compounds that modulates the cell membranes, might be involved in the process leading to metastasis.
- Cancer is a disease of inappropriate tissue accumulation. This derangement is most evident clinically when tumor tissue bulk compromises the function of vital organs. Contrary to what is generally thought, human malignant disorders are usually not diseases of rapid cell proliferation. In fact, the cells of most common cancers proliferate more slowly than many cells in normal tissues. It is a relatively slow accumulation of tumor tissue within vital organs that proves fatal to most patients who die of cancer.
- Chemotherapeutic agents share one characteristic: they are usually more effective in killing or damaging malignant cells than normal cells. However, the fact that they do harm normal cells indicates their potential for toxicity. Nearly all chemotherapeutic agents currently in use interfere with DNA synthesis, with the provision of precursors for DNA and RNA synthesis, or with mitosis. Such drugs are most effective against cycling cells. The mechanism of cell death after treatment with any single agent or combination of agents is complex and is likely to include more than one process. Because most clinically detectable tumors are composed mostly of non-cycling cells, it is not surprising that chemotherapy is not always effective in eradicating cancer.
- The strategy of cancer treatment is to shift tumor cells from a non-cycling compartment to a cycling compartment. Several methods that promote this shift form the basis for combined-modality treatment. Surgery is most commonly used to reduce tumor size and thus facilitate re-entry of cancer cells into the cell cycle. After the primary tumor is completely removed, microscopic metastases may remain at distant sites. Because of their small size, the micrometastases are composed principally of cycling cells Small numbers of cells that remain at primary tumor site are also likely to re-enter the cell cycle. Thus, the remaining cancer cells are often susceptible to chemotherapy. Radiation therapy or chemotherapy alone can also be used to reduce tumor bulk and thus recruit cells into the cycling cell compartment.
- Combination drug therapy is, therefore, the basis for most chemotherapy employed at present. Combination chemotherapy uses the different mechanisms of action and cytotoxic potentials of multiple drugs. However, even though the chemotherapeutic agents are more effective in killing or damaging malignant cells than normal cells, the fact that they do harm normal cells indicates their great potential for toxicity. For chemotherapy to be effective, the patient must be in good physiologic condition.
- Cancer treatment requires inhibition of a variety of factors including tumor cell proliferation, metastatic dissemination of cancer cells to other parts of the body, invasion, tumor-induced neovascularization, and enhancement of host immunological responses and cytotoxicity.
- Conventional cancer chemotherapeutic agents have often been selected on the basis of their cytotoxicity to tumor cells. However, some anticancer agents have adverse effects on the patient's immunological system. Unfortunately, for the vast majority of conventional antineoplastic agents the margin between an effective dose and a toxic dose, e.g., the therapeutic index, is extremely low. Thus, it would be greatly advantageous if a cancer therapy or treatment could be developed that would afford noncytotoxic protection against factors that might lead to growth, progression and metastasis of invasive cancers.
- Accordingly, in some embodiments, the present technology provides a method for the prevention and/or treatment of primary and metastatic neoplasms that involves using a fatty acid analogue, or a lipid comprising a fatty acid analogue, of the present technology to treat a patient suffering from a cancer.
- The two essential features of cancer are invasion and metastasis. At one extreme, microinvasion of the basement membrane characterizes the transition from neoplasia to cancer, and at the other extreme, metastases generally lead to death. Invasion into the underlying connective tissue by primary tumor proceeds in stages and is facilitated by various mediators produced by the tumor cells. Tumor cells that have not invaded the basement membrane and remain confined within the epithelium are termed carcinoma in situ. Metastases, on the other hand, may form when circulating tumor cells with adherent lymphocytes and platelets are trapped in capillaries and the tumor cell membrane interacts with the capillary endothelium. The capillary endothelial junctions retract, and tumor cell ligands bind to receptors on the endothelial and basement membranes.
- Tumor cells then release collagenase IV, which destroys collagen IV, a major component of the underlying basement membrane. Invasion of the subcapillary connective tissue is aided by binding to the glycoproteins laminin and fibronectin, by the release of proteases that destroy the matrix, and by the secretion of motility and chemotactic factors. Tumor cells then may proliferate and synthesize platelet aggregatory factors such as thromboxanes and procoagulants, thereby leading to the deposition of a fibrin cocoon around the cells. Such a cocoon may protect the micrometastasis from attack by the host's immune system.
- Cancers that can be prevented and/or treated by the compositions and methods of the present technology include, but are not limited to, human sarcomas and carcinomas, e.g. carcinomas, e.g., colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemias, e.g., acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease. Specific examples of such cancers are described in the sections below.
- Skin Disorders
- As discussed in WO 02/26218, proliferative skin diseases are widespread throughout the world and afflict millions of humans and their domesticated animals. Proliferative skin diseases are characterized by keratinocyte cell proliferation, or division, and may also be associated with incomplete epidermal differentiation. Psoriasis is the most serious of the proliferative skin diseases with which this technology is concerned.
- Psoriasis is a genetically determined disease of the skin characterized by two biological hallmarks. First, there is a profound epidermal hyperproliferation related to accelerated and incomplete differentiation. Second, there is a marked inflammation of both epidermis and dermis with an increased recruitment of T lymphocytes, and in some cases, formation of neutrophil microabcesses. Many pathologic features of psoriasis can be attributed to alterations in the growth and maturation of epidermal keratinocytes, with increased proliferation of epidermal cells, occurring within 0.2 mm of the skin's surface.
- Traditional investigations into the pathogenesis of psoriasis have focused on the increased proliferation and hyperplasia of the epidermis. In normal skin, the time for a cell to move from the basal layer through the granular layer is 4 to 5 weeks. In psoriatic lesions, the time is decreased sevenfold to tenfold because of a shortened cell cycle time, an increase in the absolute number of cells capable of proliferating, and an increased proportion of cells that are actually dividing. The hyperproliferative phenomenon is also expressed, although to a substantially smaller degree, in the clinically uninvolved skin of psoriatic patients.
- A common form of psoriasis, psoriasis vulgaris, is characterized by well-demarcated erythematous plaques covered by thick, silvery scales. A characteristic finding is the isomorphic response (Koebner phenomenon), in which new psoriatic lesions arise at sites of cutaneous trauma. Lesions are often localized to the extensor surfaces of the extremities, and the nails and scalp are also commonly involved.
- Therapeutic efforts in psoriasis are aimed at decreasing the proliferative rate of the epidermis, either by direct action on cell division or indirectly by reducing the immunological response. For patients with localized, limited psoriasis, administration of topical corticosteroids is the most convenient outpatient therapy.
- Rapid improvement may be seen with this approach, but the beneficial short-term efficacy is limited and chronic topical corticosteroid treatment is not advisable. Side effects from chronic topical corticosteroid therapy can include atrophy of the skin, development of tolerance to the agent used (tachyphylaxis), and serious exacerbation of the disease after discontinuation. Pituitary-adrenal suppression is a potential and serious complication of potent topical corticosteroid therapy, particularly when the agent covers a large portion of the body surface and is used under occlusive dressings.
- The retinoids, particularly etretinate, either alone or in combination with PUVA, are also an effective treatment for psoriasis. Etretinate is especially useful in the exfoliative and pustular varieties of psoriasis. However, several major potential complications must be monitored in patients placed on retinoids. As a class, the retinoids are potent teratogens and should not be given to women of childbearing age who are not using adequate contraception.
- Etretinate, like other retinoids, can produce elevations in cholesterol and triglyceride levels; therefore dietary regulation may be necessary. In addition, because etretinate can induce hepatotoxicity, liver function tests should be performed before and at regular intervals during use of the drug.
- Considering the complications and side effects attendant to the use of different drugs and photochemotherapy currently used in treating a skin proliferative disease such as psoriasis, there is a need for a new method and a new composition to inhibit keratinocyte proliferation to alleviate the symptoms of skin proliferation diseases.
- Inflammatory and Auto-Immune Disorders
- As discussed in WO 02/43728, interleukins, interferons, colony stimulating factors and TNF-alpha are examples of a group of diverse multi-functional proteins called cytokines. Cytokines are a class of secreted soluble proteins normally present in very low concentration in a variety of cells. Lymphoid, inflammatory hemopoietic, and other cells such as connective tissue cells (e.g. fibroblasts, osteoblasts) secrete a variety of cytokines which regulate the immune, inflammatory, repair, and acute phase responses by controlling cell proliferation, differentiation, and effector functions. The effects of cytokines are mediated through binding to high affinity receptors on specific cell types.
- An important cytokine is IL-10, a 35-40 kDa peptide produced by helper T-cells, B-cells, monocytes, macrophages, and other cell types. In vitro, IL-10 has demonstrated immunosuppressive properties as evidenced by its ability to suppress cytokine production including IL-1 and TNFα. IL-10 also inhibits activation of other inflammatory cytokines, and therefore has potent anti-inflammatory activity.
- It has been of recent interest to administer-IL-10 in the treatment of certain conditions characterized by excessive IL-1 and TNF-alpha production. Such diseases or conditions include loosening of prosthetic joint implants, inflammation, diabetes, cancer, graft versus host diseases, viral, fungal and bacterial infections, lipopolysaccharide endotoxin shock, diseases of depressed bone marrow function, thrombocytopenia, osteoporosis, spondyloarthropathies, Paget's disease, inflammatory bowel disease, arthritis, osteoarthritis, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and connective tissue diseases.
- For example, purified IL-10 has been shown in vitro to suppress certain types of viral infections. U.S. Pat. No. 5,665,345 discloses a method for inhibiting replication of the human immunodeficiency virus, retro-viruses, and Kaposi sarcoma in human cells by administering IL-10.
- IL-10 has also been suggested for use in the treatment of certain cancers. U.S. Pat. No. 5,570,190 discloses administering exogenous IL-10 to treat mammals suffering from acute myelogenous leukemia and acute lymphocytic leukemia. IL-10 is said to be administered either in the purified or recombinant form and is believed to inhibit the proliferation of acute leukemia blast cells. Similarly, IL-10 was shown to inhibit bone marrow metastasis in severe combined immunodeficient mice.
- The above conventional approaches to treating conditions characterized by excessive IL-1 and TNF-alpha production have been limited to administering exogenous purified or recombinant IL-10 intravenously. Since IL-10 is a protein, it is difficult to infuse intravenously into a mammal because proteins often leach out of solution and bind to the plastic or glass used in intravenous administration sets. Also, proteins are often incompatible and precipitate when mixed with physiological solutions such as dextrose or saline. In addition, oral and topical routes are unavailable for IL-10 administration. The oral route is unavailable because protein is degraded in the gastrointestinal tract. None of the above approaches suggests enhancing endogenous IL-10 production in mammals for prophylaxis and treatment of diseases or conditions.
- Further, it is known that IL-10 is a powerful deactivator of macrophages and T cells, and inadequate production has been implicated in various autoimmune and inflammatory disorders.
- As shown in U.S. Pat. No. 8,178,713, embodiments of the compounds provided herein enhance both LPS and PHA stimulated IL-10, and suppress PHA stimulated IL-2 production in PBMC from healthy blood donors. These findings suggested a marked anti-inflammatory net effect of the present compounds by both enhancing the release of the anti-inflammatory cytokine IL-10 and by suppressing the release of the inflammatory cytokine IL-2. Second, the findings suggested that the present compounds may modulate both monocyte (e.g., LPS stimulation) and lymphocyte activation (e.g., PHA stimulation). Finally, the in vitro effect of the present compounds on activated PBMC from healthy blood donors may reflect the situation in various patient populations characterized by enhanced inflammatory activation in vivo. In fact, ex vivo activated PBMC from healthy controls, may represent the relevant target cells for therapeutically intervention in vivo in various inflammatory disorders.
- In addition, or in the alternative, embodiments of the compound or composition of the present technology are useful in the treatment of the disorders listed in WO/1998/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, hemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumor growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischemia, ischemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurode generation, Alzheimer's disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.
- In addition, or in the alternative, embodiments of the compound or composition of the present technology are useful in the treatment of disorders listed in WO/1998/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g., for treating immune deficiency, including infection with human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumor immunity); regulation of hematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilizing specific cell types to sites of injury or infection); hemostatic and thrombolytic activity (e.g. for treating hemophilia and stroke); anti-inflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behavior; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.
- In addition, or in the alternative, embodiments of the composition of the present technology are useful in the treatment of disorders listed in WO/1998/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, e.g., inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididimo-orchitis, infertility, orchidal trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g., retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fondus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillaim-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumor cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.
- Treatment
- Embodiments of the technology include any therapeutic application that can benefit a human or non-human animal, for example a mammal. As such, both human and veterinary treatments are within the scope of the present technology.
- Treatment may be in respect of an existing condition or it may be prophylactic. It may be of an adult, a juvenile, an infant, a fetus, or a part of any of the aforesaid (e.g., an organ, tissue, cell, or nucleic acid molecule).
- In some embodiments, an active agent for use in treatment is administered via any appropriate route and at any appropriate dosage. Dosages can vary between wide limits, depending upon the nature of the treatment, the age and condition of the individual to be treated, etc., and a physician will ultimately determine appropriate dosages to be used. However, without being bound by any particular dosages, a daily dosage of a compound of the present technology of from 1 μg to 1 mg/kg body weight may be suitable. The dosage may be repeated as often as appropriate. If side effects develop, the amount and/or frequency of the dosage can be reduced, in accordance with good clinical practice.
- Polymorphic Form(s) and/or Asymmetric Carbon(s)
- Embodiments of compounds according to the present technology may exist in a polymorphic form. In addition, embodiments of compounds according to the present technology may contain one or more asymmetric carbon atoms and therefore exist in two or more stereoisomeric forms. Where an agent contains an alkenyl or alkenylene group, cis (E) and trans (Z) isomerism may also occur. The present technology includes the individual stereoisomers of the agent and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
- Separation of diastereoisomers and/or cis and trans isomers may be achieved by conventional techniques, e.g., by fractional crystallization, chromatography, or H.P.L.C. of a stereoisomeric mixture of the agent or a suitable salt or derivative thereof. An individual enantiomer of a compound of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
- Isotopic Variations
- The present technology also includes all suitable isotopic variations of the agent or a pharmaceutically acceptable salt thereof. An isotopic variation of an agent of the present technology or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine such as 2H, 3H, 13C, 15N, 17O, 18O, 31P, 32P, 35S, 18F, and 36C1, respectively. Certain isotopic variations of the agent and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as 3H or 14C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, e.g., 3H, and carbon-14, e.g., 14C, isotopes are particularly useful for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, e.g., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present technology and pharmaceutically acceptable salts thereof of this technology can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- Pro-Drug
- In some embodiments, compounds according to the technology are derived from a prodrug. Prodrugs are entities that may or may not possess pharmacological activity as such, but may be administered (such as orally or parenterally) and thereafter subject to bioactivation (for example metabolized) in the body to form the agent of the present technology which is pharmacologically active. Examples of prodrugs include entities that have certain protected group(s) and that may not possess pharmacological activity as such, but may, in certain instances, be administered (such as orally or parenterally) and thereafter metabolized in the body to form the agent of the present technology that are pharmacologically active.
- Pro-Moiety
- In some embodiments, the technology encompasses certain moieties known as “pro-moieties”, for example as described in “Design of Prodrugs” by H. Bundgaard, Elsevier, 1985 (the disclosure of which is hereby incorporated by reference). In some embodiments, a pro-moiety may be placed on appropriate functionalities of the agents. Such prodrugs are also included within the scope of the technology.
- Derivative
- The term “derivative” or “derivatized” as used herein includes chemical modification of an agent. Illustrative of such chemical modifications would be replacement of hydrogen by a halo group, an alkyl group, an acyl group, or an amino group.
- Chemical Modification
- In one embodiment of the present technology, the agent may be a chemically modified agent. The chemical modification of an agent of the present technology may either enhance or reduce hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction, or dipole interaction between the agent and the target. In some embodiments, the identified agent may act as a model (for example, a template) for the development of other compounds.
- Although the disclosure herein refers to certain illustrated embodiments, it is to be understood that these embodiments are presented by way of example and not by way of limitation.
- Combination with Sialic Acid Analogs
- In some embodiments, the lipid compositions described above (e.g., the natural lipid compositions and structured lipid compositions) may be used in combination with one or more sialic acid analogs. As used herein sialic acid analogs include sialic acids and sialic acid precursors. Preferably, sialic acids or sialic acid precursors are selected from the group consisting of n-glycolylneuraminic acid, n-acetylneuraminic acid and N-Acetyl-D-mannosamine. In some embodiments, the composition may comprise two or more of the following sialic acids: Neuraminic acid, 5-N-Acetyl-4-O-acetyl-neuraminic acid, 5-N-Acetyl-7-O-acetyl-neuraminic acid, 5-N-Acetyl-8-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-neuraminic acid, 5-N-Acetyl-4,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-8,9-di-O-acetyl-neuraminic acid, 5-N-Acetyl-7,8,9-tri-O-acetyl-neuraminic acid, 5-N-Acetyl-9-O-L-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-4-O-acetyl-9-O-lactyl-acetyl-neuraminic acid, 5-N-Acetyl-8-O-methyl-neuraminic acid, 5-N-Acetyl-9-O-acetyl-8-O-methyl-neuraminic acid, 5-N-Acetyl-8-O-sulpho-neuraminic acid, 5-N-Acetyl-9-O-phosphoro-neuraminic acid, 5-N-Acetyl-2-deoxy-2,3-didehydro-neuraminic acid, 5-N-Acetyl-9-O-acetyl-2-deoxy-2,3-didehydro-neuraminic acid, 5-N-Acetyl-2-deoxy-2,3-didehydro-9-O-lactyl-neuraminic acid, 5-N-Acetyl-2,7-anhydro-neuraminic acid, 4-O-Acetyl-5-N-glycolyl-neuraminic acid, 7-O-Acetyl-5-N-glycolyl-neuraminic acid, 8-O-Acetyl-5-N-glycolyl-neuraminic acid, 9-O-Acetyl-5-N-glycolyl-neuraminic acid, 7,9-Di-O-acetyl-5-N-glycolyl-neuraminic acid, 8,9-Di-O-acetyl-5-N-glycolyl-neuraminic acid, 7,8,9-Tri-O-acetyl-5-N-glycolyl-neuraminic acid, 5-N-glycolyl-9-O-lactyl-neuraminic acid, 5-N-glycolyl-8-O-methyl-neuraminic acid, 9-O-Acetyl-5-N-glycolyl-8-O-methyl-neuraminic acid, 7,9-di-O-Acetyl-5-N-glycolyl-8-O-methyl-neuraminic acid, 5-N-glycolyl-8-O-sulpho-neuraminic acid, N—(O-acetyl)glycolylneuraminic acid, N-(0-Methyl)glycolylneuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-neuraminic acid, 9-O-Acetyl-2-deoxy-2,3-didehydo-5-N-glycolyl-neuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-9-0-lactyl-neuraminic acid, 2-Deoxy-2,3-didehydro-5-N-glycolyl-8-O-methyl-neuraminic acid, 2,7-Anhydro-5-N-glycolyl-neuraminic acid, 2,7-Anhydro-5-N-glycolyl-8-O-methyl-neuraminic acid, 2-Keto-3-deoxynononic acid, and 9-O-Acetyl-2-keto-3-deoxynononic acid. In some embodiments, the compositions may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sialic acid analogs. In some embodiments, the sialic acid analogs have a purity selected from the group consisting of greater than 90%, 95%, 99%, and 99.5% pure.
- The sialic acid precursor may be co-formulated in the same delivery vehicle as the lipid composition, or may be provided in a separated delivery vehicle. In some embodiments, the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day. In some embodiments, the sialic acid composition or sialic acid precursor composition is provided in a daily dosage selected from the group consisting of 0.1 to 10 mg/150 kg subject/day, 0.3 to 5 mg/150 kg subject/day, and 0.5 to 2 mg/150 kg subject/day. In some embodiments, the administering is selected from the group consisting of enteral administration, parenteral administration, oral administration, sublingual administration, subcutaneous administration, intramuscular administration, and intravenous administration.
- Thus, the lipid composition/sialic acid compositions may be provided in a single dosage form or a part of treatment regime where the lipid composition and sialic acid are co-administered. It is contemplated that these compositions may be utilized for the uses described above.
- TTA has shown promise as an agent for the treatment of various metabolic conditions and related conditions, including metabolic syndrome, diabetes, obesity, fatty liver, and hypertension. TTA also shows promise as a nutritional supplement that can be used to reduce weight and improve body composition. See e.g., U.S. Pat. Nos. 7,902,399; 7,659,242; 7,378,443; 7,230,029; 7,026,356; 6,441,036; 6,417,232; and 6; 365; 628, all of which are incorporated by reference herein in their entirety.
- TTA has properties very similar to natural fatty acids, the main difference being that TTA is not oxidized by the mitochondrial beta-oxidation system. However, the presence of non-beta-oxidizable fatty acid analogues has been shown to increase the beta-oxidation of other fatty acids.
- For example, administration of TTA to rats for 12 weeks nearly doubled the hepatic and plasma content of monounsaturated fatty acids (mainly oleic acid), while polyunsaturated fatty acids (mainly linoleic acid and DHA) decreased. Thus TTA modifies the composition of lipids in various tissues. TTA also modifies fat content and it is anticipated that TTA also modifies fat distribution.
- Feeding moderate doses of TTA to animals like rats, mice, rabbits, and dogs decreases plasma cholesterol and triacylglycerol levels within days of treatment. Tetradecylselenoacetic (TSA) has the same effects. TTA compounds with sulfur substituted in positions 5 or 7 increase beta-oxidation of other lipids and it is thus anticipated that also fatty acid analogous such as TTA lower plasma levels of triglycerides and cholesterol. TTA and TSA are far more potent in this respect than polyunsaturated fatty acids like EPA.
- An important mechanism of action of 3-thia fatty acids is a significant increase in mitochondrial fatty acid oxidation, which reduces the availability of fatty acids for esterification. The synthesis of triacylglycerol and cholesterol is reduced and the secretion of VLDL from the liver is decreased. This has the effect of reducing the production of LDL. All these effects seem to be at least partly mediated by peroxisome proliferator activated receptors (PPAR), ubiquitous transcription factors involved in the regulation of lipid metabolism.
- As such, the benefits of non-beta-oxidizable fatty acid analogues such as TTA and TSA are many. However, TTA compositions that have been marketed in the United States and Europe for human consumption have been associated with side effects, including lethargy, muscle cramps and muscle pain. It is likely that these side effects are due to contaminants in the commercially produced TTA. Accordingly, during the development of embodiments of the technology, experiments were performed to provide a synthesis of TTA that has reduced side effects and to test the use of such TTA compositions in human nutrition.
- 1-bromotetradecane (Aldrich 195332) and thioglycolic acid (Fluka 88650) were obtained from Sigma-Aldrich. In some embodiments, a method for the synthesis of TTA comprises distillation of bromotetradecane-1 to provide a reagent for the synthesis. In particular, a mass of 29.5 kg of commercial bromotetradecane-1 was distilled in two steps at 79° C. under reduced pressure; the two distillates were combined and totaled 25.0 kg. A dark residue of 2.7 kg was removed.
- Then, to synthesize TTA, 7.6 kg NaOH was carefully dissolved in 126.7 kg of methanol while stirring at room temperature. Then a mass of 9.2 kg of thioglycolic acid was weighed in a protective layer of about 2.5 kg of methanol and transferred to the reactor while stirring. Subsequently, 25.0 kg of the distilled 1-bromotetradecane preparation under a protective layer of 2.5 kg of methanol was slowly transferred (e.g., over a time of about a half hour to avoid clumping) to the reactor while stirring. Heating started when about half the amount of bromtetradecane-1 was added. The mixture was stirred under reflux conditions in the reactor at about 65° C. for about 20 hours. After cooling to approximately 55 to 60° C., 50 kg of citric acid dissolved in about 75 kg of hot water were added under heavy stirring. The temperature was kept at approximately 50 to 60° C. Quick addition of late and fast phase separation to limit the formation of methyl was utilized.
- Stirring was stopped and the bottom water was drained off as quickly as possible after phase separation. The temperature in the oil phase was increased to 85 to 90° C. during stirring and the composition was kept under vacuum to reduce the amount of methanol. The oil phase was washed 6 times with 30-50 liters of hot water containing about 2 kg of citric acid each time. After washing, fatty acids were dried at 85 to 90° C. under vacuum. The yield was 20 kg.
- Crystallization: The liquid TTA (20 kg) was mixed at approximately 70° C. with 100 of kg room-temperature acetone. After cooling to 30 to 35° C. 145 kg of fresh acetone were added to the mix to provide a total of 245 kg acetone added. The mixture was then cooled to −30° C. and filtered. After drainage of the liquid, the crystal phase was dried under vacuum and heated to about 40° C. The yield was 19.9 kg.
- All publications and patents mentioned in the above specification are herein incorporated by reference in their entirety for all purposes. Various modifications and variations of the described compositions, methods, and uses of the technology will be apparent to those skilled in the art without departing from the scope and spirit of the technology as described. Although the technology has been described in connection with specific exemplary embodiments, it should be understood that the technology as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the technology that are obvious to those skilled in pharmacology, biochemistry, medical science, or related fields are intended to be within the scope of the following claims.
Claims (13)
1. A structured phospholipid composition comprising phospholipid molecules of the following structure:
wherein one of R1 and R2 is a non-beta-oxidizable fatty acid analogue moiety and the other of R1 and R2 is a bioactive fatty acid moiety selected from the group consisting of an omega-3 fatty acid moiety, on omega-6 fatty acid moiety, a polyunsaturated fatty acid moiety, a conjugated linoleic fatty acid moiety, and combinations thereof, and R3 is a choline, ethanolamine, serine or inositol group.
2. The structured phospholipid composition of claim 1 , wherein said composition comprises greater than 10%, 20%, 30%, 40%, 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R1.
3. The structured phospholipid composition of claim 1 , wherein said composition comprises greater than 50%, 80%, 90% or 99% on a molar basis of said non-beta-oxidizable fatty acid analogue moiety at position R2.
4. The structured phospholipid composition of claim 1 , comprising greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moieties or combinations thereof at position R2.
5. The structured phospholipid composition of claim 1 , comprising greater than about 50%, 80%, 90% or 99% on a molar basis of said bioactive fatty acid moiety at position R1.
6. The structured phospholipid composition of claim 4 , wherein said bioactive fatty acid moiety is selected from the group consisting of EPA, DHA and a combination thereof.
7. The structured phospholipid composition of claim 4 , wherein said bioactive fatty acid moiety is EPA.
8. The structured phospholipid composition of claim 4 , wherein said bioactive fatty acid moiety is DHA.
9. The structured phospholipid composition of claim 4 , wherein said bioactive fatty acid moiety is conjugated linoleic acid.
10. A pharmaceutical composition comprising the structured lipid of claim 1 and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 wherein the structured lipid comprises TTA.
12. The pharmaceutical composition of claim 10 wherein structured lipid comprises an ether link between a lipid tail and a lipid headgroup.
13. The pharmaceutical composition according to claim 10 , admixed with at least one of a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/384,307 US20190367541A1 (en) | 2013-03-11 | 2019-04-15 | Natural lipids containing non-oxidizable fatty acids |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361775834P | 2013-03-11 | 2013-03-11 | |
PCT/IB2014/001254 WO2014140934A2 (en) | 2013-03-11 | 2014-03-10 | Natural lipids containing non-oxidizable fatty acids |
US201514774434A | 2015-09-10 | 2015-09-10 | |
US15/725,431 US10259833B2 (en) | 2013-03-11 | 2017-10-05 | Natural lipids containing non-oxidizable fatty acids |
US16/384,307 US20190367541A1 (en) | 2013-03-11 | 2019-04-15 | Natural lipids containing non-oxidizable fatty acids |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/725,431 Continuation US10259833B2 (en) | 2013-03-11 | 2017-10-05 | Natural lipids containing non-oxidizable fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190367541A1 true US20190367541A1 (en) | 2019-12-05 |
Family
ID=51211269
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/774,434 Abandoned US20160024125A1 (en) | 2013-03-11 | 2014-03-10 | Natural lipids containing non-oxidizable fatty acids |
US15/725,431 Active US10259833B2 (en) | 2013-03-11 | 2017-10-05 | Natural lipids containing non-oxidizable fatty acids |
US16/384,307 Abandoned US20190367541A1 (en) | 2013-03-11 | 2019-04-15 | Natural lipids containing non-oxidizable fatty acids |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/774,434 Abandoned US20160024125A1 (en) | 2013-03-11 | 2014-03-10 | Natural lipids containing non-oxidizable fatty acids |
US15/725,431 Active US10259833B2 (en) | 2013-03-11 | 2017-10-05 | Natural lipids containing non-oxidizable fatty acids |
Country Status (6)
Country | Link |
---|---|
US (3) | US20160024125A1 (en) |
EP (1) | EP2968568A2 (en) |
AU (1) | AU2014229506B2 (en) |
CA (1) | CA2904827C (en) |
HK (1) | HK1220606A1 (en) |
WO (1) | WO2014140934A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220288095A1 (en) * | 2019-07-26 | 2022-09-15 | Lifescience As | Sialic acid for use in the treatment of psoriasis |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5838215A (en) * | 1981-09-01 | 1983-03-05 | Shigeru Tokiwa | Anticholesteremic and preventive or remedy for thrombosis |
US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
GB8813012D0 (en) | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
JP3394278B2 (en) | 1992-12-03 | 2003-04-07 | ファナック株式会社 | Visual sensor coordinate system setting jig and setting method |
US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
NO952796D0 (en) | 1995-07-14 | 1995-07-14 | Rolf Berge | Fatty acid analogues with non-oxidizable B-site, preparation and use in crepes |
US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
JP2000517297A (en) | 1996-08-07 | 2000-12-26 | ダーウィン・ディスカバリー・リミテッド | Hydroxamic acid derivatives and carboxylic acid derivatives having MMP and TNF inhibitory activities |
US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
EP2341127B1 (en) * | 2000-01-28 | 2015-05-27 | DSM IP Assets B.V. | Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors |
NO328803B1 (en) | 2000-03-03 | 2010-05-18 | Thia Medica | New fatty acid analogues |
NO20003591L (en) | 2000-07-13 | 2002-01-14 | Thia Medica As | Fatty acid analogues for the treatment of cancer |
NO20004844L (en) | 2000-09-27 | 2002-05-10 | Thia Medica As | Fatty acid analogues for the treatment of proliferative skin diseases |
NO324555B1 (en) | 2000-09-27 | 2007-11-19 | Thia Medica As | Use of fatty acid analogues to prevent and / or treat proliferative skin diseases. |
NO20006008L (en) | 2000-11-28 | 2002-05-29 | Thia Medica As | Fatty acid analogues for the treatment of inflammatory and autoimmune diseases |
NO324557B1 (en) | 2000-11-28 | 2007-11-19 | Thia Medica As | Use of fatty acid analogues to prevent and / or treat inflammatory and / or autoimmune disorders. |
FR2828487B1 (en) | 2001-08-09 | 2005-05-27 | Genfit S A | NOVEL COMPOUNDS DERIVED FROM FATTY ACIDS, PREPARATION AND USES |
JP5008258B2 (en) * | 2002-06-20 | 2012-08-22 | アイシー・ベック・リミテッド | Sulfur-containing phospholipid derivatives |
US7659242B2 (en) * | 2004-07-19 | 2010-02-09 | Thia Medica As | Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities |
NO324533B1 (en) * | 2004-07-19 | 2007-11-19 | Thia Medica As | Material prepared from a combination of non-β-oxidizable fatty acid analogues and a protein material, as well as the use thereof. |
CN101765661B (en) | 2007-06-01 | 2014-08-06 | 索拉兹米公司 | Production of oil in microorganisms |
US9428779B2 (en) * | 2010-02-03 | 2016-08-30 | Sapphire Energy, Inc. | Transformation of algae for increasing lipid production |
-
2014
- 2014-03-10 EP EP14741365.2A patent/EP2968568A2/en not_active Withdrawn
- 2014-03-10 AU AU2014229506A patent/AU2014229506B2/en active Active
- 2014-03-10 US US14/774,434 patent/US20160024125A1/en not_active Abandoned
- 2014-03-10 CA CA2904827A patent/CA2904827C/en active Active
- 2014-03-10 WO PCT/IB2014/001254 patent/WO2014140934A2/en active Application Filing
-
2016
- 2016-07-20 HK HK16108611.4A patent/HK1220606A1/en unknown
-
2017
- 2017-10-05 US US15/725,431 patent/US10259833B2/en active Active
-
2019
- 2019-04-15 US US16/384,307 patent/US20190367541A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014229506A1 (en) | 2015-10-08 |
US10259833B2 (en) | 2019-04-16 |
AU2014229506B2 (en) | 2017-04-13 |
EP2968568A2 (en) | 2016-01-20 |
CA2904827A1 (en) | 2014-09-18 |
WO2014140934A3 (en) | 2015-04-30 |
WO2014140934A2 (en) | 2014-09-18 |
CA2904827C (en) | 2020-10-27 |
US20160024125A1 (en) | 2016-01-28 |
HK1220606A1 (en) | 2017-05-12 |
US20180030073A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11628152B2 (en) | Lipid compositions containing bioactive fatty acids | |
US20120264966A1 (en) | Sulfur-containing phospholipid derivatives | |
US10993925B2 (en) | Lipid formulations containing bioactive fatty acids | |
US20100266681A1 (en) | Fatty acid alcohols | |
JP4165904B2 (en) | Hydrolysis optimized lipid emulsion and use thereof | |
JP2017222650A (en) | Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same | |
US10259833B2 (en) | Natural lipids containing non-oxidizable fatty acids | |
WO2007039945A1 (en) | Lipid metabolism improving composition | |
JP2008521888A (en) | Sphingolipids in the treatment and prevention of steatosis or hepatotoxicity and its sequelae | |
JP4643009B2 (en) | Novel compounds for cancer treatment | |
US20170014432A1 (en) | Compositions and methods for reducing chronic low-level inflammation | |
KR20090046777A (en) | Modulation of the immune system by inositol phopholipids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOBESITA AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERGEN TEKNOLOGIOVERFOERING AS;REEL/FRAME:053343/0742 Effective date: 20200629 |